PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17157960-2	2007	In this study we show that membranes prepared from embryos of Drosophila melanogaster possess neprilysin-like activity that is inhibited by phosphoramidon and thiorphan, both inhibitors of mammalian neprilysin.	phosphoramidon	140-154	membrane metalloendopeptidase	Homo sapiens	94-104
17157960-2	2007	In this study we show that membranes prepared from embryos of Drosophila melanogaster possess neprilysin-like activity that is inhibited by phosphoramidon and thiorphan, both inhibitors of mammalian neprilysin.	phosphoramidon	140-154	membrane metalloendopeptidase	Homo sapiens	199-209
16633356-13	2006	Additionally, by measuring the production of ET-1(1-31), we showed that a chymase-like enzyme is involved in this process when ECE and NEP are inhibited by phosphoramidon.	phosphoramidon	156-170	neprilysin	Oryctolagus cuniculus	135-138
17112488-7	2006	Phosphoramidon, a neprilysin inhibitor, attenuated these effects of neprilysin.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	18-28
17112488-7	2006	Phosphoramidon, a neprilysin inhibitor, attenuated these effects of neprilysin.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	68-78
17028040-8	2006	Thus, our main purpose for this study was to examine the effects of both big ET-1 and ET-1 to clarify the role of phosphoramidon in inhibiting the conversion of big ET-1 to ET-1, by investigating the systemic blood pressure, microvascular blood flow velocity, and diameters of arterioles and venules of the rat mesentery.	phosphoramidon	114-128	endothelin 1	Rattus norvegicus	165-177
17028040-17	2006	In the second group of experiments, cumulative injections of phosphoramidon (30 mg/kg/10 min) were administered 10 min prior to the infusion of big ET-1.	phosphoramidon	61-75	endothelin 1	Rattus norvegicus	148-152
17028040-18	2006	Phosphoramidon significantly suppressed the long-lasting significant pressor effect and significantly inhibited the dose-dependent increase and dose-dependent decrease in the microvascular blood flow velocity produced by big ET-1 in the rat mesenteric microcirculation.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	225-229
17028040-20	2006	Moreover, phosphoramidon markedly inhibited the conversion of big ET-1 to ET-1 in the rat mesenteric microcirculation, which may suggest an inhibition of the enzyme which converts big ET-1 to ET-1.	phosphoramidon	10-24	endothelin 1	Rattus norvegicus	66-78
17028040-20	2006	Moreover, phosphoramidon markedly inhibited the conversion of big ET-1 to ET-1 in the rat mesenteric microcirculation, which may suggest an inhibition of the enzyme which converts big ET-1 to ET-1.	phosphoramidon	10-24	endothelin 1	Rattus norvegicus	184-196
16406141-2	2006	By using dermal microdialysis we explored the effect of phosphoramidon (NEP blocker), captopril (ACE blocker) and a mixture of both drugs on the intensity of electrically-induced CGRP-mediated neurogenic flare.	phosphoramidon	56-70	calcitonin related polypeptide alpha	Homo sapiens	179-183
16406141-5	2006	Electrically released CGRP levels could be measured directly in perfusates containing phosphoramidon and the mixture.	phosphoramidon	86-100	calcitonin related polypeptide alpha	Homo sapiens	22-26
16406141-6	2006	Again, CGRP levels were elevated in phosphoramidon treated sites, and significantly reduced upon adding captopril.	phosphoramidon	36-50	calcitonin related polypeptide alpha	Homo sapiens	7-11
15993898-7	2005	Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone.	phosphoramidon	72-86	membrane metallo endopeptidase	Mus musculus	5-8
16391412-5	2005	Therapeutic administration of phosphoramidon, an inhibitor of ECE-1 activity, not only led to a 53.2% drop in the ET-1, but also produced a dose-dependent reduction (up to 50.9%) in the mucosal level of leptin and up to 42.3% decline in the rate of ulcer healing.	phosphoramidon	30-44	endothelin converting enzyme 1	Rattus norvegicus	62-67
16391412-5	2005	Therapeutic administration of phosphoramidon, an inhibitor of ECE-1 activity, not only led to a 53.2% drop in the ET-1, but also produced a dose-dependent reduction (up to 50.9%) in the mucosal level of leptin and up to 42.3% decline in the rate of ulcer healing.	phosphoramidon	30-44	endothelin 1	Rattus norvegicus	114-118
16391412-5	2005	Therapeutic administration of phosphoramidon, an inhibitor of ECE-1 activity, not only led to a 53.2% drop in the ET-1, but also produced a dose-dependent reduction (up to 50.9%) in the mucosal level of leptin and up to 42.3% decline in the rate of ulcer healing.	phosphoramidon	30-44	leptin	Rattus norvegicus	203-209
15874973-9	2005	Extraluminal administration of PD-145065, BQ-123, and phosphoramidon blocked the constriction response to CART peptide (P<0.01).	phosphoramidon	54-68	CART prepropeptide	Rattus norvegicus	106-110
15963503-8	2005	Inhibition of NEP with phosphoramidon increased flare intensity (P < 0.002) and size (P < 0.01), while blocking ACE had no effect on neurogenic vasodilation.	phosphoramidon	23-37	membrane metalloendopeptidase	Homo sapiens	14-17
15963503-9	2005	CGRP release could be measured in microdialysis samples after phosphoramidon perfusion only (P < 0.03), not in samples with captopril or saline perfusion.	phosphoramidon	62-76	calcitonin related polypeptide alpha	Homo sapiens	0-4
16169283-5	2005	The combined NEP/endothelin-converting enzyme inhibitor (NEP/ECE inhibitor), phosphoramidon (10 microM) or the specific inhibitor of the NEP, thiorphan (10 microM) resulted in an enhanced magnitude of CNP-induced relaxation without significant change in the EC50 both on endothelium intact and endothelium deprived preparations.	phosphoramidon	77-91	natriuretic peptide C	Homo sapiens	201-204
15993898-7	2005	Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone.	phosphoramidon	72-86	membrane metallo endopeptidase	Mus musculus	23-26
15993898-7	2005	Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone.	phosphoramidon	72-86	membrane metallo endopeptidase	Mus musculus	23-26
15993898-7	2005	Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone.	phosphoramidon	72-86	myeloperoxidase	Mus musculus	138-141
15993898-7	2005	Both NEP(-/-) mice and NEP(+/+) mice pretreated with the NEP antagonist phosphoramidon (10 mg/kg s.c.) had significant elevations of lung MPO and worsened lung histology compared to NEP(+/+) mice given elastase alone.	phosphoramidon	72-86	membrane metallo endopeptidase	Mus musculus	23-26
15764737-4	2005	Treatment with 10 microM phosphoramidon (NEP inhibitor) or 10 microM amastatin (APM inhibitor) potentiated DAKD-elicited responses, whereas 1 microM captopril (ACE inhibitor) had no significant effects.	phosphoramidon	25-39	membrane metalloendopeptidase	Homo sapiens	41-44
16117692-10	2005	The retinal PM Big ET-1 converting activity was inhibited by phosphoramidon, thiorphan, and acidification.	phosphoramidon	61-75	endothelin 1	Bos taurus	19-23
15969636-7	2005	Phosphoramidon, thiorphan, acidification, and phenanthroline inhibited PM ECE activity; the cytosolic ECE activity was not affected by phenanthroline but was inhibited by the others.	phosphoramidon	0-14	endothelin converting enzyme 1	Homo sapiens	74-77
15969636-9	2005	Pepstatin, a potent inhibitor of cathepsins, and phosphoramidon, a potent inhibitor of ECE, inhibited the cytosolic conversion of Big ET-1 peptide by 46% and 35%, respectively, whereas the combination of both inhibited the cytosolic activity by 93%.	phosphoramidon	49-63	endothelin converting enzyme 1	Homo sapiens	87-90
15969636-9	2005	Pepstatin, a potent inhibitor of cathepsins, and phosphoramidon, a potent inhibitor of ECE, inhibited the cytosolic conversion of Big ET-1 peptide by 46% and 35%, respectively, whereas the combination of both inhibited the cytosolic activity by 93%.	phosphoramidon	49-63	endothelin 1	Homo sapiens	134-138
16021085-3	2005	STUDY DESIGN: Forearm blood flow was measured by venous occlusion plethysmography during intra-arterial infusion of phosphoramidon, an endothelin-converting enzyme inhibitor, for 60 minutes, which was followed by co-infusion with endothelin-1 for 30 minutes.	phosphoramidon	116-130	endothelin 1	Homo sapiens	230-242
15956117-4	2005	Phosphoramidon, a dual neutral endopeptidase and endothelin-converting enzyme inhibitor, blocked both pressor responses to endothelin-1 (1-31) and big endothelin-1 but not those afforded by endothelin-1.	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	123-135
15956117-4	2005	Phosphoramidon, a dual neutral endopeptidase and endothelin-converting enzyme inhibitor, blocked both pressor responses to endothelin-1 (1-31) and big endothelin-1 but not those afforded by endothelin-1.	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	151-163
15956117-4	2005	Phosphoramidon, a dual neutral endopeptidase and endothelin-converting enzyme inhibitor, blocked both pressor responses to endothelin-1 (1-31) and big endothelin-1 but not those afforded by endothelin-1.	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	151-163
15956117-7	2005	Furthermore, injection of big endothelin-1 concomitantly with phosphoramidon induced an increase in endothelin-1 (1-31) plasma levels.	phosphoramidon	62-76	endothelin-1	Oryctolagus cuniculus	30-42
15956117-7	2005	Furthermore, injection of big endothelin-1 concomitantly with phosphoramidon induced an increase in endothelin-1 (1-31) plasma levels.	phosphoramidon	62-76	endothelin-1	Oryctolagus cuniculus	100-112
15956117-8	2005	Finally, intracardiac-administered endothelin-1 (1-31) induced an increase of endothelin-1 plasma levels, which are markedly reduced by phosphoramidon and thiorphan but not by CGS 35066.	phosphoramidon	136-150	endothelin-1	Oryctolagus cuniculus	35-47
15956117-8	2005	Finally, intracardiac-administered endothelin-1 (1-31) induced an increase of endothelin-1 plasma levels, which are markedly reduced by phosphoramidon and thiorphan but not by CGS 35066.	phosphoramidon	136-150	endothelin-1	Oryctolagus cuniculus	78-90
16280098-4	2005	Pretreatment with phosphoramidon, an inhibitor of ECE-1 activity, not only led to a decline in ECE-1 and ET-1 generation, but also produced a dose-dependent reduction in the mucosal level of leptin and the extent of mucosal damage caused by indomethacin.	phosphoramidon	18-32	endothelin converting enzyme 1	Rattus norvegicus	50-55
16280098-4	2005	Pretreatment with phosphoramidon, an inhibitor of ECE-1 activity, not only led to a decline in ECE-1 and ET-1 generation, but also produced a dose-dependent reduction in the mucosal level of leptin and the extent of mucosal damage caused by indomethacin.	phosphoramidon	18-32	endothelin converting enzyme 1	Rattus norvegicus	95-100
16280098-4	2005	Pretreatment with phosphoramidon, an inhibitor of ECE-1 activity, not only led to a decline in ECE-1 and ET-1 generation, but also produced a dose-dependent reduction in the mucosal level of leptin and the extent of mucosal damage caused by indomethacin.	phosphoramidon	18-32	endothelin 1	Rattus norvegicus	105-109
16280098-4	2005	Pretreatment with phosphoramidon, an inhibitor of ECE-1 activity, not only led to a decline in ECE-1 and ET-1 generation, but also produced a dose-dependent reduction in the mucosal level of leptin and the extent of mucosal damage caused by indomethacin.	phosphoramidon	18-32	leptin	Rattus norvegicus	191-197
16280098-5	2005	This effect of phosphoramidon, however, was subject to suppression by the exogenous ET-1 administration.	phosphoramidon	15-29	endothelin 1	Rattus norvegicus	84-88
15172962-13	2004	Big ET-1 also contracted the ductus sphincter but differed from ET-1 for its lesser potency and inhibition by phosphoramidon (50 microm).	phosphoramidon	110-124	EDN1	Ovis aries	4-8
15151517-9	2004	The effects of big ET-1([1-38]) and phosphoramidon suggest the presence of endogenous ECE activity in the skin.	phosphoramidon	36-50	endothelin converting enzyme 1	Homo sapiens	86-89
15177934-6	2004	The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody.	phosphoramidon	178-192	epidermal growth factor receptor	Homo sapiens	30-34
15177934-6	2004	The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody.	phosphoramidon	178-192	mitogen-activated protein kinase 1	Homo sapiens	35-38
15177934-6	2004	The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody.	phosphoramidon	178-192	AKT serine/threonine kinase 1	Homo sapiens	39-42
15177934-6	2004	The NT-induced stimulation of EGFR/ERK/Akt phosphorylation and DNA synthesis was inhibited by EGFR-tyrosine kinase inhibitors (AG1478, PD153035), metallo-endopeptidase inhibitor phosphoramidon and by heparin, but not by neutralizing anti-EGF antibody.	phosphoramidon	178-192	epidermal growth factor receptor	Homo sapiens	94-98
14659804-4	2003	Force and [Na(+)](i) increase were abolished by inhibition of the Na(+)/H(+) exchanger (NHE) with the inhibitor HOE642, blockade of endothelin receptors with the nonselective antagonist TAK044 and by inhibition of the endothelin-converting enzyme with phosphoramidon.	phosphoramidon	252-266	solute carrier family 9 member C1	Homo sapiens	88-91
14972450-6	2004	Cell number was reduced by 54.4 per cent of the control by culture with 10(-6)m GnRH for 24 h. However, phosphoramidon, a NEP specific inhibitor, inhibited antiproliferative effect of GnRH and reverted to the control level.	phosphoramidon	104-118	gonadotropin releasing hormone 1	Homo sapiens	80-84
14972450-6	2004	Cell number was reduced by 54.4 per cent of the control by culture with 10(-6)m GnRH for 24 h. However, phosphoramidon, a NEP specific inhibitor, inhibited antiproliferative effect of GnRH and reverted to the control level.	phosphoramidon	104-118	membrane metalloendopeptidase	Homo sapiens	122-125
14972450-6	2004	Cell number was reduced by 54.4 per cent of the control by culture with 10(-6)m GnRH for 24 h. However, phosphoramidon, a NEP specific inhibitor, inhibited antiproliferative effect of GnRH and reverted to the control level.	phosphoramidon	104-118	gonadotropin releasing hormone 1	Homo sapiens	184-188
15148521-3	2004	Degradation of SP was inhibited by a metal chelator, o-phenanthroline, and also by specific inhibitors of endopeptidase-24.11, thiorphan and phosphoramidon.	phosphoramidon	141-155	tachykinin 1	Mus musculus	15-17
15804063-7	2003	Phosphoramidon can protect the myocardial injury in rats and its mechanism may be to inhibit ECE and reduce the endothelins production.	phosphoramidon	0-14	endothelin converting enzyme 1	Rattus norvegicus	93-96
14501953-1	2003	We tested the hypothesis that metalloendopeptidase inhibition using phosphoramidon during induction of endotoxemia 24 h later would down-regulate the protein expression of myocardial inducible nitric oxide synthase (iNOS) and phosphorylation of p38-mitogen-activated protein kinase (p38-MAPK).	phosphoramidon	68-82	thimet oligopeptidase 1	Rattus norvegicus	30-50
14501953-1	2003	We tested the hypothesis that metalloendopeptidase inhibition using phosphoramidon during induction of endotoxemia 24 h later would down-regulate the protein expression of myocardial inducible nitric oxide synthase (iNOS) and phosphorylation of p38-mitogen-activated protein kinase (p38-MAPK).	phosphoramidon	68-82	nitric oxide synthase 2	Rattus norvegicus	183-214
14501953-1	2003	We tested the hypothesis that metalloendopeptidase inhibition using phosphoramidon during induction of endotoxemia 24 h later would down-regulate the protein expression of myocardial inducible nitric oxide synthase (iNOS) and phosphorylation of p38-mitogen-activated protein kinase (p38-MAPK).	phosphoramidon	68-82	nitric oxide synthase 2	Rattus norvegicus	216-220
14501953-1	2003	We tested the hypothesis that metalloendopeptidase inhibition using phosphoramidon during induction of endotoxemia 24 h later would down-regulate the protein expression of myocardial inducible nitric oxide synthase (iNOS) and phosphorylation of p38-mitogen-activated protein kinase (p38-MAPK).	phosphoramidon	68-82	mitogen activated protein kinase 14	Rattus norvegicus	245-281
14501953-1	2003	We tested the hypothesis that metalloendopeptidase inhibition using phosphoramidon during induction of endotoxemia 24 h later would down-regulate the protein expression of myocardial inducible nitric oxide synthase (iNOS) and phosphorylation of p38-mitogen-activated protein kinase (p38-MAPK).	phosphoramidon	68-82	mitogen activated protein kinase 14	Rattus norvegicus	283-291
14501953-8	2003	This LPS-induced left ventricular ET-1 elevation at 24 h was significantly reduced by phosphoramidon.	phosphoramidon	86-100	endothelin 1	Rattus norvegicus	34-38
14501953-11	2003	Also, LPS-induced upregulated protein expression of myocardial-inducible nitric oxide synthase and increased levels of nitric oxide byproducts at 24 h were blocked by phosphoramidon.	phosphoramidon	167-181	nitric oxide synthase 2	Rattus norvegicus	63-94
14501953-12	2003	Phosphoramidon inhibited LPS-induced down-regulated expression of myocardial endothelial nitric oxide synthase and upregulated p38-MAPK phosphorylation.	phosphoramidon	0-14	mitogen activated protein kinase 14	Rattus norvegicus	127-130
14500390-7	2003	Cytotoxicity of CPI-0004Na was inhibited by phosphoramidon, a known inhibitor of CD10 enzymatic activity.	phosphoramidon	44-58	membrane metalloendopeptidase	Homo sapiens	81-85
12885426-6	2003	Investigations were also performed to determine whether the administration of phosphoramidon, an endothelin-converting enzyme (ECE) inhibitor, and BQ-123, an endothelin receptor ET(A) antagonist, suppresses angiogenesis and VEGF expression.	phosphoramidon	78-92	vascular endothelial growth factor A	Rattus norvegicus	224-228
12827039-0	2003	The effects of phosphoramidon on the expression of human endothelin-converting enzyme-1 (ECE-1) isoforms.	phosphoramidon	15-29	endothelin converting enzyme 1	Homo sapiens	57-87
12827039-0	2003	The effects of phosphoramidon on the expression of human endothelin-converting enzyme-1 (ECE-1) isoforms.	phosphoramidon	15-29	endothelin converting enzyme 1	Homo sapiens	89-94
12827039-2	2003	This process is inhibited by phosphoramidon through binding to the catalytic domain of ECE-1.	phosphoramidon	29-43	endothelin converting enzyme 1	Homo sapiens	87-92
12827039-5	2003	It is not known, however, whether phosphoramidon has similar effects on the expression of other ECE-1 isoforms.	phosphoramidon	34-48	endothelin converting enzyme 1	Homo sapiens	96-101
12827039-10	2003	Taken together, our results demonstrate that phosphoramidon differentially affects the expression of three human ECE-1 isoforms.	phosphoramidon	45-59	endothelin converting enzyme 1	Homo sapiens	113-118
12654643-2	2003	Incubation of SP-A with P. aeruginosa organisms from several clinical isolates resulted in concentration- and temperature-dependent degradation of SP-A that was inhibited by a metalloproteinase inhibitor, phosphoramidon.	phosphoramidon	205-219	surfactant protein A1	Homo sapiens	14-18
12962299-5	2003	Application of 10(-4)-M phosphoramidon resulted in a statistically significant decrease in big ET-1-induced contraction in E+ and E- segments; 10(-5)-M and 10(-6)-M [22D-Val]big ET-1 [16-38] in E- segments produced no statistically significant effect.	phosphoramidon	24-38	endothelin 1	Rattus norvegicus	95-99
12962299-5	2003	Application of 10(-4)-M phosphoramidon resulted in a statistically significant decrease in big ET-1-induced contraction in E+ and E- segments; 10(-5)-M and 10(-6)-M [22D-Val]big ET-1 [16-38] in E- segments produced no statistically significant effect.	phosphoramidon	24-38	endothelin 1	Rattus norvegicus	178-182
12654643-2	2003	Incubation of SP-A with P. aeruginosa organisms from several clinical isolates resulted in concentration- and temperature-dependent degradation of SP-A that was inhibited by a metalloproteinase inhibitor, phosphoramidon.	phosphoramidon	205-219	surfactant protein A1	Homo sapiens	147-151
12431739-7	2002	Complete inhibition of the endopeptidic hydrolysis of the LomTK-1 by a disc homogenate required a combination of captopril and the neprilysin inhibitor, phosphoramidon, providing biochemical evidence for a neprilysin-like peptidase, in addition to Ance, in imaginal discs of D. melanogaster.	phosphoramidon	153-167	Neprilysin-like 11	Drosophila melanogaster	131-141
12434178-7	2002	This ECE-activity could be inhibited by Captopril and Phosporamidon, suggesting a potency for prevention and therapy of cerebral vasospasm.	phosphoramidon	54-67	endothelin converting enzyme 1	Rattus norvegicus	5-8
12541324-5	2003	The enzyme was acted upon by the NEP inhibitors phosphoramidon (IC(50), 0.64 microM) and thiorphan (IC(50), 1.23 microM), and the detergent-solubilized enzyme had an Mr of approximately 300,000 and a neutral pH optimum.	phosphoramidon	48-62	membrane metalloendopeptidase	Homo sapiens	33-36
12499645-5	2002	The MAPK activation was also inhibited by the endothelin receptor antagonist cyclo(D-alpha-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl) (BQ123) and by the endothelin-converting enzyme inhibitor phosphoramidon.	phosphoramidon	198-212	mitogen activated protein kinase 3	Rattus norvegicus	4-8
12392915-9	2002	Phosphoramidon-treated CD1 mice survived the acute infection.	phosphoramidon	0-14	CD1 antigen complex	Mus musculus	23-26
12431739-7	2002	Complete inhibition of the endopeptidic hydrolysis of the LomTK-1 by a disc homogenate required a combination of captopril and the neprilysin inhibitor, phosphoramidon, providing biochemical evidence for a neprilysin-like peptidase, in addition to Ance, in imaginal discs of D. melanogaster.	phosphoramidon	153-167	Neprilysin-like 11	Drosophila melanogaster	206-216
12393059-1	2002	Previous in vitro studies showed that the degradation of [Met(5)]enkephalin-Arg-Gly-Leu by cerebral membrane preparations is almost completely prevented by a mixture of three peptidase inhibitors: amastatin, captopril and phosphoramidon.	phosphoramidon	222-236	proenkephalin	Rattus norvegicus	65-75
12099999-9	2002	This increase is attributed to the higher conversion rate of big ET-1 to ET-1 because the ET-converting enzyme (ECE) inhibitor phosphoramidon, at a concentration of 10(-6) mol/L, causes an inhibition in the response to big ET-1 by 52.6% in normal kidneys, whereas this inhibition with the same concentration of phosphoramidon was found to be significantly decreased in kidneys isolated from GLY-pretreated rabbits.	phosphoramidon	127-141	endothelin-1	Oryctolagus cuniculus	65-77
12477147-10	2002	ECE-1 inhibitors, phosphoramidon and FR-901533, inhibited vascular ECE-1 activity by more than 80%.	phosphoramidon	18-32	endothelin converting enzyme 1	Homo sapiens	0-5
12477147-10	2002	ECE-1 inhibitors, phosphoramidon and FR-901533, inhibited vascular ECE-1 activity by more than 80%.	phosphoramidon	18-32	endothelin converting enzyme 1	Homo sapiens	67-72
12208785-5	2002	NEP inhibition with phosphoramidon did not affect the bradykinin concentration-response curve (CRC), nor did combined NEP/ACE inhibition with omapatrilat exert a further leftward shift on top of the approximately 10 fold leftward shift of the bradykinin CRC observed with ACE inhibition alone.	phosphoramidon	20-34	membrane metalloendopeptidase	Homo sapiens	0-3
12220742-3	2002	NMB cells express neutral endopeptidase (NEP) activity that can be specifically inhibited by phosphoramidon (PA).	phosphoramidon	93-107	membrane metalloendopeptidase	Homo sapiens	18-39
12220742-3	2002	NMB cells express neutral endopeptidase (NEP) activity that can be specifically inhibited by phosphoramidon (PA).	phosphoramidon	93-107	membrane metalloendopeptidase	Homo sapiens	41-44
12220742-3	2002	NMB cells express neutral endopeptidase (NEP) activity that can be specifically inhibited by phosphoramidon (PA).	phosphoramidon	109-111	membrane metalloendopeptidase	Homo sapiens	18-39
12220742-3	2002	NMB cells express neutral endopeptidase (NEP) activity that can be specifically inhibited by phosphoramidon (PA).	phosphoramidon	109-111	membrane metalloendopeptidase	Homo sapiens	41-44
12220742-4	2002	Our data now show that phosphoramidon treatment increases the efficacy of VIP-stimulated neuroblastoma proliferation.	phosphoramidon	23-37	vasoactive intestinal peptide	Homo sapiens	74-77
12363040-5	2002	Inhibition of NEP/CD10 by the NEP inhibitor phosphoramidon or by an anti-CD10 monoclonal antibody significantly increased apoptosis induction.	phosphoramidon	44-58	membrane metalloendopeptidase	Homo sapiens	14-17
12363040-5	2002	Inhibition of NEP/CD10 by the NEP inhibitor phosphoramidon or by an anti-CD10 monoclonal antibody significantly increased apoptosis induction.	phosphoramidon	44-58	membrane metalloendopeptidase	Homo sapiens	18-22
12363040-5	2002	Inhibition of NEP/CD10 by the NEP inhibitor phosphoramidon or by an anti-CD10 monoclonal antibody significantly increased apoptosis induction.	phosphoramidon	44-58	membrane metalloendopeptidase	Homo sapiens	30-33
12193062-9	2002	Cleavage of bradykinin by PgPepO occurs at the Pro(7)-Phe(8) bond and is inhibited by the NEP and ECE-1 inhibitor phosphoramidon in a pH-dependent fashion (IC(50) =10 microM at pH 7.0) but not by thiorphan, an NEP-specific inhibitor.	phosphoramidon	114-128	endothelin converting enzyme 1	Homo sapiens	98-103
12099999-9	2002	This increase is attributed to the higher conversion rate of big ET-1 to ET-1 because the ET-converting enzyme (ECE) inhibitor phosphoramidon, at a concentration of 10(-6) mol/L, causes an inhibition in the response to big ET-1 by 52.6% in normal kidneys, whereas this inhibition with the same concentration of phosphoramidon was found to be significantly decreased in kidneys isolated from GLY-pretreated rabbits.	phosphoramidon	127-141	endothelin-1	Oryctolagus cuniculus	65-69
12099999-9	2002	This increase is attributed to the higher conversion rate of big ET-1 to ET-1 because the ET-converting enzyme (ECE) inhibitor phosphoramidon, at a concentration of 10(-6) mol/L, causes an inhibition in the response to big ET-1 by 52.6% in normal kidneys, whereas this inhibition with the same concentration of phosphoramidon was found to be significantly decreased in kidneys isolated from GLY-pretreated rabbits.	phosphoramidon	311-325	endothelin-1	Oryctolagus cuniculus	65-77
12099999-9	2002	This increase is attributed to the higher conversion rate of big ET-1 to ET-1 because the ET-converting enzyme (ECE) inhibitor phosphoramidon, at a concentration of 10(-6) mol/L, causes an inhibition in the response to big ET-1 by 52.6% in normal kidneys, whereas this inhibition with the same concentration of phosphoramidon was found to be significantly decreased in kidneys isolated from GLY-pretreated rabbits.	phosphoramidon	311-325	endothelin-1	Oryctolagus cuniculus	65-69
12137746-5	2002	Phosphoramidon, a potent inhibitor of NEP, reduced the liberated amino acids to about a half, suggesting that NEP is a responsible enzyme for GnRH degradation.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	38-41
12110606-7	2002	Phosphoramidon (5 and 10 mg kg(-1)) reduced both pressor and PIP effects of ET-1(1-31).	phosphoramidon	0-14	prolactin-inducible protein homolog	Cavia porcellus	61-64
12193101-11	2002	In another experiment phosphoramidon treatment was also tested in CD1 mice, which have a high mortality during the acute phase of infection with 5 x 10(4) trypomastigotes of the Brazil strain.	phosphoramidon	22-36	CD1 antigen complex	Mus musculus	66-69
12182783-9	2002	Preincubation with phosphoramidon (10(-4) mol/L) resulted in a small yet significant inhibition of the contraction induced by big ET-1.	phosphoramidon	19-33	endothelin 1	Homo sapiens	130-134
12137746-5	2002	Phosphoramidon, a potent inhibitor of NEP, reduced the liberated amino acids to about a half, suggesting that NEP is a responsible enzyme for GnRH degradation.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	110-113
12137746-5	2002	Phosphoramidon, a potent inhibitor of NEP, reduced the liberated amino acids to about a half, suggesting that NEP is a responsible enzyme for GnRH degradation.	phosphoramidon	0-14	gonadotropin releasing hormone 1	Homo sapiens	142-146
11909608-4	2002	Phosphoramidon, an inhibitor of neutral endopeptidase 24.11 (neprilysin, CD10), was ineffective at 10 microM, but at 100 microM, significant increase in the maximum response was achieved by neurokinin A in detrusor strips with and without mucosa.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	32-59
12021551-6	2002	In contrast, the expression of neutral endopeptidase (NEP), a cell surface peptide with hydrolyzing activity of SP, was increased in fibroblasts stimulated with SP after 24 h. The administration of NEP inhibitor (phosphoramidon) to the fibroblasts induced higher SP production.	phosphoramidon	213-227	membrane metalloendopeptidase	Homo sapiens	31-52
12021551-6	2002	In contrast, the expression of neutral endopeptidase (NEP), a cell surface peptide with hydrolyzing activity of SP, was increased in fibroblasts stimulated with SP after 24 h. The administration of NEP inhibitor (phosphoramidon) to the fibroblasts induced higher SP production.	phosphoramidon	213-227	membrane metalloendopeptidase	Homo sapiens	54-57
12021551-6	2002	In contrast, the expression of neutral endopeptidase (NEP), a cell surface peptide with hydrolyzing activity of SP, was increased in fibroblasts stimulated with SP after 24 h. The administration of NEP inhibitor (phosphoramidon) to the fibroblasts induced higher SP production.	phosphoramidon	213-227	tachykinin precursor 1	Homo sapiens	112-114
12021551-6	2002	In contrast, the expression of neutral endopeptidase (NEP), a cell surface peptide with hydrolyzing activity of SP, was increased in fibroblasts stimulated with SP after 24 h. The administration of NEP inhibitor (phosphoramidon) to the fibroblasts induced higher SP production.	phosphoramidon	213-227	tachykinin precursor 1	Homo sapiens	161-163
12021551-6	2002	In contrast, the expression of neutral endopeptidase (NEP), a cell surface peptide with hydrolyzing activity of SP, was increased in fibroblasts stimulated with SP after 24 h. The administration of NEP inhibitor (phosphoramidon) to the fibroblasts induced higher SP production.	phosphoramidon	213-227	membrane metalloendopeptidase	Homo sapiens	198-201
12021551-6	2002	In contrast, the expression of neutral endopeptidase (NEP), a cell surface peptide with hydrolyzing activity of SP, was increased in fibroblasts stimulated with SP after 24 h. The administration of NEP inhibitor (phosphoramidon) to the fibroblasts induced higher SP production.	phosphoramidon	213-227	tachykinin precursor 1	Homo sapiens	161-163
11897392-7	2002	Phosphoramidon inhibited both these cleavages, but with markedly different potencies, indicating the presence in the fly brain of two NEP-like enzymes with different substrate and inhibitor specificity.	phosphoramidon	0-14	Neprilysin-like 11	Drosophila melanogaster	134-137
11909608-4	2002	Phosphoramidon, an inhibitor of neutral endopeptidase 24.11 (neprilysin, CD10), was ineffective at 10 microM, but at 100 microM, significant increase in the maximum response was achieved by neurokinin A in detrusor strips with and without mucosa.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	61-71
11909608-4	2002	Phosphoramidon, an inhibitor of neutral endopeptidase 24.11 (neprilysin, CD10), was ineffective at 10 microM, but at 100 microM, significant increase in the maximum response was achieved by neurokinin A in detrusor strips with and without mucosa.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	73-77
11909608-4	2002	Phosphoramidon, an inhibitor of neutral endopeptidase 24.11 (neprilysin, CD10), was ineffective at 10 microM, but at 100 microM, significant increase in the maximum response was achieved by neurokinin A in detrusor strips with and without mucosa.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	190-202
11882619-5	2002	NEP inhibitor phosphoramidon (100 nmol/L), or omapatrilat, which inhibits both NEP and ACE, did not potentiate bradykinin in CHO/B(2) cells.	phosphoramidon	14-28	membrane metalloendopeptidase	Homo sapiens	0-3
11818328-5	2002	Serum-stimulated proliferation was attenuated by inhibiting either endogenous ET-1 release with phosphoramidon (10(-5) mol/L) or its action with PD145065 (10(-5) mol/L).	phosphoramidon	96-110	endothelin 1	Homo sapiens	78-82
11882619-8	2002	Arachidonic acid release by bradykinin from CHO/NEP-B(2) cells was also augmented by 100 nmol/L phosphoramidon or omapatrilat about 3-fold, and again, the inhibitors resensitized the desensitized B(2) receptor.	phosphoramidon	96-110	kininogen 1	Homo sapiens	28-38
11882619-8	2002	Arachidonic acid release by bradykinin from CHO/NEP-B(2) cells was also augmented by 100 nmol/L phosphoramidon or omapatrilat about 3-fold, and again, the inhibitors resensitized the desensitized B(2) receptor.	phosphoramidon	96-110	membrane metalloendopeptidase	Homo sapiens	48-51
11882619-8	2002	Arachidonic acid release by bradykinin from CHO/NEP-B(2) cells was also augmented by 100 nmol/L phosphoramidon or omapatrilat about 3-fold, and again, the inhibitors resensitized the desensitized B(2) receptor.	phosphoramidon	96-110	bradykinin receptor B2	Homo sapiens	196-209
11687727-2	2001	Posthemorrhagic vasospasm can be counteracted by the administration of phosphoramidon, which blocks the endothelin converting enzyme (ECE) responsible for the conversion of big endothelin into a fully active ET1 peptide.	phosphoramidon	71-85	endothelin converting enzyme 1	Rattus norvegicus	104-132
11747295-5	2001	This NEP-induced degradation was completely inhibited by the NEP inhibitors thiorphan and phosphoramidon.	phosphoramidon	90-104	membrane metalloendopeptidase	Homo sapiens	5-8
11747295-5	2001	This NEP-induced degradation was completely inhibited by the NEP inhibitors thiorphan and phosphoramidon.	phosphoramidon	90-104	membrane metalloendopeptidase	Homo sapiens	61-64
11764001-6	2001	), an NK2 receptor antagonist, significantly inhibited the phosphoramidon-induced enhancement of BK-induced bronchoconstriction, although FK888 (3 mg kg(-1), i.v.	phosphoramidon	59-73	substance-K receptor	Cavia porcellus	6-18
11740152-5	2001	The specific involvement of ET-1 in the angiogenic effect mediated by CHO-ET-1 was demonstrated by the reduction or abolition of neovascularized CHO-ET-1 nodules by (1) bosentan, a mixed antagonist of ET(A)/ET(B) receptors, (2) an ET(A) receptor antagonist (Ru69986) and (3) phosporamidon, an inhibitor of endothelin-converting enzyme-1 (ECE-1).	phosphoramidon	275-288	endothelin-1	Cricetulus griseus	28-32
11740152-5	2001	The specific involvement of ET-1 in the angiogenic effect mediated by CHO-ET-1 was demonstrated by the reduction or abolition of neovascularized CHO-ET-1 nodules by (1) bosentan, a mixed antagonist of ET(A)/ET(B) receptors, (2) an ET(A) receptor antagonist (Ru69986) and (3) phosporamidon, an inhibitor of endothelin-converting enzyme-1 (ECE-1).	phosphoramidon	275-288	endothelin-1	Cricetulus griseus	74-78
11740152-5	2001	The specific involvement of ET-1 in the angiogenic effect mediated by CHO-ET-1 was demonstrated by the reduction or abolition of neovascularized CHO-ET-1 nodules by (1) bosentan, a mixed antagonist of ET(A)/ET(B) receptors, (2) an ET(A) receptor antagonist (Ru69986) and (3) phosporamidon, an inhibitor of endothelin-converting enzyme-1 (ECE-1).	phosphoramidon	275-288	endothelin-1	Cricetulus griseus	74-78
11687727-2	2001	Posthemorrhagic vasospasm can be counteracted by the administration of phosphoramidon, which blocks the endothelin converting enzyme (ECE) responsible for the conversion of big endothelin into a fully active ET1 peptide.	phosphoramidon	71-85	endothelin converting enzyme 1	Rattus norvegicus	134-137
11687727-2	2001	Posthemorrhagic vasospasm can be counteracted by the administration of phosphoramidon, which blocks the endothelin converting enzyme (ECE) responsible for the conversion of big endothelin into a fully active ET1 peptide.	phosphoramidon	71-85	endothelin 1	Rattus norvegicus	208-211
11687727-6	2001	The ECE inhibitor phosphoramidon was administered in a dose of 40 nmol in 50 microl of cerebrospinal fluid three times: 20 min before SAH, 60 min after SAH, and 24 hours after SAH.	phosphoramidon	18-32	endothelin converting enzyme 1	Rattus norvegicus	4-7
11561101-10	2001	Phosphoramidon (10 mg/kg), an endothelin converting enzyme inhibitor, markedly blunted U46619-induced changes on CBF and MBF (p < 0.05).	phosphoramidon	0-14	CCAAT/enhancer binding protein zeta	Rattus norvegicus	113-124
11447035-7	2001	Conversely, pretreatment of wild-type mice with the NEP inhibitor phosphoramidon exacerbated enteritis.	phosphoramidon	66-80	membrane metallo endopeptidase	Mus musculus	52-55
11337485-7	2001	Furthermore, we show that overexpression of ECE-1 in Chinese hamster ovary cells, which lack endogenous ECE activity, reduces extracellular Abeta concentration by up to 90% and that this effect is completely reversed by treatment of the cells with phosphoramidon.	phosphoramidon	248-262	endothelin-converting enzyme 1	Cricetulus griseus	44-49
11558680-6	2001	Phosphoramidon, a neutral endopeptidase inhibitor, shifted the apparent potency of ANP to values equivalent to that of BNP, suggesting these kidney cell/slices rapidly degrade ANP but not BNP.	phosphoramidon	0-14	natriuretic peptide type A	Mus musculus	83-86
11558680-6	2001	Phosphoramidon, a neutral endopeptidase inhibitor, shifted the apparent potency of ANP to values equivalent to that of BNP, suggesting these kidney cell/slices rapidly degrade ANP but not BNP.	phosphoramidon	0-14	natriuretic peptide type A	Mus musculus	176-179
11466223-7	2001	Uterine NK(2)R mRNA levels remain stable during the course of pregnancy and at Day 1 postpartum; and the contractions elicited by activating selectively the NK(2) receptor in the presence of the neutral endopeptidase inhibitor phosphoramidon (1 microM) were similar in early, mid, or late pregnancy.	phosphoramidon	227-241	tachykinin receptor 2	Rattus norvegicus	157-171
11404259-6	2001	Coincubation with phosphoramidon augmented the effect of 10(-9) and 10(-8) M bradykinin.	phosphoramidon	18-32	kininogen 1	Homo sapiens	77-87
11472982-6	2001	Addition of an ET-A receptor antagonist (BQ123) or an inhibitor of ET-1 synthesis (phosphoramidon) reduced the proliferation induced by serum, confirming an autocrine role for ET-1.	phosphoramidon	83-97	endothelin 1	Homo sapiens	67-71
11248431-2	2001	Intrastriatal administration of phosphoramidon (PRN, 5 microM), a dual inhibitor of ECE and neutral endopeptidase (NEP), significantly increased infarct volume to hypoxia with a significant attenuation of CBF(LDF).	phosphoramidon	32-46	endothelin converting enzyme 1	Rattus norvegicus	84-87
11278416-0	2001	Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases.	phosphoramidon	111-125	membrane metalloendopeptidase	Homo sapiens	0-10
11278416-1	2001	To identify the amyloid beta peptide (Abeta) 1-42-degrading enzyme whose activity is inhibited by thiorphan and phosphoramidon in vivo, we searched for neprilysin (NEP) homologues and cloned neprilysin-like peptidase (NEPLP) alpha, NEPLP beta, and NEPLP gamma cDNAs.	phosphoramidon	112-126	membrane metalloendopeptidase	Homo sapiens	164-167
11278416-2	2001	We expressed NEP, phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PEX), NEPLPs, and damage-induced neuronal endopeptidase (DINE) in 293 cells as 95- to 125-kDa proteins and found that the enzymatic activities of PEX, NEPLP alpha, and NEPLP beta, as well as those of NEP and DINE, were sensitive to thiorphan and phosphoramidon.	phosphoramidon	345-359	membrane metalloendopeptidase	Homo sapiens	13-16
11278416-5	2001	These data suggest that, among the endopeptidases whose activities are sensitive to thiorphan and phosphoramidon, NEP is the most potent Abeta-degrading enzyme in vivo.	phosphoramidon	98-112	membrane metalloendopeptidase	Homo sapiens	114-117
11459133-0	2001	Endothelium-dependent relaxation in response to low concentrations of bradykinin is enhanced by phosphoramidon, bosentan and BQ-123 in bovine coronary arteries in vitro.	phosphoramidon	96-110	kininogen 1	Bos taurus	70-80
11440542-8	2001	The level of hCG secretion from the FSK-treated cells was further enhanced when the cells were treated in the presence of the NEP inhibitor phosphoramidon.	phosphoramidon	140-154	hypertrichosis 2 (generalised, congenital)	Homo sapiens	13-16
11440542-8	2001	The level of hCG secretion from the FSK-treated cells was further enhanced when the cells were treated in the presence of the NEP inhibitor phosphoramidon.	phosphoramidon	140-154	membrane metalloendopeptidase	Homo sapiens	126-129
11438756-5	2001	The naturally derived metalloproteinase inhibitor phosphoramidon was docked in the active site of this model and comparisons with the respective NEP complex were made.	phosphoramidon	50-64	membrane metalloendopeptidase	Homo sapiens	145-148
11248431-2	2001	Intrastriatal administration of phosphoramidon (PRN, 5 microM), a dual inhibitor of ECE and neutral endopeptidase (NEP), significantly increased infarct volume to hypoxia with a significant attenuation of CBF(LDF).	phosphoramidon	32-46	membrane metallo-endopeptidase	Rattus norvegicus	92-113
11248431-2	2001	Intrastriatal administration of phosphoramidon (PRN, 5 microM), a dual inhibitor of ECE and neutral endopeptidase (NEP), significantly increased infarct volume to hypoxia with a significant attenuation of CBF(LDF).	phosphoramidon	32-46	membrane metallo-endopeptidase	Rattus norvegicus	115-118
11248431-2	2001	Intrastriatal administration of phosphoramidon (PRN, 5 microM), a dual inhibitor of ECE and neutral endopeptidase (NEP), significantly increased infarct volume to hypoxia with a significant attenuation of CBF(LDF).	phosphoramidon	32-46	CCAAT/enhancer binding protein zeta	Rattus norvegicus	205-213
11078325-1	2000	Phosphoramidon has been shown to inhibit endothelin-converting enzyme-1 (ECE-1) in a remarkably pH-dependent manner (Ahn et al.	phosphoramidon	0-14	endothelin converting enzyme 1	Homo sapiens	41-71
11099107-6	2000	PGE2 at 10(-5) M reduced the expression of ET-1 at the mRNA and protein levels but did not exert any significant modification at lower concentrations from 10(-10) to 10(6) M. Phosphoramidon, an endothelin converting enzyme (ECE) inhibitor, drastically decreased the amount of ET-1 accumulating in the culture medium in basal conditions or after UVB irradiation.	phosphoramidon	175-189	endothelin converting enzyme 1	Homo sapiens	224-227
11137456-5	2000	The endopeptidase PE, with a molecular weight of 45 kDa, was inhibited 100% by EDTA and pOHMB and resistant to PMSF, thyorphan, E64 and phosphoramidon, when we used the mentioned substrates.	phosphoramidon	136-150	prolyl endopeptidase	Homo sapiens	18-20
11223883-7	2001	NEP family members are potential therapeutic targets, for example in cardiovascular and inflammatory disorders, and potent and selective inhibitors such as phosphoramidon have contributed to understanding enzyme function.	phosphoramidon	156-170	membrane metalloendopeptidase	Homo sapiens	0-3
11223883-8	2001	Inhibitor design should be facilitated by the recent three-dimensional structural solution of the NEP-phosphoramidon complex.	phosphoramidon	102-116	membrane metalloendopeptidase	Homo sapiens	98-101
11385696-2	2001	In pig intravesical ureteral strips pretreated with phosphoramidon (10(-5) mol/L) to block the endopeptidase activities, isometric force recordings showed that SP, NKA, and the NK2 receptor selective agonist [beta-Ala(8)]-NKA (4-10), all three induced contractions, with the following potency order: NKA > [beta-Ala(8) ]-NKA (4-10) > SP.	phosphoramidon	52-66	tachykinin precursor 1	Homo sapiens	164-167
11385696-2	2001	In pig intravesical ureteral strips pretreated with phosphoramidon (10(-5) mol/L) to block the endopeptidase activities, isometric force recordings showed that SP, NKA, and the NK2 receptor selective agonist [beta-Ala(8)]-NKA (4-10), all three induced contractions, with the following potency order: NKA > [beta-Ala(8) ]-NKA (4-10) > SP.	phosphoramidon	52-66	tachykinin receptor 2	Homo sapiens	177-189
11385696-2	2001	In pig intravesical ureteral strips pretreated with phosphoramidon (10(-5) mol/L) to block the endopeptidase activities, isometric force recordings showed that SP, NKA, and the NK2 receptor selective agonist [beta-Ala(8)]-NKA (4-10), all three induced contractions, with the following potency order: NKA > [beta-Ala(8) ]-NKA (4-10) > SP.	phosphoramidon	52-66	tachykinin precursor 1	Homo sapiens	222-225
11385696-2	2001	In pig intravesical ureteral strips pretreated with phosphoramidon (10(-5) mol/L) to block the endopeptidase activities, isometric force recordings showed that SP, NKA, and the NK2 receptor selective agonist [beta-Ala(8)]-NKA (4-10), all three induced contractions, with the following potency order: NKA > [beta-Ala(8) ]-NKA (4-10) > SP.	phosphoramidon	52-66	tachykinin precursor 1	Homo sapiens	222-225
11385696-2	2001	In pig intravesical ureteral strips pretreated with phosphoramidon (10(-5) mol/L) to block the endopeptidase activities, isometric force recordings showed that SP, NKA, and the NK2 receptor selective agonist [beta-Ala(8)]-NKA (4-10), all three induced contractions, with the following potency order: NKA > [beta-Ala(8) ]-NKA (4-10) > SP.	phosphoramidon	52-66	tachykinin precursor 1	Homo sapiens	222-225
11145756-6	2000	Phosphoramidon and a specific ECE-1 inhibitor, FR901533, inhibited ECE-1 activity by over 90%.	phosphoramidon	0-14	endothelin converting enzyme 1	Homo sapiens	67-72
11078325-1	2000	Phosphoramidon has been shown to inhibit endothelin-converting enzyme-1 (ECE-1) in a remarkably pH-dependent manner (Ahn et al.	phosphoramidon	0-14	endothelin converting enzyme 1	Homo sapiens	73-78
11092533-6	2000	The NEP enzyme activity in these cell lines correlated with cell-surface protein levels and was abolished by the NEP inhibitor phosphoramidon.	phosphoramidon	127-141	membrane metalloendopeptidase	Homo sapiens	4-7
11092533-6	2000	The NEP enzyme activity in these cell lines correlated with cell-surface protein levels and was abolished by the NEP inhibitor phosphoramidon.	phosphoramidon	127-141	membrane metalloendopeptidase	Homo sapiens	113-116
11011035-6	2000	Exogenous endothelin-1 (1-100 nM) did not affect the catecholamine output responses, but it inhibited the responses under treatment with phosphoramidon and FR139317.	phosphoramidon	137-151	endothelin 1	Rattus norvegicus	10-22
11145282-2	2000	In this study using phosphoramidon, a potent inhibitor of endothelin-converting enzyme-1 (ECE-1), we investigated the influence of ET-1 on the expression of constitutive (cNOS) and inducible nitric oxide synthase (NOS-2) during gastric mucosal injury caused by indomethacin.	phosphoramidon	20-34	endothelin converting enzyme 1	Rattus norvegicus	58-88
11145282-2	2000	In this study using phosphoramidon, a potent inhibitor of endothelin-converting enzyme-1 (ECE-1), we investigated the influence of ET-1 on the expression of constitutive (cNOS) and inducible nitric oxide synthase (NOS-2) during gastric mucosal injury caused by indomethacin.	phosphoramidon	20-34	endothelin converting enzyme 1	Rattus norvegicus	90-95
11145282-6	2000	Pretreatment with phosphoramidon produced dose-dependent reduction in the extent of mucosal damage caused by indomethacin, accompanied by a significant recovery in the expression of cNOS, and a marked decline in ECE-1, epithelial cell apoptosis and the mucosal level of ET-1.	phosphoramidon	18-32	nitric oxide synthase 3	Rattus norvegicus	182-186
11145282-6	2000	Pretreatment with phosphoramidon produced dose-dependent reduction in the extent of mucosal damage caused by indomethacin, accompanied by a significant recovery in the expression of cNOS, and a marked decline in ECE-1, epithelial cell apoptosis and the mucosal level of ET-1.	phosphoramidon	18-32	endothelin converting enzyme 1	Rattus norvegicus	212-217
11145282-6	2000	Pretreatment with phosphoramidon produced dose-dependent reduction in the extent of mucosal damage caused by indomethacin, accompanied by a significant recovery in the expression of cNOS, and a marked decline in ECE-1, epithelial cell apoptosis and the mucosal level of ET-1.	phosphoramidon	18-32	endothelin 1	Rattus norvegicus	270-274
10951272-8	2000	Moreover, in the presence of phosphoramidon, a stable inhibitor of neprilysin, we observed an increased efficiency of alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone to stimulate both tyrosinase activity and microphthalmia expression.	phosphoramidon	29-43	membrane metalloendopeptidase	Homo sapiens	67-77
11005759-10	2000	Inhibition of the cell-surface protease neutral endopeptidase (NEP) by phosphoramidon potentiated the effect of exogenous SP; therefore endogenous NEP attenuates SP-induced plasma extravasation.	phosphoramidon	71-85	membrane metallo-endopeptidase	Rattus norvegicus	40-61
11005759-10	2000	Inhibition of the cell-surface protease neutral endopeptidase (NEP) by phosphoramidon potentiated the effect of exogenous SP; therefore endogenous NEP attenuates SP-induced plasma extravasation.	phosphoramidon	71-85	membrane metallo-endopeptidase	Rattus norvegicus	63-66
11121595-5	2000	The endothelin-converting enzyme (ECE) inhibitor, phosphoramidon, and endothelin type-A (ETA) receptor antagonist BQ-123 reduced expression of CD44 in VSMC.	phosphoramidon	50-64	CD44 antigen	Mus musculus	143-147
11121595-6	2000	ET-1 reversed the reduction of CD44 expression by phosphoramidon.	phosphoramidon	50-64	endothelin 1	Mus musculus	0-4
11121595-6	2000	ET-1 reversed the reduction of CD44 expression by phosphoramidon.	phosphoramidon	50-64	CD44 antigen	Mus musculus	31-35
11121595-10	2000	ET-1 reversed the suppression of oHA-induced proliferation by phosphoramidon.	phosphoramidon	62-76	endothelin 1	Mus musculus	0-4
11016327-9	2000	CONCLUSIONS: In the present study phosphoramidon potentiated the effect of BK in the absence of nitric oxide and prostaglandins in porcine-isolated coronary artery.	phosphoramidon	34-48	kininogen 1	Homo sapiens	75-77
10951272-8	2000	Moreover, in the presence of phosphoramidon, a stable inhibitor of neprilysin, we observed an increased efficiency of alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone to stimulate both tyrosinase activity and microphthalmia expression.	phosphoramidon	29-43	tyrosinase	Homo sapiens	205-215
10640916-8	1999	Pretreatment with phosphoramidon, an NEP inhibitor, also enhanced SP- and ET-1-induced bronchoconstriction.	phosphoramidon	18-32	endothelin-1	Cavia porcellus	74-78
10894105-11	2000	Neurokinin A contractility in the presence of phosphoramidon indicated that the enhanced contractility following cytokine exposure was not due to a reduction in endogenous neutral endopeptidase activity.	phosphoramidon	46-60	tachykinin precursor 1	Homo sapiens	0-12
10799294-3	2000	The mucosal activity of ECE-1, characterized by sensitivity to phosphoramidon, was associated with microsomal fraction and showed an elevated (3.1-fold) level in the alcohol diet group.	phosphoramidon	63-77	endothelin converting enzyme 1	Rattus norvegicus	24-29
10803579-6	2000	The addition of the NEP enzyme inhibitor phosphoramidon to PC3 and LNCaP-OM1 or the NEP competitive inhibitor CGS 24592 to LNCaP-OM1 blocked the increase in NEP enzyme activity and reversed the DHT-induced growth inhibition.	phosphoramidon	41-55	proprotein convertase subtilisin/kexin type 1	Homo sapiens	59-62
10749759-10	2000	In addition, L1 cells showed greater ECE-1 activity than L2 cells, and in both, the activity was sensitive to the metalloprotease inhibitor phosphoramidon.	phosphoramidon	140-154	endothelin-converting enzyme 1	Ovis aries	37-42
10720586-9	2000	Finally, systemically administered big ET-1, but not big ET-2, induced a phosphoramidon-sensitive increase in plasma IR-ET.	phosphoramidon	73-87	endothelin-1	Oryctolagus cuniculus	39-43
10704724-5	2000	With the putative ECE inhibitor phosphoramidon (10(-3) M) in the bath a small rightwards shift of the CEC for big ET-1 was observed in control segments and a more marked one in de-endothelialized segments.	phosphoramidon	32-46	endothelin converting enzyme 1	Rattus norvegicus	18-21
10704724-5	2000	With the putative ECE inhibitor phosphoramidon (10(-3) M) in the bath a small rightwards shift of the CEC for big ET-1 was observed in control segments and a more marked one in de-endothelialized segments.	phosphoramidon	32-46	endothelin 1	Rattus norvegicus	114-118
10749671-7	2000	The recombinant enzyme exhibited neprilysin-like peptidase activity and was efficiently inhibited by phosphoramidon and thiorphan, two inhibitors of neprilysin.	phosphoramidon	101-115	membrane metallo-endopeptidase-like 1	Mus musculus	33-58
10749671-7	2000	The recombinant enzyme exhibited neprilysin-like peptidase activity and was efficiently inhibited by phosphoramidon and thiorphan, two inhibitors of neprilysin.	phosphoramidon	101-115	membrane metallo endopeptidase	Mus musculus	33-43
10750028-3	2000	Synthesis of ET-2 by ACHN cells was inhibited by phosphoramidon (IC(50( congruent with11 microM).	phosphoramidon	49-63	endothelin 2	Homo sapiens	13-17
10669592-0	2000	Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon.	phosphoramidon	69-83	membrane metalloendopeptidase	Homo sapiens	42-52
10669592-4	2000	Here we describe the crystal structure of the extracellular domain (residues 52-749) of human NEP complexed with the generic metalloproteinase inhibitor phosphoramidon at 2.1 A resolution.	phosphoramidon	153-167	membrane metalloendopeptidase	Homo sapiens	94-97
10672972-5	2000	In other experiments, nitrous oxide antinociception was significantly enhanced by 30-min pretreatment with phosphoramidon, an inhibitor of endopeptidase 24.11, which has been implicated in DYN degradation, but not bestatin or captopril, which inhibit aminopeptidase and angiotensin-converting enzyme, respectively.	phosphoramidon	107-121	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	270-299
10694217-6	2000	Phosphoramidon (10 microM) also produced an inhibition of the response to big ET-1 that was equivalent to that produced by CGS 26393 (10 microM).	phosphoramidon	0-14	endothelin 1	Homo sapiens	78-82
10401760-2	1999	We, therefore, tested whether inhibition of ET-1-converting enzyme by phosphoramidon (PA) would attenuate rejection in a rat model of chronic cardiac allograft rejection (Lewis [LEW] to F344).	phosphoramidon	70-84	endothelin 1	Rattus norvegicus	44-48
10571076-7	1999	The purified enzyme was strongly inhibited by phosphoramidon, and converted big endothelin-1 to endothelin-1.	phosphoramidon	46-60	endothelin 1	Homo sapiens	80-92
10571076-7	1999	The purified enzyme was strongly inhibited by phosphoramidon, and converted big endothelin-1 to endothelin-1.	phosphoramidon	46-60	endothelin 1	Homo sapiens	96-108
10455291-4	1999	Increases in [Ca2+]i caused by ET-1(1-31), big ET-1 and ET-2(1-31) were completely inhibited by 10(-4)M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10(-5)M thiorphan, a NEP inhibitor.	phosphoramidon	104-118	endothelin 1	Homo sapiens	31-35
10455291-4	1999	Increases in [Ca2+]i caused by ET-1(1-31), big ET-1 and ET-2(1-31) were completely inhibited by 10(-4)M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10(-5)M thiorphan, a NEP inhibitor.	phosphoramidon	104-118	endothelin 1	Homo sapiens	47-51
10455291-4	1999	Increases in [Ca2+]i caused by ET-1(1-31), big ET-1 and ET-2(1-31) were completely inhibited by 10(-4)M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10(-5)M thiorphan, a NEP inhibitor.	phosphoramidon	104-118	endothelin 2	Homo sapiens	56-60
10455291-4	1999	Increases in [Ca2+]i caused by ET-1(1-31), big ET-1 and ET-2(1-31) were completely inhibited by 10(-4)M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10(-5)M thiorphan, a NEP inhibitor.	phosphoramidon	104-118	membrane metalloendopeptidase	Homo sapiens	150-153
10455291-4	1999	Increases in [Ca2+]i caused by ET-1(1-31), big ET-1 and ET-2(1-31) were completely inhibited by 10(-4)M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10(-5)M thiorphan, a NEP inhibitor.	phosphoramidon	104-118	endothelin converting enzyme 1	Homo sapiens	185-188
10455291-4	1999	Increases in [Ca2+]i caused by ET-1(1-31), big ET-1 and ET-2(1-31) were completely inhibited by 10(-4)M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10(-5)M thiorphan, a NEP inhibitor.	phosphoramidon	104-118	membrane metalloendopeptidase	Homo sapiens	226-229
10542292-8	1999	This activity of SEP was inhibited by phosphoramidon and the neutral endopeptidase 24.11 specific inhibitor thiorphan, but it was only partially inhibited by the endothelin-converting enzyme specific inhibitor FR901533.	phosphoramidon	38-52	membrane metallo-endopeptidase-like 1	Mus musculus	17-20
10352425-4	1999	In the rat proximal tubule, phosphoramidon and thiorphan inhibited NEP activity, with IC50 values of 26.6 +/- 6.0 and 6.9 +/- 1.6 nmol/l, respectively.	phosphoramidon	28-42	membrane metallo-endopeptidase	Rattus norvegicus	67-70
10401760-2	1999	We, therefore, tested whether inhibition of ET-1-converting enzyme by phosphoramidon (PA) would attenuate rejection in a rat model of chronic cardiac allograft rejection (Lewis [LEW] to F344).	phosphoramidon	86-88	endothelin 1	Rattus norvegicus	44-48
10401760-4	1999	Plasma ET-1 levels in Fisher 344 (F344) recipients were 0.8+/-0.1 pg/ml in water-treated rats and 0.2+/-0.2 pg/ml (P<0.01) in PA-treated rats, demonstrating that the PA treatment protocol effectively lowered ET-1 biosynthesis.	phosphoramidon	129-131	endothelin 1	Rattus norvegicus	7-11
10401760-4	1999	Plasma ET-1 levels in Fisher 344 (F344) recipients were 0.8+/-0.1 pg/ml in water-treated rats and 0.2+/-0.2 pg/ml (P<0.01) in PA-treated rats, demonstrating that the PA treatment protocol effectively lowered ET-1 biosynthesis.	phosphoramidon	169-171	endothelin 1	Rattus norvegicus	7-11
10401760-6	1999	Inhibition of ET-1 secretion by PA improved allograft survival to 28.8+/-3.3 days (P<0.01, n=8).	phosphoramidon	32-34	endothelin 1	Rattus norvegicus	14-18
10352019-5	1999	Northern blot analysis showed that ECE-1 (and not ECE-2) is specifically expressed in Sertoli cells; competitive enzyme immunoassay of ET production showed that Sertoli cell monolayers are capable of cleaving big ET-1, an activity inhibited by the ECE inhibitor phosphoramidon.	phosphoramidon	262-276	endothelin converting enzyme 1	Homo sapiens	35-38
10222335-4	1999	ECE-1 and ECE-2 can be differentiated by pH dependence for optimal activity and by sensitivity to phosphoramidon, which shows selectivity for ECE-2 over ECE-1 and PD159790, a novel ECE-1 selective inhibitor.	phosphoramidon	98-112	endothelin converting enzyme 1	Homo sapiens	0-5
10352019-5	1999	Northern blot analysis showed that ECE-1 (and not ECE-2) is specifically expressed in Sertoli cells; competitive enzyme immunoassay of ET production showed that Sertoli cell monolayers are capable of cleaving big ET-1, an activity inhibited by the ECE inhibitor phosphoramidon.	phosphoramidon	262-276	endothelin converting enzyme 1	Homo sapiens	35-40
10341317-13	1999	Phosphoramidon and 1,10-phenanthroline dose-dependently inhibited shedding of the IL-4R, even in nonactivated T cells.	phosphoramidon	0-14	interleukin 4 receptor	Homo sapiens	82-87
10217651-7	1999	Phosphoramidon-sensitive ECE activity and immunodetectable amounts of ECE protein in left ventricular membrane preparations did not differ between NF and DCM hearts.	phosphoramidon	0-14	endothelin converting enzyme 1	Homo sapiens	25-28
10228105-7	1999	Inhalation of peptidase inhibitors (phosphoramidon plus captopril) potentiated the effect of both hIL-17 and rIL-1beta.	phosphoramidon	36-50	interleukin 17A	Homo sapiens	98-104
10228105-7	1999	Inhalation of peptidase inhibitors (phosphoramidon plus captopril) potentiated the effect of both hIL-17 and rIL-1beta.	phosphoramidon	36-50	interleukin 1 beta	Rattus norvegicus	109-118
10228105-8	1999	Inhalation of a neutral endopeptidase inhibitor (phosphoramidon) alone also increased the neutrophil count for hIL-17, whereas an angiotensin-converting enzyme inhibitor (captopril) alone did not.	phosphoramidon	49-63	interleukin 17A	Homo sapiens	111-117
10215677-9	1999	The peptidase inhibitor phosphoramidon increased in a dose-related manner the plasma steady-state level of hBNP 1.7 +/- 0.4-fold during continuous i.v.	phosphoramidon	24-38	natriuretic peptide B	Homo sapiens	107-111
10220569-5	1999	This cytokine-stimulated release of ET-1 was inhibited by a series of dual endothelin-converting enzyme (ECE)/neutral endopeptidase inhibitors, phosphoramidon, CGS 26303, and CGS 26393, with an accompanying increase in big ET-1 release but with no effect on expression of mRNA for prepro-ET-1.	phosphoramidon	144-158	endothelin 1	Homo sapiens	36-40
10222335-4	1999	ECE-1 and ECE-2 can be differentiated by pH dependence for optimal activity and by sensitivity to phosphoramidon, which shows selectivity for ECE-2 over ECE-1 and PD159790, a novel ECE-1 selective inhibitor.	phosphoramidon	98-112	endothelin converting enzyme 2	Homo sapiens	10-15
10222335-4	1999	ECE-1 and ECE-2 can be differentiated by pH dependence for optimal activity and by sensitivity to phosphoramidon, which shows selectivity for ECE-2 over ECE-1 and PD159790, a novel ECE-1 selective inhibitor.	phosphoramidon	98-112	endothelin converting enzyme 2	Homo sapiens	142-147
10222335-4	1999	ECE-1 and ECE-2 can be differentiated by pH dependence for optimal activity and by sensitivity to phosphoramidon, which shows selectivity for ECE-2 over ECE-1 and PD159790, a novel ECE-1 selective inhibitor.	phosphoramidon	98-112	endothelin converting enzyme 1	Homo sapiens	153-158
10222335-4	1999	ECE-1 and ECE-2 can be differentiated by pH dependence for optimal activity and by sensitivity to phosphoramidon, which shows selectivity for ECE-2 over ECE-1 and PD159790, a novel ECE-1 selective inhibitor.	phosphoramidon	98-112	endothelin converting enzyme 1	Homo sapiens	153-158
10222335-6	1999	At pH 6.9, conversion of big ET-1 was inhibited markedly by 30 micromol/L PD159790 and by 100 micromol/L phosphoramidon but not by 0.1 micromol/L phosphoramidon.	phosphoramidon	105-119	endothelin 1	Homo sapiens	29-33
10222335-7	1999	In contrast, ECE activity was unaffected by 30 micromol/L PD159790 but was inhibited markedly by 0.1 and 100 micromol/L phosphoramidon at pH 5.	phosphoramidon	120-134	endothelin converting enzyme 1	Homo sapiens	13-16
10190051-2	1999	ET-1-immunoreactivity (ET-IR) was detected in the epithelial and smooth muscle layers of tracheal sections from normal guinea pigs and it was enhanced slightly by phosphoramidon (1 microM) treatment.	phosphoramidon	163-177	endothelin-1	Cavia porcellus	0-4
10334507-3	1999	The cGMP formation stimulated by ANP in LLC-PK1 cells was significantly decreased by pre-treatment of the peptide with rat renal brush-border membranes, and the inactivation of ANP was inhibited by neutral endopeptidase inhibitors, phosphoramidon and S-thiorphan.	phosphoramidon	232-246	natriuretic peptides A	Sus scrofa	33-36
10334507-3	1999	The cGMP formation stimulated by ANP in LLC-PK1 cells was significantly decreased by pre-treatment of the peptide with rat renal brush-border membranes, and the inactivation of ANP was inhibited by neutral endopeptidase inhibitors, phosphoramidon and S-thiorphan.	phosphoramidon	232-246	natriuretic peptide A	Rattus norvegicus	177-180
10334507-5	1999	In addition, phosphoramidon potentiated the natriuresis with a low dose (7.5 pmol min(-1) kg(-1)) of ANP but not of BNP in rats.	phosphoramidon	13-27	natriuretic peptide A	Rattus norvegicus	101-104
9888460-5	1999	In vitro stimulation of T47D cell growth by bombesin (BN) was enhanced to 138% of control levels (bombesin alone) by the addition of the selective endopeptidase EC 3.4.24.11 inhibitor phosphoramidon (0.1 ng ml(-1)).	phosphoramidon	184-198	gastrin releasing peptide	Homo sapiens	98-106
9878818-9	1999	Furthermore, morphine, in a dose-dependent manner, increased the hemolymph levels of alpha-MSH and ACTH (1-39) in a naloxone and phosphoramidon antagonizable manner, indicating a neutral endopeptidase (24.11; NEP) mediated cleavage.	phosphoramidon	129-143	proopiomelanocortin	Homo sapiens	99-103
10070497-7	1998	Naloxone (mu-opioid receptor antagonist) (4.82 +/- 1.02 nmol/mg protein) and phosphoramidon (NEP inhibitor) (4.66 +/- 1.00 nmol/mg protein) inhibited morphine-activated NEP, whereas glibenclamide (ATP-sensitive potassium channel antagonist) and chelerythrine (protein kinase C inhibitor) had no effects.	phosphoramidon	77-91	membrane metallo-endopeptidase	Rattus norvegicus	93-96
9888460-5	1999	In vitro stimulation of T47D cell growth by bombesin (BN) was enhanced to 138% of control levels (bombesin alone) by the addition of the selective endopeptidase EC 3.4.24.11 inhibitor phosphoramidon (0.1 ng ml(-1)).	phosphoramidon	184-198	gastrin releasing peptide	Homo sapiens	44-52
9888460-5	1999	In vitro stimulation of T47D cell growth by bombesin (BN) was enhanced to 138% of control levels (bombesin alone) by the addition of the selective endopeptidase EC 3.4.24.11 inhibitor phosphoramidon (0.1 ng ml(-1)).	phosphoramidon	184-198	gastrin releasing peptide	Homo sapiens	54-56
10070497-7	1998	Naloxone (mu-opioid receptor antagonist) (4.82 +/- 1.02 nmol/mg protein) and phosphoramidon (NEP inhibitor) (4.66 +/- 1.00 nmol/mg protein) inhibited morphine-activated NEP, whereas glibenclamide (ATP-sensitive potassium channel antagonist) and chelerythrine (protein kinase C inhibitor) had no effects.	phosphoramidon	77-91	membrane metallo-endopeptidase	Rattus norvegicus	169-172
10374426-12	1998	L-NMA and phosphoramidon obviously reduced the plasma levels of NO and ET-1 to below their respective baseline levels, and showed transient effect of increase on blood pressure.	phosphoramidon	10-24	endothelin-1	Oryctolagus cuniculus	71-75
9676729-2	1998	First, by amplifying endothelin B receptor numbers through the use of phosphoramidon and intact cell-binding techniques, we demonstrated the presence of these receptors in human umbilical vein endothelial cells (100% endothelin B receptors), human aortic smooth-muscle cells (22% endothelin B, 78% endothelin A receptors), and human bronchial smooth-muscle cells (55% endothelin B, 45% endothelin A receptors) by using [125I]-endothelin-1 radioligand binding.	phosphoramidon	70-84	endothelin receptor type B	Homo sapiens	21-42
9515580-6	1998	However phosphoramidon (100 microM), an inhibitor of ECE and NEP, almost abolished specific binding, indicating that both NEP and ECE cleave big ET-1 in the kidney.	phosphoramidon	8-22	endothelin converting enzyme 1	Homo sapiens	53-56
9515580-6	1998	However phosphoramidon (100 microM), an inhibitor of ECE and NEP, almost abolished specific binding, indicating that both NEP and ECE cleave big ET-1 in the kidney.	phosphoramidon	8-22	membrane metalloendopeptidase	Homo sapiens	61-64
9515580-6	1998	However phosphoramidon (100 microM), an inhibitor of ECE and NEP, almost abolished specific binding, indicating that both NEP and ECE cleave big ET-1 in the kidney.	phosphoramidon	8-22	membrane metalloendopeptidase	Homo sapiens	122-125
9515580-6	1998	However phosphoramidon (100 microM), an inhibitor of ECE and NEP, almost abolished specific binding, indicating that both NEP and ECE cleave big ET-1 in the kidney.	phosphoramidon	8-22	endothelin converting enzyme 1	Homo sapiens	130-133
9515580-6	1998	However phosphoramidon (100 microM), an inhibitor of ECE and NEP, almost abolished specific binding, indicating that both NEP and ECE cleave big ET-1 in the kidney.	phosphoramidon	8-22	endothelin 1	Homo sapiens	145-149
9543242-4	1998	Phosphoramidon enhanced the contractile response to neurokinin A and substance P, but not to neuropeptide gamma, [Sar9, Met(O2)11]substance P or senktide.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	52-64
9484239-3	1998	The release of the amyloid precursor protein from both SH-SY5Y and IMR-32 neuronal cells by alpha-secretase was blocked by batimastat and other related synthetic hydroxamic acid-based zinc metalloprotease inhibitors, but not by the structurally unrelated zinc metalloprotease inhibitors enalaprilat and phosphoramidon.	phosphoramidon	303-317	amyloid beta precursor protein	Homo sapiens	19-44
9537830-6	1998	The half-life of TNF-alpha induced membrane-associated ICAM-1 on rat astrocytes is approximately 5 h. The proteolytic cleavage process for the conversion of membrane-associated ICAM-1 to sICAM-1 was sensitive to Batimastat (BB94) and phosphoramidon, two inhibitors of metalloproteases, whereas inhibitors of serine-, cysteine-, aspartic-, and chymotrypsin-like proteases had no effect on this process.	phosphoramidon	234-248	tumor necrosis factor	Rattus norvegicus	17-26
9537830-6	1998	The half-life of TNF-alpha induced membrane-associated ICAM-1 on rat astrocytes is approximately 5 h. The proteolytic cleavage process for the conversion of membrane-associated ICAM-1 to sICAM-1 was sensitive to Batimastat (BB94) and phosphoramidon, two inhibitors of metalloproteases, whereas inhibitors of serine-, cysteine-, aspartic-, and chymotrypsin-like proteases had no effect on this process.	phosphoramidon	234-248	intercellular adhesion molecule 1	Rattus norvegicus	55-61
9537830-6	1998	The half-life of TNF-alpha induced membrane-associated ICAM-1 on rat astrocytes is approximately 5 h. The proteolytic cleavage process for the conversion of membrane-associated ICAM-1 to sICAM-1 was sensitive to Batimastat (BB94) and phosphoramidon, two inhibitors of metalloproteases, whereas inhibitors of serine-, cysteine-, aspartic-, and chymotrypsin-like proteases had no effect on this process.	phosphoramidon	234-248	intercellular adhesion molecule 1	Rattus norvegicus	177-183
9543242-4	1998	Phosphoramidon enhanced the contractile response to neurokinin A and substance P, but not to neuropeptide gamma, [Sar9, Met(O2)11]substance P or senktide.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	69-80
9473154-4	1998	RESULTS: The artery membranes hydrolysed bigET-1 to ET-1 through a partly phosphoramidon-sensitive pathway.	phosphoramidon	74-88	endothelin 1	Homo sapiens	44-48
9533826-7	1998	Pre-treatment with phosphoramidon (1 micron) an ECE-inhibitor, followed by TNF-alpha stimulation, decreased ir-ET-1 levels.	phosphoramidon	19-33	endothelin converting enzyme 1	Homo sapiens	48-51
9533826-7	1998	Pre-treatment with phosphoramidon (1 micron) an ECE-inhibitor, followed by TNF-alpha stimulation, decreased ir-ET-1 levels.	phosphoramidon	19-33	tumor necrosis factor	Homo sapiens	75-84
9533826-7	1998	Pre-treatment with phosphoramidon (1 micron) an ECE-inhibitor, followed by TNF-alpha stimulation, decreased ir-ET-1 levels.	phosphoramidon	19-33	endothelin 1	Homo sapiens	111-115
9473154-6	1998	Phosphoramidon decreased pEC50% for bigET-1-evoked contractions (p < 0.05; n = 8), without affecting the response to ET-1.	phosphoramidon	0-14	endothelin 1	Homo sapiens	39-43
9472729-2	1998	Although both phosphoramidon and thiorphan are metalloprotease inhibitors, the ECE activity is inhibited by phosphoramidon but not by thiorphan, a specific inhibitor of NEP.	phosphoramidon	14-28	endothelin converting enzyme 1	Rattus norvegicus	79-82
9595383-7	1998	In contrast, conversion of big ET-3 (10 nM) under the same conditions was not detected in either intact or permeabilized cells after 2 h. Big ET-3 and big ET-1 were converted by a phosphoramidon-sensitive/thiorphan-insensitive enzyme on the surface of confluent cultures of human umbilical vein smooth-muscle cells, with concentrations of the corresponding mature peptides increasing by 99.5 +/- 14.5 pM and 222.2 +/- 11.6 pM, respectively.	phosphoramidon	180-194	endothelin 3	Homo sapiens	31-35
9595383-7	1998	In contrast, conversion of big ET-3 (10 nM) under the same conditions was not detected in either intact or permeabilized cells after 2 h. Big ET-3 and big ET-1 were converted by a phosphoramidon-sensitive/thiorphan-insensitive enzyme on the surface of confluent cultures of human umbilical vein smooth-muscle cells, with concentrations of the corresponding mature peptides increasing by 99.5 +/- 14.5 pM and 222.2 +/- 11.6 pM, respectively.	phosphoramidon	180-194	endothelin 3	Homo sapiens	142-146
9595383-7	1998	In contrast, conversion of big ET-3 (10 nM) under the same conditions was not detected in either intact or permeabilized cells after 2 h. Big ET-3 and big ET-1 were converted by a phosphoramidon-sensitive/thiorphan-insensitive enzyme on the surface of confluent cultures of human umbilical vein smooth-muscle cells, with concentrations of the corresponding mature peptides increasing by 99.5 +/- 14.5 pM and 222.2 +/- 11.6 pM, respectively.	phosphoramidon	180-194	endothelin 1	Homo sapiens	155-159
9595388-6	1998	Phosphoramidon inhibited the wild-type ECE-1 with an IC50 of 1.5 microM, but it was about sixfold weaker for the C412S mutant.	phosphoramidon	0-14	endothelin converting enzyme 1	Rattus norvegicus	39-44
9595528-5	1998	Membrane ECE activity was phosphoramidon-sensitive, in contrast to the cytosolic activity capable of producing ET-1 from big ET-1.	phosphoramidon	26-40	endothelin converting enzyme 1	Homo sapiens	9-12
9595400-8	1998	Furthermore, phosphoramidon attenuated human big ET-1-induced contractions only in the umbilical artery and not in the vein.	phosphoramidon	13-27	endothelin 1	Homo sapiens	49-53
9595400-9	1998	Such observations, in terms of substrate selectivity and phosphoramidon sensitivity, suggest the presence of distinct ECE activities in human vein and arteries.	phosphoramidon	57-71	endothelin converting enzyme 1	Homo sapiens	118-121
9595402-5	1998	In the presence of phosphoramidon (10(-4) M in segments with an intact endothelium or 5 x 10(-4) M in de-endothelialized segments), there was only a small shift to the right of the concentration-effect curve for big ET-1.	phosphoramidon	19-33	endothelin 1	Rattus norvegicus	216-220
9472729-2	1998	Although both phosphoramidon and thiorphan are metalloprotease inhibitors, the ECE activity is inhibited by phosphoramidon but not by thiorphan, a specific inhibitor of NEP.	phosphoramidon	108-122	endothelin converting enzyme 1	Rattus norvegicus	79-82
9472729-4	1998	Phosphoramidon significantly decreased ET-1 levels, causing a concomitant big ET-1 increase and dose-dependently attenuated indomethacin-induced gastric mucosal damage.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	39-43
9472729-4	1998	Phosphoramidon significantly decreased ET-1 levels, causing a concomitant big ET-1 increase and dose-dependently attenuated indomethacin-induced gastric mucosal damage.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	78-82
9533650-4	1998	Peptidase inhibition by captopril and phosphoramidon increased the relaxant effect and duration of action for original VIP but not for the VIP analog.	phosphoramidon	38-52	VIP peptides	Cavia porcellus	119-122
9422810-18	1997	Big ET-1 was also unaffected by thiorphan but antagonized in a concentration-dependent manner by phosphoramidon (10(-5) M and 10(-4) M).	phosphoramidon	97-111	endothelin 1	Homo sapiens	4-8
9493857-6	1998	Phosphoramidon inhibited the metabolism of NT by LNCaP cells.	phosphoramidon	0-14	neurotensin	Homo sapiens	43-45
9537817-7	1997	Transforming growth factor-beta1 (TGF-beta1) (40 pM) also significantly enhanced the pressor responses to norepinephrine (10(-6) M) and this enhancement was significantly inhibited by phosphoramidon.	phosphoramidon	184-198	transforming growth factor, beta 1	Rattus norvegicus	0-32
9537817-7	1997	Transforming growth factor-beta1 (TGF-beta1) (40 pM) also significantly enhanced the pressor responses to norepinephrine (10(-6) M) and this enhancement was significantly inhibited by phosphoramidon.	phosphoramidon	184-198	transforming growth factor, beta 1	Rattus norvegicus	34-43
9422810-23	1997	To conclude we have demonstrated the presence of a phosphoramidon-sensitive ECE on the smooth muscle layer of the human umbilical vein which can convert big ET-1, big ET-2(1-37), big ET-2(1-38) and big ET-3 to their mature biologically active forms.	phosphoramidon	51-65	endothelin converting enzyme 1	Homo sapiens	76-79
9422810-23	1997	To conclude we have demonstrated the presence of a phosphoramidon-sensitive ECE on the smooth muscle layer of the human umbilical vein which can convert big ET-1, big ET-2(1-37), big ET-2(1-38) and big ET-3 to their mature biologically active forms.	phosphoramidon	51-65	endothelin 1	Homo sapiens	157-161
9422810-23	1997	To conclude we have demonstrated the presence of a phosphoramidon-sensitive ECE on the smooth muscle layer of the human umbilical vein which can convert big ET-1, big ET-2(1-37), big ET-2(1-38) and big ET-3 to their mature biologically active forms.	phosphoramidon	51-65	endothelin 2	Homo sapiens	167-171
9422810-23	1997	To conclude we have demonstrated the presence of a phosphoramidon-sensitive ECE on the smooth muscle layer of the human umbilical vein which can convert big ET-1, big ET-2(1-37), big ET-2(1-38) and big ET-3 to their mature biologically active forms.	phosphoramidon	51-65	endothelin 2	Homo sapiens	183-187
9422810-23	1997	To conclude we have demonstrated the presence of a phosphoramidon-sensitive ECE on the smooth muscle layer of the human umbilical vein which can convert big ET-1, big ET-2(1-37), big ET-2(1-38) and big ET-3 to their mature biologically active forms.	phosphoramidon	51-65	endothelin 3	Homo sapiens	202-206
9426079-0	1997	Neutral endopeptidase inhibition with inhaled phosphoramidon: no effect on bronchial responsiveness to adenosine 5"-monophosphate (AMP) in asthma.	phosphoramidon	46-60	membrane metalloendopeptidase	Homo sapiens	0-21
9401774-17	1997	However, when angiotensin-converting enzyme and neutral endopeptidase were inhibited by perindoprilat (10 microM) and phosphoramidon (1 microM), respectively, bradykinin (1 microM) significantly inhibited the S-I efflux in epithelium-intact preparations as well as in epithelium-denuded preparations.	phosphoramidon	118-132	angiotensin I converting enzyme	Rattus norvegicus	14-43
9401784-7	1997	Kininases were identified by ramiprilat, phosphoramidon, diprotin A and 2-mercaptoethanol or apstatin as specific inhibitors of ACE, neutral endopeptidase 24.11 (NEP), dipeptidylaminopeptidase IV and aminopeptidase P (APP), respectively.	phosphoramidon	41-55	angiotensin I converting enzyme	Rattus norvegicus	128-131
9401784-7	1997	Kininases were identified by ramiprilat, phosphoramidon, diprotin A and 2-mercaptoethanol or apstatin as specific inhibitors of ACE, neutral endopeptidase 24.11 (NEP), dipeptidylaminopeptidase IV and aminopeptidase P (APP), respectively.	phosphoramidon	41-55	membrane metallo-endopeptidase	Rattus norvegicus	133-160
9426079-3	1997	We have, therefore, investigated the change in bronchial reactivity to adenosine 5"-monophosphate (AMP), after treatment with inhaled phosphoramidon, a potent neutral endopeptidase (NEP) inhibitor, in a double-blind, placebo-controlled, randomized study of 12 asthmatic subjects.	phosphoramidon	134-148	membrane metalloendopeptidase	Homo sapiens	182-185
9196090-6	1997	We found that among ETs, only ET-1 was steadily released under basal conditions over 24 h. The basal production was attenuated by both phosphoramidon and CGS 26 303, dual NEP and ECE inhibitors.	phosphoramidon	135-149	endothelin 1	Homo sapiens	30-34
9357856-8	1997	ANP, BNP, and CNP (10(-9) to 10(-5) M) + phosphoramidon (10(-6) M) caused a concentration-dependent elevation in cGMP with an order of potency ANP > BNP > CNP.	phosphoramidon	41-55	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	14-17
9357856-8	1997	ANP, BNP, and CNP (10(-9) to 10(-5) M) + phosphoramidon (10(-6) M) caused a concentration-dependent elevation in cGMP with an order of potency ANP > BNP > CNP.	phosphoramidon	41-55	natriuretic peptide B	Homo sapiens	152-155
9357856-8	1997	ANP, BNP, and CNP (10(-9) to 10(-5) M) + phosphoramidon (10(-6) M) caused a concentration-dependent elevation in cGMP with an order of potency ANP > BNP > CNP.	phosphoramidon	41-55	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	161-164
9227507-11	1997	Removal of endogenous ET-1 with either phosphoramidon or BQ-123 significantly augments cytokine-stimulated NO.	phosphoramidon	39-53	endothelin 1	Rattus norvegicus	22-26
9227507-13	1997	To further test the effect of ET-1 on iNOS, we treated cells with phosphoramidon to inhibit endogenous ET-1 synthesis and then administered ET-1 (10(-9) to 10(-7) M).	phosphoramidon	66-80	endothelin 1	Rattus norvegicus	103-107
9227507-13	1997	To further test the effect of ET-1 on iNOS, we treated cells with phosphoramidon to inhibit endogenous ET-1 synthesis and then administered ET-1 (10(-9) to 10(-7) M).	phosphoramidon	66-80	endothelin 1	Rattus norvegicus	103-107
9375329-6	1997	Constriction was not affected by removing extracellular Ca2+ but was abolished after treatment with ryanodine to deplete intracellular Ca2+ stores, with the endothelin-1 synthesis inhibitor phosphoramidon, with the endothelin A-receptor antagonist BQ-123, with the protein kinase C inhibitor staurosporine, or with glutaraldehyde to reduce endothelial cell deformability.	phosphoramidon	190-204	endothelin 1	Homo sapiens	157-169
9196090-10	1997	These data suggest that ET-1 is simultaneously produced and degraded by guinea-pig tracheal epithelial cells via phosphoramidon-sensitive ECE and NEP pathways, respectively.	phosphoramidon	113-127	endothelin 1	Homo sapiens	24-28
9196090-10	1997	These data suggest that ET-1 is simultaneously produced and degraded by guinea-pig tracheal epithelial cells via phosphoramidon-sensitive ECE and NEP pathways, respectively.	phosphoramidon	113-127	membrane metalloendopeptidase	Homo sapiens	146-149
9085052-4	1997	Big-endothelin-1, but not endothelin-1 actions were inhibited by phosphoramidon.	phosphoramidon	65-79	endothelin 1	Rattus norvegicus	4-16
8994440-6	1997	The size of the neointima was effectively reduced by phosphoramidon, an inhibitor of neutral metalloproteases, including ECE-1.	phosphoramidon	53-67	endothelin converting enzyme 1	Homo sapiens	121-126
9051300-2	1997	An obligatory step in the biosynthesis of endothelin-1 (ET-1) is the conversion of its inactive precursor, big ET-1, into the mature form by the action of specific, phosphoramidon-sensitive, endothelin converting enzyme(s) (ECE).	phosphoramidon	165-179	endothelin 1	Rattus norvegicus	42-54
9051300-2	1997	An obligatory step in the biosynthesis of endothelin-1 (ET-1) is the conversion of its inactive precursor, big ET-1, into the mature form by the action of specific, phosphoramidon-sensitive, endothelin converting enzyme(s) (ECE).	phosphoramidon	165-179	endothelin 1	Rattus norvegicus	56-60
9051300-2	1997	An obligatory step in the biosynthesis of endothelin-1 (ET-1) is the conversion of its inactive precursor, big ET-1, into the mature form by the action of specific, phosphoramidon-sensitive, endothelin converting enzyme(s) (ECE).	phosphoramidon	165-179	endothelin 1	Rattus norvegicus	111-115
9051300-2	1997	An obligatory step in the biosynthesis of endothelin-1 (ET-1) is the conversion of its inactive precursor, big ET-1, into the mature form by the action of specific, phosphoramidon-sensitive, endothelin converting enzyme(s) (ECE).	phosphoramidon	165-179	endothelin converting enzyme 1	Rattus norvegicus	191-222
9051300-2	1997	An obligatory step in the biosynthesis of endothelin-1 (ET-1) is the conversion of its inactive precursor, big ET-1, into the mature form by the action of specific, phosphoramidon-sensitive, endothelin converting enzyme(s) (ECE).	phosphoramidon	165-179	endothelin converting enzyme 1	Rattus norvegicus	224-227
9051300-6	1997	In renal cortical slices incubated with big ET-1, pretreatment with phosphoramidon (an ECE inhibitor) reduced tissue immunoreactive ET-1 to a level similar to that of cortical tissue not exposed to big ET-1.	phosphoramidon	68-82	endothelin 1	Rattus norvegicus	44-48
9051300-6	1997	In renal cortical slices incubated with big ET-1, pretreatment with phosphoramidon (an ECE inhibitor) reduced tissue immunoreactive ET-1 to a level similar to that of cortical tissue not exposed to big ET-1.	phosphoramidon	68-82	endothelin converting enzyme 1	Rattus norvegicus	87-90
9051300-6	1997	In renal cortical slices incubated with big ET-1, pretreatment with phosphoramidon (an ECE inhibitor) reduced tissue immunoreactive ET-1 to a level similar to that of cortical tissue not exposed to big ET-1.	phosphoramidon	68-82	endothelin 1	Rattus norvegicus	132-136
9051300-6	1997	In renal cortical slices incubated with big ET-1, pretreatment with phosphoramidon (an ECE inhibitor) reduced tissue immunoreactive ET-1 to a level similar to that of cortical tissue not exposed to big ET-1.	phosphoramidon	68-82	endothelin 1	Rattus norvegicus	132-136
9051300-7	1997	This confirms the presence and effectiveness of ECE inhibition by phosphoramidon.	phosphoramidon	66-80	endothelin converting enzyme 1	Rattus norvegicus	48-51
9108624-3	1997	Inhibition of NEP by phosphoramidon (10 mg/kg, i.v.)	phosphoramidon	21-35	membrane metallo-endopeptidase	Rattus norvegicus	14-17
9094756-5	1997	Through a partly phosphoramidon-sensitive enzymatic activity, endothelin-1 (ET-1) was formed independently of bigET1-31.	phosphoramidon	17-31	endothelin 1	Homo sapiens	62-74
9094756-5	1997	Through a partly phosphoramidon-sensitive enzymatic activity, endothelin-1 (ET-1) was formed independently of bigET1-31.	phosphoramidon	17-31	endothelin 1	Homo sapiens	76-80
9085052-8	1997	These results indicate that the pharmacological responses to big-endothelin-1 in aortic endothelial cells are due to the extracellular phosphoramidon-sensitive conversion to endothelin-1.	phosphoramidon	135-149	endothelin 1	Rattus norvegicus	65-77
9085052-8	1997	These results indicate that the pharmacological responses to big-endothelin-1 in aortic endothelial cells are due to the extracellular phosphoramidon-sensitive conversion to endothelin-1.	phosphoramidon	135-149	endothelin 1	Rattus norvegicus	174-186
9110381-3	1997	Treatment of Clara cells with 1 mM phosphoramidon strongly suppressed (80%) the conversion of big-ET-1 to ET-1 during 1, 2 and 6 h incubation periods.	phosphoramidon	35-49	endothelin 1	Homo sapiens	98-102
9110381-3	1997	Treatment of Clara cells with 1 mM phosphoramidon strongly suppressed (80%) the conversion of big-ET-1 to ET-1 during 1, 2 and 6 h incubation periods.	phosphoramidon	35-49	endothelin 1	Homo sapiens	106-110
9110381-6	1997	Phosphoramidon and thiorphan (1 mM) reduced the amount of ir-ET generated from exogenous human big-ET-2 (10(-8) M) by 69 and 56%, respectively.	phosphoramidon	0-14	endothelin 2	Homo sapiens	99-103
9126883-6	1997	Pre-incubation of tissue with a metalloprotease ECE inhibitor phosphoramidon (10 microM) strongly inhibited the response to big ET-1, but not to ET-1.	phosphoramidon	62-76	endothelin converting enzyme 1	Rattus norvegicus	48-51
9015192-5	1997	Finally, we found that thymopentin and to a lesser extent phosphoramidon, a specific endopeptidase 24.11 inhibitor, induced up-regulation of CD4 and CD8 molecules at the thymocyte cell surface.	phosphoramidon	58-72	CD4 molecule	Homo sapiens	141-144
9015192-5	1997	Finally, we found that thymopentin and to a lesser extent phosphoramidon, a specific endopeptidase 24.11 inhibitor, induced up-regulation of CD4 and CD8 molecules at the thymocyte cell surface.	phosphoramidon	58-72	CD8a molecule	Homo sapiens	149-152
9117086-16	1997	Degradation of [3H]-BK was not influenced by ramiprilat, but was inhibited by 85% in the presence of phosphoramidon.	phosphoramidon	101-115	kininogen 1	Bos taurus	20-22
9117086-17	1997	Phosporamidon markedly inhibited the generation of [1-7]- and [1-5]-BK and nearly abolished the formation of [1-3]- and [2-3]-BK.	phosphoramidon	0-13	kininogen 1	Bos taurus	68-70
9117086-17	1997	Phosporamidon markedly inhibited the generation of [1-7]- and [1-5]-BK and nearly abolished the formation of [1-3]- and [2-3]-BK.	phosphoramidon	0-13	kininogen 1	Bos taurus	126-128
9296343-7	1997	These results indicate that phosphoramidon-sensitive endothelin converting enzyme activity is highly present in stomach and phosphoramidon, by inhibiting the conversion of big endothelin-1 to endothelin-1 attenuated the gastric mucosal damage in this model.	phosphoramidon	28-42	endothelin 1	Rattus norvegicus	176-188
9296343-7	1997	These results indicate that phosphoramidon-sensitive endothelin converting enzyme activity is highly present in stomach and phosphoramidon, by inhibiting the conversion of big endothelin-1 to endothelin-1 attenuated the gastric mucosal damage in this model.	phosphoramidon	28-42	endothelin 1	Rattus norvegicus	192-204
9296343-7	1997	These results indicate that phosphoramidon-sensitive endothelin converting enzyme activity is highly present in stomach and phosphoramidon, by inhibiting the conversion of big endothelin-1 to endothelin-1 attenuated the gastric mucosal damage in this model.	phosphoramidon	124-138	endothelin 1	Rattus norvegicus	176-188
9296343-7	1997	These results indicate that phosphoramidon-sensitive endothelin converting enzyme activity is highly present in stomach and phosphoramidon, by inhibiting the conversion of big endothelin-1 to endothelin-1 attenuated the gastric mucosal damage in this model.	phosphoramidon	124-138	endothelin 1	Rattus norvegicus	192-204
8815887-8	1996	Using a metabolically stable analog of SP, SP (5-11), or an endopeptidase inhibitor, phosphoramidon, we were able to demonstrate that CGRP enhances the SP effect by inhibiting an SP endopeptidase.	phosphoramidon	85-99	calcitonin related polypeptide alpha	Homo sapiens	134-138
9396049-3	1997	This increased NEP-like activity is blocked by phosphoramidon, a potent inhibitor of mammalian NEP.	phosphoramidon	47-61	membrane metalloendopeptidase	Homo sapiens	15-18
9396049-3	1997	This increased NEP-like activity is blocked by phosphoramidon, a potent inhibitor of mammalian NEP.	phosphoramidon	47-61	membrane metalloendopeptidase	Homo sapiens	95-98
8933767-8	1996	Decreasing ET-1 levels by inhibiting endothelin-converting enzyme with phosphoramidon normalized retinal blood flow in diabetic rats.	phosphoramidon	71-85	endothelin 1	Rattus norvegicus	11-15
8916270-1	1996	The mechanism(s) of degradation of the potent vasoconstrictor endothelin-1 (ET-1) by rat vascular smooth muscle A-10 cells, which possess the ETA receptor subtype, was investigated by incubating [125I]ET-1 (0.1 nM) with cells for 0-4 h at 37 degrees C in the presence and absence of lysosomal enzyme inhibitors, NH4Cl and chloroquine, and a neutral endopeptidase inhibitor, phosphoramidon.	phosphoramidon	374-388	endothelin 1	Rattus norvegicus	62-74
8916270-1	1996	The mechanism(s) of degradation of the potent vasoconstrictor endothelin-1 (ET-1) by rat vascular smooth muscle A-10 cells, which possess the ETA receptor subtype, was investigated by incubating [125I]ET-1 (0.1 nM) with cells for 0-4 h at 37 degrees C in the presence and absence of lysosomal enzyme inhibitors, NH4Cl and chloroquine, and a neutral endopeptidase inhibitor, phosphoramidon.	phosphoramidon	374-388	endothelin 1	Rattus norvegicus	76-80
9018495-8	1996	In addition, unlike the transient vasodilator response to ductus arteriosus compression in control studies, ET-1 blockade with BQ-123 or phosphoramidon prolonged the increase in flow caused by ductus arteriosus compression.	phosphoramidon	137-151	EDN1	Ovis aries	108-112
8901663-5	1996	In CHF patients (n = 10), phosphoramidon (a combined ECE and neutral endopeptidase inhibitor) and BQ-123 (an ETA receptor antagonist) increased FBF by 52 +/- 10% (P = .0006) and 31 +/- 6% (P = .002), respectively, and thiorphan (a selective neutral endopeptidase inhibitor) reduced FBF by 15 +/- 5% (P = .0007).	phosphoramidon	26-40	endothelin converting enzyme 1	Homo sapiens	53-56
8912717-8	1996	The increase was preceded by an increase in uPA-R- and uPA-specific mRNA, which was not observed when the proteinase inhibitor phosphoramidon was added together with dispase.	phosphoramidon	127-141	plasminogen activator, urokinase	Homo sapiens	44-47
8912717-8	1996	The increase was preceded by an increase in uPA-R- and uPA-specific mRNA, which was not observed when the proteinase inhibitor phosphoramidon was added together with dispase.	phosphoramidon	127-141	plasminogen activator, urokinase	Homo sapiens	55-58
8938666-3	1996	The metalloprotease inhibitor phosphoramidon (30 mumol/l) almost abolished the contractile response to big ET-1, whereas the ET-1-induced contraction was unaffected.	phosphoramidon	30-44	endothelin-1	Oryctolagus cuniculus	107-111
8938666-9	1996	These results suggest that externally applied big ET-1 is converted to ET-1 by a phosphoramidon-sensitive "endothelin converting enzyme" present in the vascular smooth muscle cells.	phosphoramidon	81-95	endothelin-1	Oryctolagus cuniculus	50-54
8938666-9	1996	These results suggest that externally applied big ET-1 is converted to ET-1 by a phosphoramidon-sensitive "endothelin converting enzyme" present in the vascular smooth muscle cells.	phosphoramidon	81-95	endothelin-1	Oryctolagus cuniculus	71-75
8938667-3	1996	This latter effect was increased in rat paws by captopril, an inhibitor of angiotensin-converting enzyme (ACE), administered locally in combination with diprotin A, an inhibitor of an dipeptidyl(amino)peptidase IV (DAP IV) or phosphoramidon, an inhibitor of neutral endopeptidase (NEP).	phosphoramidon	226-240	angiotensin I converting enzyme	Rattus norvegicus	106-109
9232670-3	1996	Inhibition of NEP with phosphoramidon caused cough, which was inhibited by systemic capsaicin treatment and by aerosols of a specific NK1 receptor antagonist FK 888.	phosphoramidon	23-37	membrane metalloendopeptidase	Homo sapiens	14-17
9232670-3	1996	Inhibition of NEP with phosphoramidon caused cough, which was inhibited by systemic capsaicin treatment and by aerosols of a specific NK1 receptor antagonist FK 888.	phosphoramidon	23-37	tachykinin receptor 1	Homo sapiens	134-146
9232670-5	1996	The number of coughs induced by histamine aerosols was inhibited by systemic capsaicin treatment and enhanced by pretreatment with a NEP inhibitor phosphoramidon.	phosphoramidon	147-161	membrane metalloendopeptidase	Homo sapiens	133-136
8818353-16	1996	Pretreatment with NEP inhibitors, SCH 39370 or phosphoramidon, slowed the loss of cFP-AAY-pAB from the plasma, but did not prevent inhibition of ACE.	phosphoramidon	47-61	neprilysin	Oryctolagus cuniculus	18-21
8670289-5	1996	Endothelin converting enzyme is characteristically inhibited by phosphoramidon and other metalloproteinase inhibitors including EDTA, o-phenanthroline, and diethylpyrocarbonate, but not by inhibitors of other classes of proteases or thiorphan.	phosphoramidon	64-78	endothelin 1	Homo sapiens	0-10
8841832-13	1996	SR 140333, SR 48968, and SR 142801 blocked the enhancement by phosphoramidon of the response to SP, NKA, and NKB, respectively.	phosphoramidon	62-76	tachykinin 1	Mus musculus	96-98
8841832-13	1996	SR 140333, SR 48968, and SR 142801 blocked the enhancement by phosphoramidon of the response to SP, NKA, and NKB, respectively.	phosphoramidon	62-76	tachykinin 1	Mus musculus	100-103
8889700-4	1996	Degradation of bradykinin was strongly inhibited by phosphoramidon and thiorphan, which are specific inhibitors of neutral metalloendopeptidase-24.11.	phosphoramidon	52-66	thimet oligopeptidase 1	Rattus norvegicus	123-143
8687431-4	1996	EDTA, phosphoramidon and thiorphan inhibit the proteolysis of PAMP by NEP.	phosphoramidon	6-20	adrenomedullin	Homo sapiens	62-66
8687431-4	1996	EDTA, phosphoramidon and thiorphan inhibit the proteolysis of PAMP by NEP.	phosphoramidon	6-20	membrane metalloendopeptidase	Homo sapiens	70-73
8670289-6	1996	The inhibition by phosphoramidon is competitive with big porcine endothelin-1 suggestive of a common binding site for substrate and inhibitor.	phosphoramidon	18-32	endothelin 1	Homo sapiens	65-77
8636398-4	1996	Coincubation with UK73967 or phosphoramidon, inhibitors of NEP, potentiated all of the effects of ANP and BNP on the neutrophil functions, and the NEP inhibitors protected degradation of ANP and BNP by the neutrophils.	phosphoramidon	29-43	membrane metalloendopeptidase	Homo sapiens	59-62
8828809-2	1996	The specific ECE activity was demonstrated by a phosphoramidon dose-dependent decrease in ET-1 level with a concomitant increase in big ET-1 level.	phosphoramidon	48-62	endothelin converting enzyme 1	Homo sapiens	13-16
8828809-3	1996	By using a specific neutral endopeptidase 24.11 (NEP 24.11) inhibitor, thiorphan, it was also shown that the phosphoramidon-sensitive ET-1 degrading activity in this cell line is due to the NEP 24.11 activity.	phosphoramidon	109-123	membrane metalloendopeptidase	Homo sapiens	20-47
8828809-3	1996	By using a specific neutral endopeptidase 24.11 (NEP 24.11) inhibitor, thiorphan, it was also shown that the phosphoramidon-sensitive ET-1 degrading activity in this cell line is due to the NEP 24.11 activity.	phosphoramidon	109-123	membrane metalloendopeptidase	Homo sapiens	49-58
8828809-3	1996	By using a specific neutral endopeptidase 24.11 (NEP 24.11) inhibitor, thiorphan, it was also shown that the phosphoramidon-sensitive ET-1 degrading activity in this cell line is due to the NEP 24.11 activity.	phosphoramidon	109-123	membrane metalloendopeptidase	Homo sapiens	190-199
8636398-4	1996	Coincubation with UK73967 or phosphoramidon, inhibitors of NEP, potentiated all of the effects of ANP and BNP on the neutrophil functions, and the NEP inhibitors protected degradation of ANP and BNP by the neutrophils.	phosphoramidon	29-43	natriuretic peptide A	Homo sapiens	98-101
8636398-4	1996	Coincubation with UK73967 or phosphoramidon, inhibitors of NEP, potentiated all of the effects of ANP and BNP on the neutrophil functions, and the NEP inhibitors protected degradation of ANP and BNP by the neutrophils.	phosphoramidon	29-43	natriuretic peptide B	Homo sapiens	106-109
8636398-4	1996	Coincubation with UK73967 or phosphoramidon, inhibitors of NEP, potentiated all of the effects of ANP and BNP on the neutrophil functions, and the NEP inhibitors protected degradation of ANP and BNP by the neutrophils.	phosphoramidon	29-43	natriuretic peptide A	Homo sapiens	187-190
8636398-4	1996	Coincubation with UK73967 or phosphoramidon, inhibitors of NEP, potentiated all of the effects of ANP and BNP on the neutrophil functions, and the NEP inhibitors protected degradation of ANP and BNP by the neutrophils.	phosphoramidon	29-43	natriuretic peptide B	Homo sapiens	195-198
8834339-11	1996	Inhibition of SP destruction by phosphoramidon (10(-6) M) also eliminated the transient rise in CBF.	phosphoramidon	32-46	tachykinin precursor 1	Homo sapiens	14-16
8793593-7	1996	Furthermore, use of the specific neutral endopeptidase inhibitor, phosphoramidon, significantly increased the efficacy of alpha-MSH in inhibiting CPB-induced immunocyte activation.	phosphoramidon	66-80	proopiomelanocortin	Homo sapiens	122-131
8600940-0	1996	Guinea pig Clara cells secrete endothelin 1 through a phosphoramidon-sensitive pathway.	phosphoramidon	54-68	endothelin-1	Cavia porcellus	31-43
8796300-5	1996	Addition of phosphoramidon and thiorphan, which are specific inhibitors of neutral metalloendopeptidase 3.4.24.11 (NEP), strongly inhibited the degradation of bradykinin.	phosphoramidon	12-26	membrane metallo-endopeptidase	Rattus norvegicus	115-118
8587664-4	1995	In approximately half of the preparations, the peptidase inhibitors, phosphoramidon (1 microM) and bestatin (100 microM), caused a marked and well-maintained contraction (approximately 20% of neurokinin A maximum), which may indicate a role for endogenous tachykinins in the regulation of tone in this preparation.	phosphoramidon	69-83	tachykinin precursor 1	Homo sapiens	192-204
8992314-3	1996	The endopeptidase resembled mammalian neprilysin (NEP, endopeptidase 24.11) in that the enzyme activity was inhibited by phosphoramidon and thiorphan and that it cleaved AF1 on the amino side of phenylalanine.	phosphoramidon	121-135	membrane metalloendopeptidase	Homo sapiens	38-48
8992314-3	1996	The endopeptidase resembled mammalian neprilysin (NEP, endopeptidase 24.11) in that the enzyme activity was inhibited by phosphoramidon and thiorphan and that it cleaved AF1 on the amino side of phenylalanine.	phosphoramidon	121-135	membrane metalloendopeptidase	Homo sapiens	50-53
7595577-6	1995	Phosphoramidon, an inhibitor of neutral endopeptidase 24.11, decreased Met-enkephalin degradation in caudate-putamen (14%) but had no effect on that in frontal cortex.	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	32-59
8559593-3	1995	Phosphoramidon, thiorphan and SQ 28603, potent inhibitors of mammalian neprilysin (neutral endopeptidase, endopeptidase 24.11), inhibited the endopeptidase activity towards AKH-I with IC50 values of 0.13 microM, 22 microM and 6.3 microM, respectively.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	71-81
7490515-9	1995	Phosphoramidon (4 mg/kg, iv) pretreatment attenuated the increase in MAP and TPR induced by proET-1.	phosphoramidon	0-14	translocated promoter region, nuclear basket protein	Rattus norvegicus	77-80
7490515-14	1995	In phosphoramidon-treated rats, DCLHb increased MAP (99%), HR (25%), cardiac output (37%), and TPR (60%).	phosphoramidon	3-17	translocated promoter region, nuclear basket protein	Rattus norvegicus	95-98
7490515-17	1995	It is concluded that proET-1 increases blood flow to various organs and that phosphoramidon, an ECE inhibitor, could block the proET-1-induced increases in regional blood flow.	phosphoramidon	77-91	endothelin converting enzyme 1	Rattus norvegicus	96-99
8548322-6	1995	Besides, phosphoramidon per se markedly stimulated the expression of ET-1 mRNA.	phosphoramidon	9-23	endothelin 1	Rattus norvegicus	69-73
7561524-1	1995	Neutrophil responses to alpha-N-formyl-L-Met-L-Leu-L-Phe (fMLF) are modulated by inhibitors of surface membrane neutral endopeptidase (NEP), such as phosphoramidon (PPAD).	phosphoramidon	149-163	membrane metalloendopeptidase	Homo sapiens	135-138
7561524-1	1995	Neutrophil responses to alpha-N-formyl-L-Met-L-Leu-L-Phe (fMLF) are modulated by inhibitors of surface membrane neutral endopeptidase (NEP), such as phosphoramidon (PPAD).	phosphoramidon	165-169	membrane metalloendopeptidase	Homo sapiens	135-138
8528566-0	1995	Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.	phosphoramidon	0-14	endothelin 1	Homo sapiens	59-71
8528566-0	1995	Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.	phosphoramidon	0-14	endothelin 1	Homo sapiens	75-87
8528566-14	1995	However, IR CTF was still detected, suggesting that either some conversion by phosphoramidon-insensitive enzyme(s) was occurring, and/or that CTF was being protected from further degradation by phosphoramidon.5.	phosphoramidon	194-208	nuclear factor I C	Homo sapiens	142-145
8528566-2	1995	The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment (CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to phosphoramidon.	phosphoramidon	196-210	endothelin 1	Homo sapiens	29-41
8528566-2	1995	The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment (CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to phosphoramidon.	phosphoramidon	196-210	endothelin 1	Homo sapiens	43-47
8528566-2	1995	The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment (CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to phosphoramidon.	phosphoramidon	196-210	nuclear factor I C	Homo sapiens	77-96
8528566-2	1995	The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment (CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to phosphoramidon.	phosphoramidon	196-210	nuclear factor I C	Homo sapiens	98-101
8528566-2	1995	The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment (CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to phosphoramidon.	phosphoramidon	196-210	endothelin 1	Homo sapiens	142-146
8528566-13	1995	When phosphoramidon was co-infused with big ET-1, both the rise in IR ET and associated vasoconstriction were abolished.	phosphoramidon	5-19	endothelin 1	Homo sapiens	44-48
8538872-6	1995	Phosphoramidon (5 x 10(-6) M) potentiated the relaxant responses of epithelium-intact GPT to both PACAP and VIP but did not affect the responses of epithelium-denuded GPT.	phosphoramidon	0-14	VIP peptides	Cavia porcellus	108-111
8523455-10	1995	In the presence of the ET-1 converting enzyme inhibitor, phosphoramidon (1.7 mumol/l), ischaemia-induced increases of ET-1 secretion were attenuated, and this was accompanied by a time-dependent rise in coronary perfusion pressure up to 60% (P < 0.05).	phosphoramidon	57-71	endothelin 1	Rattus norvegicus	23-27
8523455-10	1995	In the presence of the ET-1 converting enzyme inhibitor, phosphoramidon (1.7 mumol/l), ischaemia-induced increases of ET-1 secretion were attenuated, and this was accompanied by a time-dependent rise in coronary perfusion pressure up to 60% (P < 0.05).	phosphoramidon	57-71	endothelin 1	Rattus norvegicus	118-122
7797512-7	1995	ECE-2 resembles ECE-1 in that it is inhibited in vitro by phosphoramidon and FR901533 but not by thiorphan or captopril, and it converts big ET-1 more efficiently than big ET-2 or big ET-3.	phosphoramidon	58-72	endothelin-converting enzyme 1	Cricetulus griseus	16-21
7592194-5	1995	Both phosphoramidon (NEP inhibitor) and captopril (ACE inhibitor) potentiated the increase in airway blood flow produced by SP in pathogen-free rats.	phosphoramidon	5-19	membrane metallo-endopeptidase	Rattus norvegicus	21-24
7797512-9	1995	(i) The sensitivity of ECE-2 to phosphoramidon is 250-fold higher as compared with ECE-1, while FR901533 inhibits both enzymes at similar concentrations.	phosphoramidon	32-46	EEF1A lysine methyltransferase 4	Cricetulus griseus	23-28
7797512-7	1995	ECE-2 resembles ECE-1 in that it is inhibited in vitro by phosphoramidon and FR901533 but not by thiorphan or captopril, and it converts big ET-1 more efficiently than big ET-2 or big ET-3.	phosphoramidon	58-72	EEF1A lysine methyltransferase 4	Cricetulus griseus	0-5
7473528-5	1995	Vasoconstriction to big endothelin-1 was abolished by co-infusion of phosphoramidon, whereas vasoconstriction to endothelin-1 was unaffected.	phosphoramidon	69-83	endothelin 1	Homo sapiens	24-36
7597662-0	1995	Effect of an inhaled neutral endopeptidase inhibitor, phosphoramidon, on baseline airway calibre and bronchial responsiveness to bradykinin in asthma.	phosphoramidon	54-68	membrane metalloendopeptidase	Homo sapiens	21-42
7597662-8	1995	RESULTS: Phosphoramidon administration caused a transient fall in FEV1 from baseline, FEV1 values decreasing 6.3% and 5.3% on the bradykinin and histamine study days, respectively.	phosphoramidon	9-23	kininogen 1	Homo sapiens	130-140
7891111-5	1995	The residual activity observed in the presence of the selective endopeptidase-24.11 inhibitor phosphoramidon was blocked by Pro-Ile or N-[1-(RS)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, inhibitors of endopeptidase-24.16 and endopeptidase-24.15, respectively.	phosphoramidon	94-108	neurolysin	Homo sapiens	212-231
7597662-9	1995	When compared with placebo, phosphoramidon elicited a small enhancement of the airways response to bradykinin, the geometric mean PC20 value (range) decreasing from 0.281 (0.015-5.575) to 0.136 (0.006-2.061) mg/ml.	phosphoramidon	28-42	kininogen 1	Homo sapiens	99-109
7597662-11	1995	CONCLUSIONS: The small increase in bronchial reactivity to bradykinin after phosphoramidon exposure suggests that endogenous airway NEP may play a modulatory role in the airways response to inflammatory peptides in human asthma.	phosphoramidon	76-90	kininogen 1	Homo sapiens	59-69
7597662-11	1995	CONCLUSIONS: The small increase in bronchial reactivity to bradykinin after phosphoramidon exposure suggests that endogenous airway NEP may play a modulatory role in the airways response to inflammatory peptides in human asthma.	phosphoramidon	76-90	membrane metalloendopeptidase	Homo sapiens	132-135
7606343-23	1995	In conclusion, urodilatin, like ANP reversed and protected against, subsequent methacholine-induced bronchoconstriction; an action enhanced by the presence of phosphoramidon (3.68 x 1O-5 M).Associated with these actions of urodilatin was a rise in cyclic GMP levels as well as the opening of ATP-sensitive K+ and small conductance Ca2+-activated K+ channels.	phosphoramidon	159-173	natriuretic peptide A	Bos taurus	32-35
7599928-0	1995	Differential effects of phosphoramidon on contractile responses to angiotensin II in rat blood vessels.	phosphoramidon	24-38	angiotensinogen	Rattus norvegicus	67-81
7599928-6	1995	Phosphoramidon blocked the responses to AII in a concentration-dependent manner, whereas even very high concentrations of phosphoramidon (100 microM) failed to affect the tension responses evoked by ET-1 and AVP in all three preparations.	phosphoramidon	0-14	angiotensinogen	Rattus norvegicus	40-43
7599928-7	1995	Low concentrations of phosphoramidon (10 microM) produced significant increases in EC50 values for AII in tail artery (P < 0.01) and mesenteric artery (P < 0.05) but not in aorta.	phosphoramidon	22-36	angiotensinogen	Rattus norvegicus	99-102
7599928-9	1995	Phosphoramidon-evoked rightward shifts in the C-R curves to AII were much higher than those to big ET-1 in both mesenteric artery and tail artery.	phosphoramidon	0-14	angiotensinogen	Rattus norvegicus	60-63
7599928-14	1995	It is concluded that the vasoconstrictor responses to AII in mesenteric artery and tail artery may be mediated by the release of endothelins from the endothelium by increased formation from big ET, an effect that is blocked by phosphoramidon.	phosphoramidon	227-241	angiotensinogen	Rattus norvegicus	54-57
7599928-14	1995	It is concluded that the vasoconstrictor responses to AII in mesenteric artery and tail artery may be mediated by the release of endothelins from the endothelium by increased formation from big ET, an effect that is blocked by phosphoramidon.	phosphoramidon	227-241	endothelin 1	Rattus norvegicus	129-140
7891111-5	1995	The residual activity observed in the presence of the selective endopeptidase-24.11 inhibitor phosphoramidon was blocked by Pro-Ile or N-[1-(RS)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, inhibitors of endopeptidase-24.16 and endopeptidase-24.15, respectively.	phosphoramidon	94-108	thimet oligopeptidase 1	Homo sapiens	236-255
7550091-0	1995	Effects of phosphoramidon on endothelin-1 and big endothelin-1 production in human aortic endothelial cells.	phosphoramidon	11-25	endothelin 1	Homo sapiens	50-62
7706315-5	1995	Phosphoramidon inhibited the hydrolysis of AZB-125I-ANP.	phosphoramidon	0-14	natriuretic peptide A	Bos taurus	52-55
7781681-10	1995	Preincubation with phosphoramidon (100 microM) reduced responses to big-endothelin-1, but not endothelin-1.	phosphoramidon	19-33	endothelin 1	Mus musculus	72-84
7550091-1	1995	Using cultured human aortic endothelial cells, we examined the effects of phosphoramidon, an endothelin converting enzyme (ECE) inhibitor, on the release of endogenous endothelin-1 (ET-1) and big endothelin-1 (big ET-1), and on the generation of ET-1 from exogenously applied big ET-1.	phosphoramidon	74-88	endothelin 1	Homo sapiens	168-180
7550091-1	1995	Using cultured human aortic endothelial cells, we examined the effects of phosphoramidon, an endothelin converting enzyme (ECE) inhibitor, on the release of endogenous endothelin-1 (ET-1) and big endothelin-1 (big ET-1), and on the generation of ET-1 from exogenously applied big ET-1.	phosphoramidon	74-88	endothelin 1	Homo sapiens	182-186
7550091-1	1995	Using cultured human aortic endothelial cells, we examined the effects of phosphoramidon, an endothelin converting enzyme (ECE) inhibitor, on the release of endogenous endothelin-1 (ET-1) and big endothelin-1 (big ET-1), and on the generation of ET-1 from exogenously applied big ET-1.	phosphoramidon	74-88	endothelin 1	Homo sapiens	196-208
7550091-2	1995	Phosphoramidon, at concentrations of 10(-6) to 2 x 10(-4) M, caused a biphasic alteration of the ET-1 release, i.e., at lower concentrations of the drug, there were slight but unexpected increases of the release, whereas higher concentrations led to a decrease which is due to the drug-induced inhibition of ECE.	phosphoramidon	0-14	endothelin 1	Homo sapiens	97-101
7550091-2	1995	Phosphoramidon, at concentrations of 10(-6) to 2 x 10(-4) M, caused a biphasic alteration of the ET-1 release, i.e., at lower concentrations of the drug, there were slight but unexpected increases of the release, whereas higher concentrations led to a decrease which is due to the drug-induced inhibition of ECE.	phosphoramidon	0-14	endothelin converting enzyme 1	Homo sapiens	308-311
7550091-4	1995	Phosphoramidon enhanced the big ET-1 release from the cells in a concentration-dependent manner.	phosphoramidon	0-14	endothelin 1	Homo sapiens	32-36
7550091-5	1995	When high concentrations of phosphoramidon were added, there was a dramatic increase in the release of big ET-1, which cannot be explained only by the drug-induced inhibition of ECE.	phosphoramidon	28-42	endothelin 1	Homo sapiens	107-111
7550091-5	1995	When high concentrations of phosphoramidon were added, there was a dramatic increase in the release of big ET-1, which cannot be explained only by the drug-induced inhibition of ECE.	phosphoramidon	28-42	endothelin converting enzyme 1	Homo sapiens	178-181
7620708-16	1995	Addition of phosphoramidon (10 microM), an inhibitor of a range of metalloendopeptidases, including neutral endopeptidase (E.C.3.4.24.11), markedly reduced the potency of cFP in these systems.	phosphoramidon	12-26	complement factor properdin	Rattus norvegicus	171-174
7550091-7	1995	The amount of ET-1 generated from exogenously applied big ET-1 was markedly decreased by phosphoramidon in a concentration-dependent manner.	phosphoramidon	89-103	endothelin 1	Homo sapiens	14-18
7620708-19	1995	Given that cFP is a poor inhibitor of ACE in the presence of phosphoramidon in vitro, it is likely that cFP is cleaved by a phosphoramidon-sensitive metallopeptidase in vivo to liberate N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala, a potent ACE inhibitor.	phosphoramidon	61-75	complement factor properdin	Rattus norvegicus	104-107
7550091-7	1995	The amount of ET-1 generated from exogenously applied big ET-1 was markedly decreased by phosphoramidon in a concentration-dependent manner.	phosphoramidon	89-103	endothelin 1	Homo sapiens	58-62
7550091-8	1995	In a similar fashion, phosphoramidon markedly inhibited ECE activity of the membrane fraction of cultured cells.	phosphoramidon	22-36	endothelin converting enzyme 1	Homo sapiens	56-59
7620708-19	1995	Given that cFP is a poor inhibitor of ACE in the presence of phosphoramidon in vitro, it is likely that cFP is cleaved by a phosphoramidon-sensitive metallopeptidase in vivo to liberate N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala, a potent ACE inhibitor.	phosphoramidon	61-75	endothelin converting enzyme-like 1	Rattus norvegicus	149-165
7550091-9	1995	Thus, ET-1 generation from exogenously applied big ET-1 reflects the functional phosphoramidon-sensitive ECE activities in human aortic endothelial cells.	phosphoramidon	80-94	endothelin 1	Homo sapiens	6-10
7550091-9	1995	Thus, ET-1 generation from exogenously applied big ET-1 reflects the functional phosphoramidon-sensitive ECE activities in human aortic endothelial cells.	phosphoramidon	80-94	endothelin 1	Homo sapiens	51-55
7550091-9	1995	Thus, ET-1 generation from exogenously applied big ET-1 reflects the functional phosphoramidon-sensitive ECE activities in human aortic endothelial cells.	phosphoramidon	80-94	endothelin converting enzyme 1	Homo sapiens	105-108
7752584-5	1995	The response of urinary NEP to known inhibitors such as phosphoramidon and thiorphan, and its dependence on pH and salt concentration was studied.	phosphoramidon	56-70	membrane metallo-endopeptidase	Rattus norvegicus	24-27
7775337-5	1995	Phosphoramidon (0.1 and 1 mM; 90 breaths), an NEP inhibitor, induced a dose-dependent increase in lung resistance to bradykinin without further enhancing BHR induced by IL-1 beta.	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	46-49
7775337-5	1995	Phosphoramidon (0.1 and 1 mM; 90 breaths), an NEP inhibitor, induced a dose-dependent increase in lung resistance to bradykinin without further enhancing BHR induced by IL-1 beta.	phosphoramidon	0-14	kininogen 1	Homo sapiens	117-127
7880721-4	1995	Both basal ET-1 production and exogenously added big ET-1 to ET-1 conversion were greatly reduced in all three cell lines in response to the metalloproteinase inhibitor phosphoramidon but were insensitive to other classes of protease inhibitors.	phosphoramidon	169-183	endothelin 1	Homo sapiens	11-15
7880721-4	1995	Both basal ET-1 production and exogenously added big ET-1 to ET-1 conversion were greatly reduced in all three cell lines in response to the metalloproteinase inhibitor phosphoramidon but were insensitive to other classes of protease inhibitors.	phosphoramidon	169-183	endothelin 1	Homo sapiens	53-65
7774663-5	1995	When big-endothelin-1 was added to the incubation medium of intact live astrocytes, it was converted into mature endothelin-1 in a time-dependent manner and the conversion was inhibited by phosphoramidon.	phosphoramidon	189-203	endothelin 1	Rattus norvegicus	9-21
7774663-5	1995	When big-endothelin-1 was added to the incubation medium of intact live astrocytes, it was converted into mature endothelin-1 in a time-dependent manner and the conversion was inhibited by phosphoramidon.	phosphoramidon	189-203	endothelin 1	Rattus norvegicus	113-125
7532371-9	1995	Phosphoramidon (5 x 10(-6)-10(-5) M), an NEP inhibitor, enhanced fibroblast proliferation in a dose-dependent manner.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	41-44
7761621-4	1995	Phosphoramidon and SCH 39370, both inhibitors of neutral endopeptidase 24.11 (NEP), markedly inhibited degradation of 125I-ET-I in lung extract and clearly less in kidney extract.	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	49-76
7761621-4	1995	Phosphoramidon and SCH 39370, both inhibitors of neutral endopeptidase 24.11 (NEP), markedly inhibited degradation of 125I-ET-I in lung extract and clearly less in kidney extract.	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	78-81
7857289-1	1995	Subcellular fractionation of the phosphoramidon sensitive membrane-bound endothelin converting enzyme (ECE-1) activity from homogenates of bovine aortic endothelial cells and the human endothelial cell line EA.hy 926, combined with studies of intact cells, shows ECE-1 to be localised primarily to the plasma membrane with the topology of an ectoenzyme.	phosphoramidon	33-47	endothelin converting enzyme 1	Bos taurus	103-108
7857289-1	1995	Subcellular fractionation of the phosphoramidon sensitive membrane-bound endothelin converting enzyme (ECE-1) activity from homogenates of bovine aortic endothelial cells and the human endothelial cell line EA.hy 926, combined with studies of intact cells, shows ECE-1 to be localised primarily to the plasma membrane with the topology of an ectoenzyme.	phosphoramidon	33-47	endothelin converting enzyme 1	Homo sapiens	263-268
7857289-3	1995	The metallopeptidase ECE-1 obtained displayed a neutral pH optimum, a molecular weight of 250 kDa on gel filtration chromatography and was inhibited by phosphoramidon with an IC50 of 0.8 microM.	phosphoramidon	152-166	endothelin converting enzyme 1	Homo sapiens	21-26
7864859-2	1995	Metalloendoprotease inhibitors (phosphoramidon and DL-thiorphan), but not captopril, inhibited the contractions elicited by human big ET-1 and big ET-2 but DL-thiorphan was less active, suggesting that a non-selective enzymatic process is involved in conversion of big ET-1 and big ET-2 in addition to a phosphoramidon-sensitive ECE.	phosphoramidon	32-46	endothelin converting enzyme 1	Homo sapiens	329-332
7857324-5	1995	In addition, the effect of phosphoramidon (10 mg.kg-1) on the pressor response to big ET-1 and its disappearance rate from the circulation were examined.	phosphoramidon	27-41	endothelin 1	Rattus norvegicus	86-90
7735698-15	1995	Our results suggest the presence of a phosphoramidon-sensitive endothelin-converting enzyme (ECE) which is responsible for the conversion of big-endothelin-1 and big-endothelin-2 to their active moieties, endothelin-1 and 2.	phosphoramidon	38-52	endothelin-1	Cavia porcellus	145-157
7735698-15	1995	Our results suggest the presence of a phosphoramidon-sensitive endothelin-converting enzyme (ECE) which is responsible for the conversion of big-endothelin-1 and big-endothelin-2 to their active moieties, endothelin-1 and 2.	phosphoramidon	38-52	endothelin-2	Cavia porcellus	166-178
7735698-15	1995	Our results suggest the presence of a phosphoramidon-sensitive endothelin-converting enzyme (ECE) which is responsible for the conversion of big-endothelin-1 and big-endothelin-2 to their active moieties, endothelin-1 and 2.	phosphoramidon	38-52	endothelin-1	Cavia porcellus	205-223
7857324-7	1995	Phosphoramidon reduced the pressor response to big ET-1 by 93%, but did not alter its rate of clearance from the circulation.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	51-55
7714833-13	1995	Big ET-1 contraction, unlike ET-1 contraction, was curtailed by the inhibitor of the ET-1-converting enzyme, phosphoramidon (50 microM).	phosphoramidon	109-123	EDN1	Ovis aries	4-8
7541210-3	1995	After pretreatment of the nasal mucosa with PA, the effects of VIP, SP and CGRP on the LDF signal, NAR and mucus production were potentiated, whereas local pretreatment with captopril did not modify these functional effects.	phosphoramidon	44-46	vasoactive intestinal peptide	Homo sapiens	63-66
7541210-3	1995	After pretreatment of the nasal mucosa with PA, the effects of VIP, SP and CGRP on the LDF signal, NAR and mucus production were potentiated, whereas local pretreatment with captopril did not modify these functional effects.	phosphoramidon	44-46	tachykinin precursor 1	Homo sapiens	68-70
7541210-3	1995	After pretreatment of the nasal mucosa with PA, the effects of VIP, SP and CGRP on the LDF signal, NAR and mucus production were potentiated, whereas local pretreatment with captopril did not modify these functional effects.	phosphoramidon	44-46	calcitonin related polypeptide alpha	Homo sapiens	75-79
8835628-0	1995	Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon.	phosphoramidon	148-162	kininogen 1	Homo sapiens	15-25
8835628-3	1995	The combination of phosphoramidon and ebelactone B completely (by 95%) inhibited bradykinin degradation in human urine.	phosphoramidon	19-33	kininogen 1	Homo sapiens	81-91
8587408-7	1995	These data confirm that exogenous big ET-1 is locally converted to ET-1 and CTF in the human forearm, at least in part by a phosphoramidon-sensitive ECE.	phosphoramidon	124-138	endothelin 1	Homo sapiens	38-42
8587408-7	1995	These data confirm that exogenous big ET-1 is locally converted to ET-1 and CTF in the human forearm, at least in part by a phosphoramidon-sensitive ECE.	phosphoramidon	124-138	endothelin 1	Homo sapiens	67-79
8587388-2	1995	Phosphoramidon dose-dependently decreased ET-1-LI production but reciprocally increased [125I]ET-1 binding capacity.	phosphoramidon	0-14	endothelin 1	Bos taurus	42-46
8587388-2	1995	Phosphoramidon dose-dependently decreased ET-1-LI production but reciprocally increased [125I]ET-1 binding capacity.	phosphoramidon	0-14	endothelin 1	Bos taurus	94-98
8587408-7	1995	These data confirm that exogenous big ET-1 is locally converted to ET-1 and CTF in the human forearm, at least in part by a phosphoramidon-sensitive ECE.	phosphoramidon	124-138	endothelin converting enzyme 1	Homo sapiens	149-152
8587388-3	1995	ET-1 and ET-3 equipotently inhibited the binding of [125I]ET-1 only in the presence of phosphoramidon.	phosphoramidon	87-101	endothelin 1	Bos taurus	0-4
8587357-3	1995	Brachial artery infusion of local doses of big ET-1 caused a slow-onset, dose-dependent forearm vasoconstriction that was abolished by co-infusion of the ECE inhibitor phosphoramidon.	phosphoramidon	168-182	endothelin 1	Homo sapiens	47-51
8587388-3	1995	ET-1 and ET-3 equipotently inhibited the binding of [125I]ET-1 only in the presence of phosphoramidon.	phosphoramidon	87-101	endothelin 1	Bos taurus	58-62
8587418-2	1995	Phosphoramidon-sensitive ECE activity was not enriched on immunomagnetically separated angiotensin-converting enzyme (ACE)-bearing luminal endothelial membranes from pig lung, whereas ACE showed a sevenfold enrichment.	phosphoramidon	0-14	endothelin converting enzyme 1	Rattus norvegicus	25-28
8587388-4	1995	Northern blot analysis revealed that ETB receptor mRNA expression was more evident in phosphoramidon-treated cells than in nontreated cells.	phosphoramidon	86-100	endothelin receptor type B	Bos taurus	37-40
8587388-5	1995	In the presence of phosphoramidon, ET-1 and ET-3 equipotently stimulated inositol 1,4,5-trisphosphate formation and [3H]-thymidine incorporation into cultured ECs.	phosphoramidon	19-33	endothelin 1	Bos taurus	35-39
8587357-3	1995	Brachial artery infusion of local doses of big ET-1 caused a slow-onset, dose-dependent forearm vasoconstriction that was abolished by co-infusion of the ECE inhibitor phosphoramidon.	phosphoramidon	168-182	endothelin converting enzyme 1	Homo sapiens	154-157
7674808-4	1995	When cells were pretreated with 100 microM phosphoramidon, the stimulation by big ET-1, but not ET-1 was abolished.	phosphoramidon	43-57	endothelin 1	Bos taurus	82-86
8587439-8	1995	In the presence of the ET-1-converting enzyme inhibitor phosphoramidon (1.7 mumol/L), ischemia-induced increases of ET-1 concentrations were attenuated in parallel with a time-dependent rise in coronary perfusion pressure.	phosphoramidon	56-70	endothelin 1	Rattus norvegicus	23-27
8587439-8	1995	In the presence of the ET-1-converting enzyme inhibitor phosphoramidon (1.7 mumol/L), ischemia-induced increases of ET-1 concentrations were attenuated in parallel with a time-dependent rise in coronary perfusion pressure.	phosphoramidon	56-70	endothelin 1	Rattus norvegicus	116-120
8587469-3	1995	In both models, phosphoramidon selectively inhibited the pressor responses to big ET-1 without influencing those to ET-1, angiotensins (AT-I and AT-II) or norepinephrine.	phosphoramidon	16-30	endothelin 1	Rattus norvegicus	82-86
8587469-5	1995	It selectively inhibited the pressor responses to big ET-1 with ID50 values of 160 micrograms/kg/min (phosphoramidon: 120 micrograms/kg/min) in the spinal rat and 6 microM (phosphoramidon: 5 microM) in the perfused rat kidney.	phosphoramidon	102-116	endothelin 1	Rattus norvegicus	54-58
8587469-5	1995	It selectively inhibited the pressor responses to big ET-1 with ID50 values of 160 micrograms/kg/min (phosphoramidon: 120 micrograms/kg/min) in the spinal rat and 6 microM (phosphoramidon: 5 microM) in the perfused rat kidney.	phosphoramidon	173-187	endothelin 1	Rattus norvegicus	54-58
8587470-0	1995	Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.	phosphoramidon	49-63	angiotensin I converting enzyme	Homo sapiens	173-202
8587470-1	1995	The structure-activity relationships of phosphoramidon analogues for inhibition of endothelin-converting enzyme (ECE), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE) were compared.	phosphoramidon	40-54	endothelin converting enzyme 1	Homo sapiens	113-116
8587470-1	1995	The structure-activity relationships of phosphoramidon analogues for inhibition of endothelin-converting enzyme (ECE), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE) were compared.	phosphoramidon	40-54	membrane metalloendopeptidase	Homo sapiens	119-146
8587470-2	1995	Phosphoramidon inhibited ECE, NEP, and ACE activities with IC50 values of 3.5, 0.034, and 78 microM, respectively.	phosphoramidon	0-14	endothelin converting enzyme 1	Homo sapiens	25-28
8587470-2	1995	Phosphoramidon inhibited ECE, NEP, and ACE activities with IC50 values of 3.5, 0.034, and 78 microM, respectively.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	30-33
8587470-2	1995	Phosphoramidon inhibited ECE, NEP, and ACE activities with IC50 values of 3.5, 0.034, and 78 microM, respectively.	phosphoramidon	0-14	angiotensin I converting enzyme	Homo sapiens	39-42
8587470-3	1995	Removal of the rhamnose moiety of phosphoramidon (dipeptide 3) reduced the potency for ECE (IC50 = 70 microM), whereas the potencies for NEP (0.003 microM) and ACE (0.20 microM) were increased.	phosphoramidon	34-48	endothelin converting enzyme 1	Homo sapiens	87-90
8587470-6	1995	These results suggest that a hydrophobic group in the P1 position of phosphoramidon analogues increases the potency for ECE significantly, whereas compounds containing a free phosphonic acid are optimal for inhibition of NEP and ACE.	phosphoramidon	69-83	endothelin converting enzyme 1	Homo sapiens	120-123
7791520-4	1995	These include: (i) one sharp activity optimum at neutral pH; (ii) characteristics typical of a metalloprotease; (iii) IC50 value for phosphoramidon of 1.8 microM (2.7 microM for HUVEC); (iv) no inhibition by captopril and thiorphan, inhibitors of angiotensin converting enzyme and neutral endopeptidase 24.11.	phosphoramidon	133-147	angiotensin I converting enzyme	Homo sapiens	247-276
7791520-4	1995	These include: (i) one sharp activity optimum at neutral pH; (ii) characteristics typical of a metalloprotease; (iii) IC50 value for phosphoramidon of 1.8 microM (2.7 microM for HUVEC); (iv) no inhibition by captopril and thiorphan, inhibitors of angiotensin converting enzyme and neutral endopeptidase 24.11.	phosphoramidon	133-147	membrane metalloendopeptidase	Homo sapiens	281-308
7674808-4	1995	When cells were pretreated with 100 microM phosphoramidon, the stimulation by big ET-1, but not ET-1 was abolished.	phosphoramidon	43-57	endothelin 1	Bos taurus	96-100
7674808-5	1995	In separate experiments, when cells were incubated with exogenous big ET-1, a time-dependent phosphoramidon-sensitive conversion to ET-1 was detected by radioimmunoassay.	phosphoramidon	93-107	endothelin 1	Bos taurus	70-74
7674808-5	1995	In separate experiments, when cells were incubated with exogenous big ET-1, a time-dependent phosphoramidon-sensitive conversion to ET-1 was detected by radioimmunoassay.	phosphoramidon	93-107	endothelin 1	Bos taurus	132-136
7674808-6	1995	These results are consistent with the presence of a phosphoramidon-sensitive endothelin converting enzyme on the surface of bovine pulmonary artery smooth muscle cells, which may play a role in regulating signalling by circulating big ET-1.	phosphoramidon	52-66	endothelin 1	Bos taurus	235-239
7705468-2	1994	Endothelin-3-evoked contractions were markedly enhanced by phosphoramidon (3.67 x 10(-5) M), unaffected by atropine (10(-5) M), and attenuated by indomethacin (10(-6) M) or nifedipine (10(-5) M).	phosphoramidon	59-73	endothelin 3	Homo sapiens	0-12
7896062-13	1994	From these results it was concluded that phosphoramidon-sensitive endothelin-converting enzyme, probably localized in microvasculature of the kidney, can convert pre-pro-endothelin-1 to endothelin-1 which is responsible for the vasoconstrictor effect of pre-pro-endothelin-1 in addition to its possible direct vasoconstrictor effect on kidney vasculature.	phosphoramidon	41-55	endothelin-1	Oryctolagus cuniculus	170-182
7896062-13	1994	From these results it was concluded that phosphoramidon-sensitive endothelin-converting enzyme, probably localized in microvasculature of the kidney, can convert pre-pro-endothelin-1 to endothelin-1 which is responsible for the vasoconstrictor effect of pre-pro-endothelin-1 in addition to its possible direct vasoconstrictor effect on kidney vasculature.	phosphoramidon	41-55	endothelin-1	Oryctolagus cuniculus	186-198
7896062-3	1994	Addition of phosphoramidon to the medium caused a potentiation in the vasoconstrictor response to endothelin-1 and greatly, but not completely, inhibited vasoconstriction induced by pre-pro-endothelin-1.	phosphoramidon	12-26	endothelin-1	Oryctolagus cuniculus	98-110
7896062-13	1994	From these results it was concluded that phosphoramidon-sensitive endothelin-converting enzyme, probably localized in microvasculature of the kidney, can convert pre-pro-endothelin-1 to endothelin-1 which is responsible for the vasoconstrictor effect of pre-pro-endothelin-1 in addition to its possible direct vasoconstrictor effect on kidney vasculature.	phosphoramidon	41-55	endothelin-1	Oryctolagus cuniculus	186-198
7896062-3	1994	Addition of phosphoramidon to the medium caused a potentiation in the vasoconstrictor response to endothelin-1 and greatly, but not completely, inhibited vasoconstriction induced by pre-pro-endothelin-1.	phosphoramidon	12-26	endothelin-1	Oryctolagus cuniculus	190-202
7921430-9	1994	The NEP inhibitor phosphoramidon tended to increase the sensitivity to BK (NS) and did not change the direction of the response.	phosphoramidon	18-32	membrane metalloendopeptidase	Homo sapiens	4-7
7535520-5	1994	In contrast, phosphoramidon potentiated BK-induced responses only at low concentrations of BK.	phosphoramidon	13-27	kininogen 1	Canis lupus familiaris	40-42
7923622-4	1994	Therefore, we examined the effect of an NEP inhibitor, phosphoramidon, on myocardial perfusion in rats after (1) stimulating sensory nerves with capsaicin and (2) inducing myocardial hypoperfusion with isoproterenol, with or without pretreatment with selective antagonists of the substance P (NK1) and bradykinin (B2) receptors.	phosphoramidon	55-69	membrane metallo-endopeptidase	Rattus norvegicus	40-43
7965744-8	1994	Phosphoramidon (50 microM) inhibited (60%) both AII-induced irET release and cell proliferation.	phosphoramidon	0-14	angiotensinogen	Rattus norvegicus	48-51
7916401-3	1994	Brachial artery infusion of local doses of proendothelin-1, the precursor to endothelin-1, caused a slow-onset dose-dependent forearm vasoconstriction which was abolished by co-infusion of phosphoramidon.	phosphoramidon	189-203	endothelin 1	Homo sapiens	46-58
7535520-5	1994	In contrast, phosphoramidon potentiated BK-induced responses only at low concentrations of BK.	phosphoramidon	13-27	kininogen 1	Canis lupus familiaris	91-93
7924171-0	1994	Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells: measurement by two-site enzyme-linked immunosorbent assays.	phosphoramidon	11-25	endothelin 1	Homo sapiens	62-74
7812611-10	1994	Both phosphoramidon and SQ-28,603, potent inhibitors of NEP, completely protected both peptides from metabolism by rNEP.	phosphoramidon	5-19	membrane metalloendopeptidase	Homo sapiens	56-59
7812611-10	1994	Both phosphoramidon and SQ-28,603, potent inhibitors of NEP, completely protected both peptides from metabolism by rNEP.	phosphoramidon	5-19	membrane metallo-endopeptidase	Rattus norvegicus	115-119
7847182-0	1994	Differential effects of phosphoramidon and captopril on NK1 receptor-mediated plasma extravasation in the rat trachea.	phosphoramidon	24-38	tachykinin receptor 1	Rattus norvegicus	56-68
7847182-7	1994	Nevertheless, the responses to substance P and neurokinin A were clearly potentiated in rats given phosphoramidon, indicating that NEP effectively degrades tachykinins in vivo.	phosphoramidon	99-113	membrane metallo-endopeptidase	Rattus norvegicus	131-134
7529108-2	1994	Phosphoramidon, a potent inhibitor of endopeptidase-24.11 (E-24.11) and thermolysin, has been shown to reduce the hypertensive effect of exogenous big endothelin-1 (big ET-1) in rats.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	151-163
7529108-2	1994	Phosphoramidon, a potent inhibitor of endopeptidase-24.11 (E-24.11) and thermolysin, has been shown to reduce the hypertensive effect of exogenous big endothelin-1 (big ET-1) in rats.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	169-173
7924171-0	1994	Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells: measurement by two-site enzyme-linked immunosorbent assays.	phosphoramidon	11-25	endothelin 1	Homo sapiens	83-95
7924171-9	1994	The secretion of both peptides was time-dependent over 12 h. The metalloprotease inhibitor phosphoramidon (1 x 10(-4) mol/l) significantly reduced the amount of endothelin-1 secreted into the medium (P < 0.05), with a concomitant increase in the secreted levels of big endothelin-1 (P < 0.01).	phosphoramidon	91-105	endothelin 1	Homo sapiens	161-173
7924171-9	1994	The secretion of both peptides was time-dependent over 12 h. The metalloprotease inhibitor phosphoramidon (1 x 10(-4) mol/l) significantly reduced the amount of endothelin-1 secreted into the medium (P < 0.05), with a concomitant increase in the secreted levels of big endothelin-1 (P < 0.01).	phosphoramidon	91-105	endothelin 1	Homo sapiens	272-284
7993815-5	1994	Addition of the CD10 inhibitor, phosphoramidon, together with IL-1 beta resulted in a left shift in the dose-response curve which corresponded to a 10-fold potentiation of the IL-1 beta effect.	phosphoramidon	32-46	membrane metalloendopeptidase	Homo sapiens	16-20
8039848-0	1994	Phosphoramidon-sensitive conversion of big endothelin-1 and degradation of endothelin-1 in rat kidney.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	43-55
8039848-0	1994	Phosphoramidon-sensitive conversion of big endothelin-1 and degradation of endothelin-1 in rat kidney.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	75-87
8039848-4	1994	Phosphoramidon (10(-4) mol/L), a metalloproteinase inhibitor, significantly suppressed the big ET-1-induced pressor action and the accumulation of immunoreactive endothelin in renal tissues.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	95-99
8039848-5	1994	On the other hand, phosphoramidon slightly but significantly sustained the ET-1-induced pressor effect.	phosphoramidon	19-33	endothelin 1	Rattus norvegicus	75-79
8039848-7	1994	When ET-1 was exogenously added to the perfusate, phosphoramidon or kelatorphan significantly increased the immunoreactive endothelin levels in renal tissues after perfusion, without affecting the disappearance rate of immunoreactive endothelin from the perfusate.	phosphoramidon	50-64	endothelin 1	Rattus norvegicus	5-9
8039848-8	1994	Therefore, the phosphoramidon-sensitive ET-1-converting enzyme in the kidney seems to contribute to the functional local conversion of big ET-1 to ET-1, and neutral endopeptidase 24.11 may be responsible for the proteolytic degradation of ET-1 in the kidney.	phosphoramidon	15-29	endothelin 1	Rattus norvegicus	40-44
8039848-8	1994	Therefore, the phosphoramidon-sensitive ET-1-converting enzyme in the kidney seems to contribute to the functional local conversion of big ET-1 to ET-1, and neutral endopeptidase 24.11 may be responsible for the proteolytic degradation of ET-1 in the kidney.	phosphoramidon	15-29	endothelin 1	Rattus norvegicus	139-151
8039848-8	1994	Therefore, the phosphoramidon-sensitive ET-1-converting enzyme in the kidney seems to contribute to the functional local conversion of big ET-1 to ET-1, and neutral endopeptidase 24.11 may be responsible for the proteolytic degradation of ET-1 in the kidney.	phosphoramidon	15-29	endothelin 1	Rattus norvegicus	139-143
7949376-6	1994	Both intact cells and membrane preparations used as the enzyme source predict similar IC50 values for phosphoramidon inhibition of ECE (ca 1 microM).	phosphoramidon	102-116	endothelin converting enzyme 1	Homo sapiens	131-134
8034569-6	1994	Expressed ECE was inhibited by phosphoramidon, but not by thiorphan.	phosphoramidon	31-45	endothelin converting enzyme 1	Rattus norvegicus	10-13
7993815-5	1994	Addition of the CD10 inhibitor, phosphoramidon, together with IL-1 beta resulted in a left shift in the dose-response curve which corresponded to a 10-fold potentiation of the IL-1 beta effect.	phosphoramidon	32-46	interleukin 1 beta	Homo sapiens	176-185
8082712-1	1994	The role of phosphoramidon-sensitive endothelin converting enzyme in the release of endogenous endothelin-1 was investigated in anesthetized rats.	phosphoramidon	12-26	endothelin 1	Rattus norvegicus	95-107
8072216-5	1994	NEP activity in rat kidney was inhibited by specific NEP inhibitors (phosphoramidon, thiorphan, SCH39370, SCH47896 and SCH48446) at micromolar concentrations.	phosphoramidon	69-83	membrane metallo-endopeptidase	Rattus norvegicus	0-3
8072216-5	1994	NEP activity in rat kidney was inhibited by specific NEP inhibitors (phosphoramidon, thiorphan, SCH39370, SCH47896 and SCH48446) at micromolar concentrations.	phosphoramidon	69-83	membrane metallo-endopeptidase	Rattus norvegicus	53-56
7938704-0	1994	Evidence for phosphoramidon-sensitive cleavage of big endothelin-1 involved in endothelin-stimulated hepatic glucose production.	phosphoramidon	13-27	endothelin 1	Rattus norvegicus	54-66
7959879-4	1994	CD10 activity was abolished by specific NEP inhibitors, including thiorphan, retrothiorphan and phosphoramidon.	phosphoramidon	96-110	membrane metalloendopeptidase	Homo sapiens	0-4
7959879-4	1994	CD10 activity was abolished by specific NEP inhibitors, including thiorphan, retrothiorphan and phosphoramidon.	phosphoramidon	96-110	membrane metalloendopeptidase	Homo sapiens	40-43
7522926-14	1994	endothelins are mediated by ETA receptors in the rat spinal cord; (2) that the pressor response and bradycardia are likely due to the activation of the sympatho-adrenal nervous system and to a vagal reflex mechanism, respectively; and (3) that a phosphoramidon-sensitive ECE converts big ET-1 to ET-1 in the rat spinal cord.	phosphoramidon	246-260	endothelin 1	Rattus norvegicus	0-11
7938704-3	1994	Thereby, big ET-1 (10 nM) induced a maximally three-fold increase (P < 0.01 vs. basal values) in hepatic glucose production at 60 min, which was almost completely abolished by concomitant infusion of 50 microM phosphoramidon, a sensitive inhibitor of the enzymatic cleavage of big ET-1 to ET-1.	phosphoramidon	213-227	endothelin 1	Rattus norvegicus	13-17
7938704-4	1994	The corresponding incremental release of glucose by big ET-1 was 20.9-fold higher in the absence of phosphoramidon than in its presence (P < 0.01).	phosphoramidon	100-114	endothelin 1	Rattus norvegicus	56-60
7938704-8	1994	In conclusion, big ET-1 induces hepatic glucose release, which is suggested to depend on intrahepatic conversion of big ET-1 to ET-1 by a phosphoramidon-sensitive pathway.	phosphoramidon	138-152	endothelin 1	Rattus norvegicus	19-23
7938704-8	1994	In conclusion, big ET-1 induces hepatic glucose release, which is suggested to depend on intrahepatic conversion of big ET-1 to ET-1 by a phosphoramidon-sensitive pathway.	phosphoramidon	138-152	endothelin 1	Rattus norvegicus	120-124
7938704-8	1994	In conclusion, big ET-1 induces hepatic glucose release, which is suggested to depend on intrahepatic conversion of big ET-1 to ET-1 by a phosphoramidon-sensitive pathway.	phosphoramidon	138-152	endothelin 1	Rattus norvegicus	120-124
8082712-7	1994	It is concluded that the release of endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia is resistant to inhibition by phosphoramidon, and at high doses, phosphoramidon potentiates hemorrhage- and hypoxia-induced increases in endothelin-1 levels, most likely by preventing its degradation.	phosphoramidon	146-160	endothelin 1	Rattus norvegicus	47-59
8082712-7	1994	It is concluded that the release of endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia is resistant to inhibition by phosphoramidon, and at high doses, phosphoramidon potentiates hemorrhage- and hypoxia-induced increases in endothelin-1 levels, most likely by preventing its degradation.	phosphoramidon	181-195	endothelin 1	Rattus norvegicus	47-59
8082712-7	1994	It is concluded that the release of endogenous endothelin-1 release stimulated by hemorrhage, cytokines and hypoxia is resistant to inhibition by phosphoramidon, and at high doses, phosphoramidon potentiates hemorrhage- and hypoxia-induced increases in endothelin-1 levels, most likely by preventing its degradation.	phosphoramidon	181-195	endothelin 1	Rattus norvegicus	253-265
8192653-2	1994	This hydrolysis was only partially inhibited (40%) by 10 microM phosphoramidon, an inhibitor of endopeptidase-24.11, but was almost totally abolished in the presence of a mixture of 10 microM phosphoramidon and 10 microM captopril, a potent inhibitor of mammalian angiotensin-converting enzyme (ACE).	phosphoramidon	64-78	angiotensin I converting enzyme	Homo sapiens	295-298
8192653-2	1994	This hydrolysis was only partially inhibited (40%) by 10 microM phosphoramidon, an inhibitor of endopeptidase-24.11, but was almost totally abolished in the presence of a mixture of 10 microM phosphoramidon and 10 microM captopril, a potent inhibitor of mammalian angiotensin-converting enzyme (ACE).	phosphoramidon	192-206	angiotensin I converting enzyme	Homo sapiens	295-298
7519178-6	1994	In the case of substance P, we demonstrate the significance of NEP in modulating the process of downregulation by use of a specific NEP inhibitor, phosphoramidon.	phosphoramidon	147-161	tachykinin precursor 1	Homo sapiens	15-26
8032633-10	1994	Neurotensin (1-11) was mainly generated by a phosphoramidon-sensitive cleavage, probably elicited by endopeptidase 24-11.	phosphoramidon	45-59	neurotensin	Canis lupus familiaris	0-11
7908871-6	1994	In renal brush border membranes, hydrolysis of PYY is substantially (> 75%) inhibited by phosphoramidon, suggesting that endopeptidase-24.11 initiates hydrolysis of PYY in this preparation.	phosphoramidon	92-106	peptide YY	Homo sapiens	47-50
7908871-6	1994	In renal brush border membranes, hydrolysis of PYY is substantially (> 75%) inhibited by phosphoramidon, suggesting that endopeptidase-24.11 initiates hydrolysis of PYY in this preparation.	phosphoramidon	92-106	peptide YY	Homo sapiens	168-171
8032603-13	1994	Both ET-1 and ET-3 (in the presence of phosphoramidon)-evoked contractions were significantly enhanced by the presence of the phorbol ester phorbol 12,13-dibutyrate (10(-8) M).	phosphoramidon	39-53	endothelin 1	Bos taurus	5-18
7909519-9	1994	In the astrocytic membrane-associated fraction, neuromedin N underwent an additional minor endoproteolytic cleavage at the Pro3-Tyr4 bond elicited by endopeptidase 24.11, as suggested by the protective effect of its blocking agent phosphoramidon.	phosphoramidon	231-245	neurotensin	Mus musculus	48-60
8182555-7	1994	A similar effectiveness of phosphoramidon was seen when transforming growth factor-beta 1 was used instead of platelets.	phosphoramidon	27-41	transforming growth factor, beta 1	Rattus norvegicus	56-89
8182555-9	1994	We also suggest that the inhibition of ET converting enzyme by phosphoramidon is more effective in the augmented condition of ET-1 production than in the basal condition.	phosphoramidon	63-77	endothelin 1	Rattus norvegicus	126-130
7519178-6	1994	In the case of substance P, we demonstrate the significance of NEP in modulating the process of downregulation by use of a specific NEP inhibitor, phosphoramidon.	phosphoramidon	147-161	membrane metalloendopeptidase	Homo sapiens	63-66
7519178-6	1994	In the case of substance P, we demonstrate the significance of NEP in modulating the process of downregulation by use of a specific NEP inhibitor, phosphoramidon.	phosphoramidon	147-161	membrane metalloendopeptidase	Homo sapiens	132-135
7914787-5	1994	In the glial cell line the hydrolysis of cholecystokinin octapeptide (CCK-8), sulphated or non-sulphated, was inhibited predominantly by the NEP inhibitor, phosphoramidon (PR).	phosphoramidon	156-170	cholecystokinin	Homo sapiens	41-56
7914787-5	1994	In the glial cell line the hydrolysis of cholecystokinin octapeptide (CCK-8), sulphated or non-sulphated, was inhibited predominantly by the NEP inhibitor, phosphoramidon (PR).	phosphoramidon	156-170	cholecystokinin	Homo sapiens	70-73
7914787-5	1994	In the glial cell line the hydrolysis of cholecystokinin octapeptide (CCK-8), sulphated or non-sulphated, was inhibited predominantly by the NEP inhibitor, phosphoramidon (PR).	phosphoramidon	156-170	membrane metalloendopeptidase	Homo sapiens	141-144
8141343-0	1994	Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme.	phosphoramidon	48-62	endothelin 1	Rattus norvegicus	73-85
8141304-0	1994	Phosphoramidon attenuates big endothelin-1-induced vasoconstriction in canine stomach.	phosphoramidon	0-14	endothelin 1	Canis lupus familiaris	30-42
8141304-6	1994	In other experiments, using 15-min peptide infusions, we found that pretreatment with phosphoramidon, an inhibitor of endothelin-converting enzyme, markedly reduced response to big endothelin-1 but not to endothelin-1.	phosphoramidon	86-100	endothelin 1	Canis lupus familiaris	181-193
8160888-3	1994	Pretreatment with 10 mg of phosphoramidon, an ET-1-converting enzyme inhibitor, blocked the hypertensive response to bET-1.	phosphoramidon	27-41	EDN1	Ovis aries	46-50
8160888-7	1994	Phosphoramidon inhibits bET-1-induced hypertension, suggesting that the fetus possesses ET-1-converting enzyme activity.	phosphoramidon	0-14	EDN1	Ovis aries	25-29
7512455-0	1994	Modulation of the effect of atrial natriuretic peptide in human and bovine bronchi by phosphoramidon.	phosphoramidon	86-100	natriuretic peptide A	Bos taurus	28-54
7512455-10	1994	Phosphoramidon potentiated atrial natriuretic peptide-induced relaxation of methacholine-induced tone and the ability of atrial natriuretic peptide to protect against methacholine-induced contraction.	phosphoramidon	0-14	natriuretic peptide A	Bos taurus	27-53
8141343-7	1994	We tentatively conclude that the phosphoramidon-sensitive conversion of Big ET-T to ET-1 is linked to the pressor action of Big ET-1 in the isolated perfused rat lung.	phosphoramidon	33-47	endothelin 1	Rattus norvegicus	84-88
8306034-7	1994	Pretreatment with phosphoramidon abolished the differential effect of acrolein on airway response to NKA.	phosphoramidon	18-32	tachykinin precursor 1	Homo sapiens	101-104
8141343-7	1994	We tentatively conclude that the phosphoramidon-sensitive conversion of Big ET-T to ET-1 is linked to the pressor action of Big ET-1 in the isolated perfused rat lung.	phosphoramidon	33-47	endothelin 1	Rattus norvegicus	128-132
8289588-4	1994	Exposure to phosphoramidon, a metalloproteinase inhibitor, significantly suppressed the pressor response to big ET-1, in a similar fashion.	phosphoramidon	12-26	endothelin 1	Rattus norvegicus	112-116
8187026-9	1994	Phosphoramidon administered by inhalation elicited a significant (P < 0.01 vs baseline and control solution) potentiation in the airway responsiveness to inhaled NKA, the NKA PD15 value decreasing to 9.45 x 10(-9) mol.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	165-168
8187026-9	1994	Phosphoramidon administered by inhalation elicited a significant (P < 0.01 vs baseline and control solution) potentiation in the airway responsiveness to inhaled NKA, the NKA PD15 value decreasing to 9.45 x 10(-9) mol.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	174-177
8187026-10	1994	The present study confirms that inhaled NKA induces a dose-related bronchoconstriction in asthmatic patients and demonstrates that inhaled phosphoramidon potentiates NKA-induced bronchoconstriction.	phosphoramidon	139-153	tachykinin precursor 1	Homo sapiens	166-169
8181798-1	1994	Neuropeptide gamma (NP gamma) induced a contractile response of the human isolated bronchus which was potentiated by the neutral endopeptidase inhibitor, phosphoramidon, but was not modified by atropine and indomethacin.	phosphoramidon	154-168	tachykinin precursor 1	Homo sapiens	0-28
7934630-11	1994	Big ET-1 caused dose-dependent pressor effects in isolated perfused rat kidney and these pressor effects were significantly suppressed by phosphoramidon.	phosphoramidon	138-152	endothelin 1	Rattus norvegicus	4-8
8020872-1	1994	The structure activity relationship of phosphoramidon analogues was studied for their ability to reduce the hypertensive effect of exogenous proET-1, probably via inhibition of an endothelin converting enzyme activity (ECE).	phosphoramidon	39-53	endothelin converting enzyme 1	Homo sapiens	219-222
8020872-4	1994	Furthermore, the tryptophan residue of phosphoramidon appeared to be particularly important for the ECE inhibition, whereas thermolysin inhibition seemed to depend greatly on the leucine residue.	phosphoramidon	39-53	endothelin converting enzyme 1	Homo sapiens	100-103
8020872-5	1994	It is concluded that in vivo ECE and thermolysin differ in the way they recognise phosphoramidon.	phosphoramidon	82-96	endothelin converting enzyme 1	Homo sapiens	29-32
8020872-6	1994	The existence of an hydrophobic pocket, specific for the recognition of the tryptophan residue of phosphoramidon, could be proposed for ECE.	phosphoramidon	98-112	endothelin converting enzyme 1	Homo sapiens	136-139
7990652-7	1994	On the other hand, in normal rats, the airway responsiveness to inhaled ACh was significantly increased by pretreatment with NEP inhibitor, phosphoramidon (3 mg/kg, i.v.	phosphoramidon	140-154	membrane metallo-endopeptidase	Rattus norvegicus	125-128
8289588-6	1994	Apparently there is a difference in potency for phosphoramidon-sensitive vasoconstriction of big ET-1 between organs and presumably regional differences in the functional phosphoramidon-sensitive conversion of big ET-1 in vasculatures.	phosphoramidon	48-62	endothelin 1	Rattus norvegicus	97-101
8289588-6	1994	Apparently there is a difference in potency for phosphoramidon-sensitive vasoconstriction of big ET-1 between organs and presumably regional differences in the functional phosphoramidon-sensitive conversion of big ET-1 in vasculatures.	phosphoramidon	171-185	endothelin 1	Rattus norvegicus	97-101
8289588-6	1994	Apparently there is a difference in potency for phosphoramidon-sensitive vasoconstriction of big ET-1 between organs and presumably regional differences in the functional phosphoramidon-sensitive conversion of big ET-1 in vasculatures.	phosphoramidon	171-185	endothelin 1	Rattus norvegicus	214-218
8289600-1	1994	Hydrolysis of fragments of the C-terminal and mid-portions of parathyroid hormone (PTH) by a phosphoramidon-insensitive metallo-endopeptidase, previously purified by us from the microvillar membranes of rat kidney, and by the microvillar membranes of rat kidney themselves were investigated using a reverse-phase HPLC, and the amino acid sequences of each produced PTH metabolite were compared after their determination with an automated gas-phase protein sequencer.	phosphoramidon	93-107	parathyroid hormone	Rattus norvegicus	62-81
8238539-3	1993	A small dose of aerosolized ovalbumin (OVA, 0.1%) produced a small increase in RL that was further increased and markedly prolonged by the neutral endopeptidase (NEP) inhibitor phosphoramidon; this bronchoconstrictor effect of OVA was markedly reduced by the NK2-receptor antagonist and was abolished by the combination of the NK1 and NK2-receptor antagonists together.	phosphoramidon	177-191	substance-K receptor	Cavia porcellus	259-271
8238539-3	1993	A small dose of aerosolized ovalbumin (OVA, 0.1%) produced a small increase in RL that was further increased and markedly prolonged by the neutral endopeptidase (NEP) inhibitor phosphoramidon; this bronchoconstrictor effect of OVA was markedly reduced by the NK2-receptor antagonist and was abolished by the combination of the NK1 and NK2-receptor antagonists together.	phosphoramidon	177-191	substance-K receptor	Cavia porcellus	335-347
8136718-5	1993	This new enzyme is clearly distinct from neutral endopeptidase (NEP, EC 3.4.24.11) and angiotensin-converting enzyme (ACE,EC 3.4.15.1), since specific inhibitors for these endopeptidases (10 microM phosphoramidon and 1 mM captopril, respectively) had no effect on their activity.	phosphoramidon	198-212	membrane metalloendopeptidase	Homo sapiens	64-67
8136718-5	1993	This new enzyme is clearly distinct from neutral endopeptidase (NEP, EC 3.4.24.11) and angiotensin-converting enzyme (ACE,EC 3.4.15.1), since specific inhibitors for these endopeptidases (10 microM phosphoramidon and 1 mM captopril, respectively) had no effect on their activity.	phosphoramidon	198-212	angiotensin I converting enzyme	Homo sapiens	118-121
8223929-0	1993	Endothelium-independent pressor effect of big endothelin-1 and its inhibition by phosphoramidon in rat mesenteric artery.	phosphoramidon	81-95	endothelin 1	Rattus norvegicus	46-58
7691676-5	1993	The neutral endopeptidase inhibitor, phosphoramidon, increased only the response to SP.	phosphoramidon	37-51	tachykinin precursor 1	Homo sapiens	84-86
7691676-10	1993	Response to SP is modulated by a phosphoramidon-sensitive enzymatic activity.	phosphoramidon	33-47	tachykinin precursor 1	Homo sapiens	12-14
8223929-3	1993	Phosphoramidon suppressed the big endothelin-1-induced pressor action without affecting the action of endothelin-1, irrespective of the presence or absence of the endothelium.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	34-46
8217029-1	1993	We reported previously that the endothelin converting enzyme (ECE) inhibitor phosphoramidon lowers mean arterial pressure (MAP) when infused in conscious, spontaneously hypertensive rats (SHRs).	phosphoramidon	77-91	endothelin converting enzyme 1	Rattus norvegicus	32-60
8284261-1	1993	We examined the effects of captopril (an angiotensin-converting enzyme inhibitor) and phosphoramidon (a selective enkephalinase inhibitor) on Tyr-Gly-Gly production during Met-enkephalin hydrolysis in plasma samples taken from individual outbred Swiss-Webster and inbred C57BL/6J and DBA/2J mice.	phosphoramidon	86-100	membrane metallo endopeptidase	Mus musculus	114-127
8284261-1	1993	We examined the effects of captopril (an angiotensin-converting enzyme inhibitor) and phosphoramidon (a selective enkephalinase inhibitor) on Tyr-Gly-Gly production during Met-enkephalin hydrolysis in plasma samples taken from individual outbred Swiss-Webster and inbred C57BL/6J and DBA/2J mice.	phosphoramidon	86-100	pro-opiomelanocortin-alpha	Mus musculus	172-186
8243532-0	1993	Big-endothelin-1 contracts rat isolated uterus via a phosphoramidon-sensitive endothelin ETA receptor-mediated mechanism.	phosphoramidon	53-67	endothelin 1	Rattus norvegicus	4-16
8243532-1	1993	The presence of a phosphoramidon-sensitive endothelin-1-converting enzyme was investigated in the rat isolated uterus.	phosphoramidon	18-32	endothelin 1	Rattus norvegicus	43-55
8243532-4	1993	The tonic contraction induced by big-endothelin-1 (10 nM) was nearly abolished by phosphoramidon (100 microM), but the response to an equieffective concentration of endothelin-1 (3 nM) was not affected.	phosphoramidon	82-96	endothelin 1	Rattus norvegicus	37-49
8223885-5	1993	Phosphoramidon (1 microM) potentiated the response to substance P without changing the order of potency of natural tachykinins.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	54-65
8223885-11	1993	Moreover, a phosphoramidon-sensitive mechanism plays a role in the regulation of the response to substance P.	phosphoramidon	12-26	tachykinin precursor 1	Homo sapiens	97-108
8106108-10	1993	Pressor responses induced by big-endothelin-1, -2 and -3 (3, 15 and 10 nmol kg-1, respectively) were markedly reduced (60, 80 and 100%) in the presence of phosphoramidon (10 mg kg-1, i.v.).	phosphoramidon	155-169	endothelin 1	Rattus norvegicus	33-56
8106108-18	1993	Phosphoramidon, but not thiorphan, concentration-dependently(10 and 100 microM) reduced big-endothelin-1 (58 and 86% respectively) and big-endothelin-2 (21 and 56%)-mediated responses.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	92-104
8106108-18	1993	Phosphoramidon, but not thiorphan, concentration-dependently(10 and 100 microM) reduced big-endothelin-1 (58 and 86% respectively) and big-endothelin-2 (21 and 56%)-mediated responses.	phosphoramidon	0-14	endothelin 2	Rattus norvegicus	139-151
8106108-19	1993	Conversely, the big-endothelin-3 effect was reduced by phosphoramidon only at 100 microM (-70%), while thiorphan acts concentration-dependently (31 and 71% at 10 and 100 microM respectively); thus, in the rat vas deferens, big-endothelin-I and -2 were as potent as their corresponding endothelins, while big-endothelin-3 was about 20 times less potent than endothelin-3.5.	phosphoramidon	55-69	endothelin 3	Rattus norvegicus	20-32
8106108-20	1993	The increasing effect of endothelin-2 (194 +/- 30% over baseline) was significantly enhanced by either 10 microM phosphoramidon (277 +/- 42%) or thiorphan (318 +/- 15%).	phosphoramidon	113-127	endothelin 2	Rattus norvegicus	25-37
8217029-1	1993	We reported previously that the endothelin converting enzyme (ECE) inhibitor phosphoramidon lowers mean arterial pressure (MAP) when infused in conscious, spontaneously hypertensive rats (SHRs).	phosphoramidon	77-91	endothelin converting enzyme 1	Rattus norvegicus	62-65
8489505-3	1993	In this paper, the presence of NEP in purified glomeruli from dog kidney was assessed by measuring phosphoramidon- and thiorphan-sensitive [D-Ala2,Leu5]enkephalin-degrading activity.	phosphoramidon	99-113	membrane metalloendopeptidase	Homo sapiens	31-34
8401914-8	1993	Phosphoramidon (10 microM) or SQ-28,603 (100 microM) totally suppressed the degradation of [125I]-ET-1 by rNEP.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	98-102
8401914-8	1993	Phosphoramidon (10 microM) or SQ-28,603 (100 microM) totally suppressed the degradation of [125I]-ET-1 by rNEP.	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	106-110
8338128-3	1993	We therefore studied maximal binding capacity of 125I-labeled ET-1 in the presence or absence of the metalloprotease inhibitors phosphoramidon, which blocks the intracellular processing of Big ET-1 to ET-1, and thiorphan, which does not block this conversion.	phosphoramidon	128-142	endothelin 1	Rattus norvegicus	193-197
8338128-3	1993	We therefore studied maximal binding capacity of 125I-labeled ET-1 in the presence or absence of the metalloprotease inhibitors phosphoramidon, which blocks the intracellular processing of Big ET-1 to ET-1, and thiorphan, which does not block this conversion.	phosphoramidon	128-142	endothelin 1	Rattus norvegicus	193-197
8338128-4	1993	Phosphoramidon inhibited the release of ET-1 by human umbilical vein endothelial cells, rat aortic endothelial cells, and rat mesangial cells, and increased 1.4- to 17-fold the maximal binding capacity in the three types of cells.	phosphoramidon	0-14	endothelin 1	Homo sapiens	40-44
8338128-6	1993	The increase in receptor binding by phosphoramidon was associated with an increase in the functional effect of ET-1, as measured by arachidonic acid release in rat mesangial cells.	phosphoramidon	36-50	endothelin 1	Rattus norvegicus	111-115
8337517-5	1993	On the other hand, phosphoramidon and MERGAPTA, inhibitors of neutral endopeptidase and carboxypeptidase N, respectively, strengthened the effect of BK.	phosphoramidon	19-33	kininogen 1	Canis lupus familiaris	149-151
8390257-3	1993	Inhibitors of angiotensin-converting enzyme (ACE; EC 3.4.15.1) and phosphoramidon, an inhibitor of neutral metalloendopeptidase (NEP; EC 3.4.24.11), were only partially effective in preventing BK degradation in semen.	phosphoramidon	67-81	membrane metalloendopeptidase	Homo sapiens	99-127
8210514-1	1993	Intracisternal (ic) injection of the neutral endopeptidase-24.11 inhibitor phosphoramidon (1-100 nmol) produced a dose-dependent inhibition of gastric acid secretion in 2-h pylorus-ligated rats.	phosphoramidon	75-89	membrane metallo-endopeptidase	Rattus norvegicus	37-64
8210514-6	1993	Moreover, phosphoramidon-induced inhibition of acid was not reduced by the centrally effective bombesin antagonist N-acetyl-GRP(20-26)-O-CH3 or by reserpine pretreatment at a dose effective to antagonize ic neurotensin-induced inhibition in acid secretion.	phosphoramidon	10-24	neurotensin	Rattus norvegicus	207-218
7689402-15	1993	The facilitatory effect of phosphoramidon (10 microM) on PGS-induced contractions was inhibited by the selective NK1 receptor antagonist, GR71251 (1 microM).	phosphoramidon	27-41	substance-P receptor	Cavia porcellus	113-125
8335860-6	1993	Phosphoramidon (10(-5) mol/L) enhanced the inhibitory effect of NPY on EFS-induced contractions at 5 Hz.	phosphoramidon	0-14	neuropeptide Y	Homo sapiens	64-67
8335860-8	1993	Phosphoramidon (10(-5) mol/L) did not affect the frequency response to EFS, but enhanced the inhibitory effect of NPY (3 x 10(-7) mol/L) on frequency response to EFS, resulting in a significant increase in the mean logarithm of frequency that produced 50% of maximal contraction (NPY: 0.79 +/- 0.09 versus NPY plus phosphoramidon: 1.18 +/- 0.15, p < 0.05).	phosphoramidon	0-14	neuropeptide Y	Homo sapiens	114-117
8335860-8	1993	Phosphoramidon (10(-5) mol/L) did not affect the frequency response to EFS, but enhanced the inhibitory effect of NPY (3 x 10(-7) mol/L) on frequency response to EFS, resulting in a significant increase in the mean logarithm of frequency that produced 50% of maximal contraction (NPY: 0.79 +/- 0.09 versus NPY plus phosphoramidon: 1.18 +/- 0.15, p < 0.05).	phosphoramidon	0-14	neuropeptide Y	Homo sapiens	280-283
8335860-8	1993	Phosphoramidon (10(-5) mol/L) did not affect the frequency response to EFS, but enhanced the inhibitory effect of NPY (3 x 10(-7) mol/L) on frequency response to EFS, resulting in a significant increase in the mean logarithm of frequency that produced 50% of maximal contraction (NPY: 0.79 +/- 0.09 versus NPY plus phosphoramidon: 1.18 +/- 0.15, p < 0.05).	phosphoramidon	0-14	neuropeptide Y	Homo sapiens	280-283
8335860-8	1993	Phosphoramidon (10(-5) mol/L) did not affect the frequency response to EFS, but enhanced the inhibitory effect of NPY (3 x 10(-7) mol/L) on frequency response to EFS, resulting in a significant increase in the mean logarithm of frequency that produced 50% of maximal contraction (NPY: 0.79 +/- 0.09 versus NPY plus phosphoramidon: 1.18 +/- 0.15, p < 0.05).	phosphoramidon	315-329	neuropeptide Y	Homo sapiens	114-117
8330216-6	1993	The histochemical staining in the transplants and the surrounding host tissue was completely blocked by a 100 nM concentration of the selective NEP inhibitors phosphoramidon or JHF-26, supporting the exclusive localization of NEP by this method.	phosphoramidon	159-173	membrane metallo-endopeptidase	Rattus norvegicus	144-147
8330216-6	1993	The histochemical staining in the transplants and the surrounding host tissue was completely blocked by a 100 nM concentration of the selective NEP inhibitors phosphoramidon or JHF-26, supporting the exclusive localization of NEP by this method.	phosphoramidon	159-173	membrane metallo-endopeptidase	Rattus norvegicus	226-229
7684296-10	1993	In the presence of phosphoramidon (10 microM), passive sensitization still increased significantly the amplitude of the contractile responses to SP and NKA including that to the maximal concentration given from 74 +/- 4% to 115 +/- 7% (n = 5, P<0.05) and from 104 +/- 9% to 146 +/- 16% (n = 5, P<0.05)of the maximal response to acetylcholine, respectively.	phosphoramidon	19-33	tachykinin precursor 1	Homo sapiens	145-147
7684296-10	1993	In the presence of phosphoramidon (10 microM), passive sensitization still increased significantly the amplitude of the contractile responses to SP and NKA including that to the maximal concentration given from 74 +/- 4% to 115 +/- 7% (n = 5, P<0.05) and from 104 +/- 9% to 146 +/- 16% (n = 5, P<0.05)of the maximal response to acetylcholine, respectively.	phosphoramidon	19-33	tachykinin precursor 1	Homo sapiens	152-155
7684296-12	1993	The relaxant response to the maximal concentration of VIP given in tissues precontracted with histamine (0.5 mM) was significantly reduced by passive sensitization from 41 +/- 4% to 25 +/- 3% (n = 5,P <0.05) of the amplitude of the precontraction in the absence of phosphoramidon and from 72 +/- 1%to 49 +/- 4% (n = 5, P<0.05) in the presence of phosphoramidon (10 microM).	phosphoramidon	268-282	vasoactive intestinal peptide	Homo sapiens	54-57
7684296-12	1993	The relaxant response to the maximal concentration of VIP given in tissues precontracted with histamine (0.5 mM) was significantly reduced by passive sensitization from 41 +/- 4% to 25 +/- 3% (n = 5,P <0.05) of the amplitude of the precontraction in the absence of phosphoramidon and from 72 +/- 1%to 49 +/- 4% (n = 5, P<0.05) in the presence of phosphoramidon (10 microM).	phosphoramidon	352-366	vasoactive intestinal peptide	Homo sapiens	54-57
7684296-13	1993	Passive sensitization significantly shifted to the right the CCRC for VIP as measured by the dose-ratios which were 10.4(95% CL: 6.6-14.1) and 6.4 (95% CL: 3.0-9.8) in the absence and in the presence of phosphoramidon,respectively.6.	phosphoramidon	203-217	vasoactive intestinal peptide	Homo sapiens	70-73
8518331-2	1993	In this study, we have examined the effects on the ET-1 pathway of 18 h exposure at 37 degrees C of cultured rat aortic smooth muscle cells to dexamethasone (DEX) and phosphoramidon.	phosphoramidon	167-181	endothelin 1	Rattus norvegicus	51-55
8395230-5	1993	The inhibitor of neutral endopeptidase, phosphoramidon (10(-8) mol/l), decreased the degradation of bradykinin in the supernatant of endothelial cells; the half-life of bradykinin was then increased from 29 +/- 1 to 46 +/- 2 minutes.	phosphoramidon	40-54	kininogen 1	Homo sapiens	100-110
8395230-5	1993	The inhibitor of neutral endopeptidase, phosphoramidon (10(-8) mol/l), decreased the degradation of bradykinin in the supernatant of endothelial cells; the half-life of bradykinin was then increased from 29 +/- 1 to 46 +/- 2 minutes.	phosphoramidon	40-54	kininogen 1	Homo sapiens	169-179
8518331-5	1993	In contrast, phosphoramidon (100 microM) inhibited ET-1 production by 60%, up-regulated ET-1 receptors and potentiated ET-1-induced calcium mobilization by 75%.	phosphoramidon	13-27	endothelin 1	Rattus norvegicus	51-55
8518331-5	1993	In contrast, phosphoramidon (100 microM) inhibited ET-1 production by 60%, up-regulated ET-1 receptors and potentiated ET-1-induced calcium mobilization by 75%.	phosphoramidon	13-27	endothelin 1	Rattus norvegicus	88-92
8431480-3	1993	The metalloproteinase inhibitor phosphoramidon inhibited the conversion of big ET-1 into mature ET-1 both in vivo and in cultured endothelial cells, suggesting that ECE may be a neutral metalloproteinase.	phosphoramidon	32-46	endothelin 1	Homo sapiens	79-83
8518331-5	1993	In contrast, phosphoramidon (100 microM) inhibited ET-1 production by 60%, up-regulated ET-1 receptors and potentiated ET-1-induced calcium mobilization by 75%.	phosphoramidon	13-27	endothelin 1	Rattus norvegicus	88-92
8518331-6	1993	These results indicate that the regulatory effects of DEX and phosphoramidon on ET-1 receptors are mediated via ET-1 production by the cells.	phosphoramidon	62-76	endothelin 1	Rattus norvegicus	80-84
8518331-6	1993	These results indicate that the regulatory effects of DEX and phosphoramidon on ET-1 receptors are mediated via ET-1 production by the cells.	phosphoramidon	62-76	endothelin 1	Rattus norvegicus	112-116
8467870-0	1993	Big endothelin-1 and big endothelin-3 are constrictor agents in the microvasculature: evidence for the local phosphoramidon-sensitive conversion of big endothelin-1.	phosphoramidon	109-123	endothelin 1	Rattus norvegicus	4-16
8467870-0	1993	Big endothelin-1 and big endothelin-3 are constrictor agents in the microvasculature: evidence for the local phosphoramidon-sensitive conversion of big endothelin-1.	phosphoramidon	109-123	endothelin 3	Rattus norvegicus	25-37
8467870-0	1993	Big endothelin-1 and big endothelin-3 are constrictor agents in the microvasculature: evidence for the local phosphoramidon-sensitive conversion of big endothelin-1.	phosphoramidon	109-123	endothelin 1	Rattus norvegicus	152-164
8467870-8	1993	Phosphoramidon (100 nmol) abolished constriction to big ET-1 (100 pmol) but not to ET-1 (10 pmol).	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	56-60
8467870-10	1993	Results suggest that a phosphoramidon-sensitive endothelin-converting enzyme situated close to microvascular vessels is important in the conversion of big ET-1.	phosphoramidon	23-37	endothelin 1	Rattus norvegicus	155-159
8482675-6	1993	The effect of FMLP was significantly modified by cholinergic blockade (61.1 +/- 6.9) and by NEP inhibition (thiorphan 38.8 +/- 5.6, phosphoramidon 52.6 +/- 4.2).	phosphoramidon	132-146	neprilysin	Oryctolagus cuniculus	92-95
8458433-3	1993	The lipoprotein ECE activity, which was optimal at pH 7.0, was inhibited by EDTA, o-phenanthroline, phosphoramidon, thiorphan, phenylmethanesulfonyl fluoride and chymostatin, but not by cysteine or aspartic proteinase inhibitors, suggesting metalloproteinase- and chymotrypsin-like properties.	phosphoramidon	100-114	endothelin converting enzyme 1	Homo sapiens	16-19
7683398-4	1993	The actions of the peptides were enhanced in the combined presence of phosphoramidon, captopril, and bestatin; the potency order remained NKA > SP > NKB.	phosphoramidon	70-84	tachykinin precursor 3	Rattus norvegicus	155-158
8449237-2	1993	injection of endothelin family peptides following administration of phosphoramidon in anesthetized Sprague-Dawley rats.	phosphoramidon	68-82	endothelin 1	Homo sapiens	13-23
8449237-6	1993	The pressor response to big ET-1 60 min after phosphoramidon injection was attenuated by roughly 60% indicating a long inhibitory half-life.	phosphoramidon	46-60	endothelin 1	Homo sapiens	28-32
8449237-7	1993	Very high doses of big ET-1 (> 20 mg/kg) were capable of over-riding the effect of phosphoramidon and produced characteristic pressor responses suggesting that the inhibition by phosphoramidon can be considered competitive in nature.	phosphoramidon	86-100	endothelin 1	Rattus norvegicus	23-27
8449237-7	1993	Very high doses of big ET-1 (> 20 mg/kg) were capable of over-riding the effect of phosphoramidon and produced characteristic pressor responses suggesting that the inhibition by phosphoramidon can be considered competitive in nature.	phosphoramidon	181-195	endothelin 1	Rattus norvegicus	23-27
8449237-9	1993	The pressor response to big ET-3 was also inhibited by phosphoramidon.	phosphoramidon	55-69	endothelin 3	Rattus norvegicus	28-32
8449237-11	1993	These results are consistent with the idea that a phosphoramidon-sensitive endothelin-converting enzyme is capable of cleaving both big ET-1 and big ET-3 to the active peptides in the rat.	phosphoramidon	50-64	endothelin 1	Rattus norvegicus	136-140
8449237-11	1993	These results are consistent with the idea that a phosphoramidon-sensitive endothelin-converting enzyme is capable of cleaving both big ET-1 and big ET-3 to the active peptides in the rat.	phosphoramidon	50-64	endothelin 3	Rattus norvegicus	149-153
8431480-3	1993	The metalloproteinase inhibitor phosphoramidon inhibited the conversion of big ET-1 into mature ET-1 both in vivo and in cultured endothelial cells, suggesting that ECE may be a neutral metalloproteinase.	phosphoramidon	32-46	endothelin 1	Homo sapiens	96-100
8431480-3	1993	The metalloproteinase inhibitor phosphoramidon inhibited the conversion of big ET-1 into mature ET-1 both in vivo and in cultured endothelial cells, suggesting that ECE may be a neutral metalloproteinase.	phosphoramidon	32-46	endothelin converting enzyme 1	Homo sapiens	165-168
8406292-1	1993	The effect of phosphoramidon on the increase in pulmonary inflation pressure (PIP) induced by endothelin-1 (ET-1) administered by aerosol in ovalbumin (OA)-sensitized and challenged guinea-pigs was investigated after pretreatment or not of the animals with the neutral endopeptidase inhibitor, phosphoramidon, the cyclooxygenase inhibitor, indomethacin or the platelet activating factor (PAF) antagonist, BN 50730.	phosphoramidon	14-28	endothelin-1	Cavia porcellus	94-106
8094056-0	1993	Big endothelin-3-induced hypertension and its inhibition by phosphoramidon in anaesthetized rats.	phosphoramidon	60-74	endothelin 3	Rattus norvegicus	4-16
8094056-2	1993	The pressor effect induced by big ET-3 was markedly attenuated by pretreatment with phosphoramidon, 5 mg/kg i.v., a dose which had no effect on the hypertensive action induced by ET-3.	phosphoramidon	84-98	endothelin 3	Rattus norvegicus	34-38
8448012-3	1993	The NEP inhibitors phosphoramidon and DL-thiorphan (1 microM) inhibited degradation of the substrate by gastric muscle membranes by 100% and by freshly dispersed gastric muscle cells by 55-60%.	phosphoramidon	19-33	membrane metalloendopeptidase	Homo sapiens	4-7
8448012-4	1993	The phosphoramidon or DL-thiorphan-inhibitable activity, attributed to NEP, of membranes was 112 +/- 4.0 pmol h-1 (micrograms protein)-1 and of cells was 4.2 +/- 0.8 nmol h-1 (10(6) cells)-1.	phosphoramidon	4-18	membrane metalloendopeptidase	Homo sapiens	71-74
8406292-1	1993	The effect of phosphoramidon on the increase in pulmonary inflation pressure (PIP) induced by endothelin-1 (ET-1) administered by aerosol in ovalbumin (OA)-sensitized and challenged guinea-pigs was investigated after pretreatment or not of the animals with the neutral endopeptidase inhibitor, phosphoramidon, the cyclooxygenase inhibitor, indomethacin or the platelet activating factor (PAF) antagonist, BN 50730.	phosphoramidon	14-28	endothelin-1	Cavia porcellus	108-112
8406292-2	1993	When guinea-pigs were pretreated by phosphoramidon (0.1 mM, aerosol for 15 min), a significant enhancement of PIP was observed after administration of ET-1 (1 or 3 micrograms ml-1, aerosol for 2 min), whereas these doses of the peptide were only slightly active in control animals.	phosphoramidon	36-50	endothelin-1	Cavia porcellus	151-155
8406292-9	1993	Moreover, this drug was moderately active in reducing the increase in PIP induced by ET-1, when the animals were pretreated by phosphoramidon.	phosphoramidon	127-141	endothelin-1	Cavia porcellus	85-89
8406292-10	1993	These results suggest that a phosphoramidon-sensitive endopeptidase-like enzyme, present in the airway tissue modulates the effect of ET-1.	phosphoramidon	29-43	endothelin-1	Cavia porcellus	134-138
7509998-4	1993	A major portion of phosphoramidon-sensitive ECE activity was distributed with a single peak at the approximately 1.05-1.2 M sucrose region, where it appeared to be cosedimented with membrane vesicles that contained the two different marker enzymes for Golgi apparatus.	phosphoramidon	19-33	endothelin converting enzyme 1	Rattus norvegicus	44-47
7509999-7	1993	A number of studies have reported that the final processing step in ET-1 biosynthesis by the hypothetical endothelin-converting enzyme (ECE) is inhibited by phosphoramidon (PHOS).	phosphoramidon	157-171	endothelin 1	Bos taurus	68-72
7509942-2	1993	The tonic contraction to big ET-1 (10 nM) was markedly blocked by phosphoramidon (100 microM), which did not modify the response to an equipotent concentration of ET-1 (3 nM).	phosphoramidon	66-80	endothelin 1	Rattus norvegicus	29-33
7509942-8	1993	Therefore, the rat uterus contains a phosphoramidon-sensitive, calcium-dependent endothelin-converting enzyme that readily converts big ET-1 into ET-1, which then contracts the myometrium via activation of ETA receptors.	phosphoramidon	37-51	endothelin 1	Rattus norvegicus	136-140
7509932-3	1993	In contrast, ET-1 and ET-3 almost equipotently inhibited forskolin-stimulated cAMP formation in bovine EC pretreated with phosphoramidon, a putative ET-1 converting-enzyme inhibitor.	phosphoramidon	122-136	endothelin 1	Bos taurus	13-26
7509999-7	1993	A number of studies have reported that the final processing step in ET-1 biosynthesis by the hypothetical endothelin-converting enzyme (ECE) is inhibited by phosphoramidon (PHOS).	phosphoramidon	157-171	endothelin converting enzyme 1	Homo sapiens	136-139
7509932-3	1993	In contrast, ET-1 and ET-3 almost equipotently inhibited forskolin-stimulated cAMP formation in bovine EC pretreated with phosphoramidon, a putative ET-1 converting-enzyme inhibitor.	phosphoramidon	122-136	endothelin 1	Bos taurus	13-17
7509942-8	1993	Therefore, the rat uterus contains a phosphoramidon-sensitive, calcium-dependent endothelin-converting enzyme that readily converts big ET-1 into ET-1, which then contracts the myometrium via activation of ETA receptors.	phosphoramidon	37-51	endothelin 1	Rattus norvegicus	146-150
7509999-7	1993	A number of studies have reported that the final processing step in ET-1 biosynthesis by the hypothetical endothelin-converting enzyme (ECE) is inhibited by phosphoramidon (PHOS).	phosphoramidon	173-177	endothelin 1	Bos taurus	68-72
7509999-7	1993	A number of studies have reported that the final processing step in ET-1 biosynthesis by the hypothetical endothelin-converting enzyme (ECE) is inhibited by phosphoramidon (PHOS).	phosphoramidon	173-177	endothelin converting enzyme 1	Homo sapiens	136-139
7510004-0	1993	Effects of phosphoramidon in endothelial cell cultures on the endogenous synthesis of endothelin-1 and on conversion of exogenous big endothelin-1 to endothelin-1.	phosphoramidon	11-25	endothelin 1	Homo sapiens	86-98
7510004-1	1993	Several studies have shown that phosphoramidon (PHOS) reduces the release of endothelin-1 (ET-1) from cultured endothelial cells.	phosphoramidon	32-46	endothelin 1	Homo sapiens	77-89
7510001-7	1993	Phosphoramidon (10 microM) infused TK blocked (92 +/- 1% inhibition) the renal responses to bET-1 and reduced the overflow of ET-1-like material onto the tissues without affecting ET-1-induced renal vasoconstriction.	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	93-97
7510004-1	1993	Several studies have shown that phosphoramidon (PHOS) reduces the release of endothelin-1 (ET-1) from cultured endothelial cells.	phosphoramidon	32-46	endothelin 1	Homo sapiens	91-95
7510004-1	1993	Several studies have shown that phosphoramidon (PHOS) reduces the release of endothelin-1 (ET-1) from cultured endothelial cells.	phosphoramidon	48-52	endothelin 1	Homo sapiens	77-89
7510001-7	1993	Phosphoramidon (10 microM) infused TK blocked (92 +/- 1% inhibition) the renal responses to bET-1 and reduced the overflow of ET-1-like material onto the tissues without affecting ET-1-induced renal vasoconstriction.	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	126-130
7510004-1	1993	Several studies have shown that phosphoramidon (PHOS) reduces the release of endothelin-1 (ET-1) from cultured endothelial cells.	phosphoramidon	48-52	endothelin 1	Homo sapiens	91-95
7510004-6	1993	The concentrations of ET-1 accumulating in the medium over 24 h from BAECs were lowered by PHOS (-27% 10 microM, -76% 100 microM).	phosphoramidon	91-95	endothelin 1	Homo sapiens	22-26
7510001-8	1993	Incubation of bET-1 with rabbit renal cortical microsomes (100 micrograms protein) resulted in the generation of ET-1-like activity, as assessed by bioassay, which was inhibited by phosphoramidon (10 microM).	phosphoramidon	181-195	endothelin-1	Oryctolagus cuniculus	15-19
7510004-7	1993	In contrast, with EA.hy 926 cells, the same concentrations of PHOS increased by five- to sixfold the amount of ET-1 present in the medium after 24-h incubation.	phosphoramidon	62-66	endothelin 1	Homo sapiens	111-115
1467845-0	1992	Phosphoramidon blocks big-endothelin-1 but not endothelin-1 enhancement of vascular permeability in the rat.	phosphoramidon	0-14	endothelin 1	Homo sapiens	26-38
7510004-8	1993	In other experiments, incubation of big ET-1 (1 microM) with intact BAECs or EA.hy 926 cells resulted in the generation of ET-1, and with both cell types this was inhibited by PHOS (IC50: BAECs = 6.4 microM; EA.hy 926 = 0.26 microM).	phosphoramidon	176-180	endothelin 1	Homo sapiens	40-44
7510004-8	1993	In other experiments, incubation of big ET-1 (1 microM) with intact BAECs or EA.hy 926 cells resulted in the generation of ET-1, and with both cell types this was inhibited by PHOS (IC50: BAECs = 6.4 microM; EA.hy 926 = 0.26 microM).	phosphoramidon	176-180	endothelin 1	Homo sapiens	123-127
7510006-0	1993	Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	46-50
7510006-0	1993	Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	56-60
7510006-2	1993	The aim of this study was to test the effects of the endothelin-converting enzyme (ECE) inhibitor phosphoramidon on pressor responses to ET-1 and its precursor, big ET-1, in isolated perfused rat kidneys and in pithed rats.	phosphoramidon	98-112	endothelin converting enzyme 1	Rattus norvegicus	53-81
7510006-2	1993	The aim of this study was to test the effects of the endothelin-converting enzyme (ECE) inhibitor phosphoramidon on pressor responses to ET-1 and its precursor, big ET-1, in isolated perfused rat kidneys and in pithed rats.	phosphoramidon	98-112	endothelin converting enzyme 1	Rattus norvegicus	83-86
7510006-2	1993	The aim of this study was to test the effects of the endothelin-converting enzyme (ECE) inhibitor phosphoramidon on pressor responses to ET-1 and its precursor, big ET-1, in isolated perfused rat kidneys and in pithed rats.	phosphoramidon	98-112	endothelin 1	Rattus norvegicus	137-141
7510006-2	1993	The aim of this study was to test the effects of the endothelin-converting enzyme (ECE) inhibitor phosphoramidon on pressor responses to ET-1 and its precursor, big ET-1, in isolated perfused rat kidneys and in pithed rats.	phosphoramidon	98-112	endothelin 1	Rattus norvegicus	165-169
7510006-4	1993	Phosphoramidon (10 microM) selectively inhibited the pressor responses to big ET-1 without altering those to ET-1, norepinephrine, angiotensin I (AT-I), or angiotensin II (AT-II).	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	78-82
7510006-4	1993	Phosphoramidon (10 microM) selectively inhibited the pressor responses to big ET-1 without altering those to ET-1, norepinephrine, angiotensin I (AT-I), or angiotensin II (AT-II).	phosphoramidon	0-14	angiotensinogen	Rattus norvegicus	172-177
7510006-7	1993	Phosphoramidon selectively inhibited the pressor responses to big ET-1 (ID50: 78 micrograms/kg/min) without affecting those to ET-1, AT-I, or AT-II.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	66-70
7510006-8	1993	These data illustrate that the pressor responses to big ET-1 in the rat, both in vivo and in vitro, are due to its conversion into ET-1 by a phosphoramidon-sensitive ECE.	phosphoramidon	141-155	endothelin 1	Rattus norvegicus	56-60
7510006-8	1993	These data illustrate that the pressor responses to big ET-1 in the rat, both in vivo and in vitro, are due to its conversion into ET-1 by a phosphoramidon-sensitive ECE.	phosphoramidon	141-155	endothelin 1	Rattus norvegicus	131-135
7510006-8	1993	These data illustrate that the pressor responses to big ET-1 in the rat, both in vivo and in vitro, are due to its conversion into ET-1 by a phosphoramidon-sensitive ECE.	phosphoramidon	141-155	endothelin converting enzyme 1	Rattus norvegicus	166-169
7510006-9	1993	In the rat, phosphoramidon selectively inhibits ECE but not ACE both in vitro and in vivo.	phosphoramidon	12-26	endothelin converting enzyme 1	Rattus norvegicus	48-51
7510007-0	1993	Pharmacologic evidence for the specificity of the phosphoramidon-sensitive endothelin-converting enzyme for big endothelin-1.	phosphoramidon	50-64	endothelin 1	Rattus norvegicus	112-124
7510007-2	1993	In these models, big ET-1 consistently induced concentration- or dose-dependent pharmacologic effects sensitive to phosphoramidon (vasopressor or prostanoid-releasing effects).	phosphoramidon	115-129	endothelin 1	Rattus norvegicus	21-25
7510007-5	1993	In this model, although big ET-1 induced a phosphoramidon-sensitive increase of the twitch response of the tissue to electrical stimulation, big ET-3, dissolved either in phosphate-buffered saline or acetic acid, remained inactive.	phosphoramidon	43-57	endothelin 1	Rattus norvegicus	28-32
7510007-6	1993	Our results, presented in the above-mentioned models, illustrate the capacity of the phosphoramidon-sensitive endothelin-converting enzyme (ECE) to discriminate between human big ET-1 and big ET-3.	phosphoramidon	85-99	endothelin converting enzyme 1	Homo sapiens	140-143
7510007-6	1993	Our results, presented in the above-mentioned models, illustrate the capacity of the phosphoramidon-sensitive endothelin-converting enzyme (ECE) to discriminate between human big ET-1 and big ET-3.	phosphoramidon	85-99	endothelin 1	Rattus norvegicus	179-183
7510008-5	1993	The production of the C-terminal fragment of big ET-1 could be detected in this partially purified preparation and was inhibited by phosphoramidon (10 microM) but not by thiorphan (10 microM).	phosphoramidon	132-146	endothelin-1	Sus scrofa	49-53
1467845-11	1992	Pretreatment with phosphoramidon (PA) blocked the response to big-ET-1 in all tissues examined but this inhibitor failed to alter the response to ET-1.	phosphoramidon	18-32	endothelin 1	Rattus norvegicus	66-70
1467845-11	1992	Pretreatment with phosphoramidon (PA) blocked the response to big-ET-1 in all tissues examined but this inhibitor failed to alter the response to ET-1.	phosphoramidon	34-36	endothelin 1	Rattus norvegicus	66-70
1467845-13	1992	We conclude from these results that the dose-dependent increase in vascular permeability induced by big-ET-1 in various tissues follows its conversion to ET-1 by the endothelin converting enzyme, a PA-sensitive process.	phosphoramidon	198-200	endothelin 1	Rattus norvegicus	104-108
1467845-13	1992	We conclude from these results that the dose-dependent increase in vascular permeability induced by big-ET-1 in various tissues follows its conversion to ET-1 by the endothelin converting enzyme, a PA-sensitive process.	phosphoramidon	198-200	endothelin 1	Rattus norvegicus	154-158
8355566-1	1993	Phosphoramidon inhibits both endothelin converting enzyme (ECE) and neutral metalloendopeptidase (NEP).	phosphoramidon	0-14	endothelin converting enzyme 1	Rattus norvegicus	29-57
8355566-1	1993	Phosphoramidon inhibits both endothelin converting enzyme (ECE) and neutral metalloendopeptidase (NEP).	phosphoramidon	0-14	endothelin converting enzyme 1	Rattus norvegicus	59-62
8355566-1	1993	Phosphoramidon inhibits both endothelin converting enzyme (ECE) and neutral metalloendopeptidase (NEP).	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	68-96
8355566-1	1993	Phosphoramidon inhibits both endothelin converting enzyme (ECE) and neutral metalloendopeptidase (NEP).	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	98-101
8355566-11	1993	In anesthetized normotensive rats, phosphoramidon (0.01-1.0 mg/kg/min x 30 min) dose-dependently inhibited the BP responses to big endothelin-1 (BET-1) without blocking the pressor responses to ET-1.	phosphoramidon	35-49	endothelin 1	Rattus norvegicus	131-143
8355566-14	1993	It is concluded that the antihypertensive action of SCH 32615 and low doses of phosphoramidon can be attributed to the inhibition of NEP which may presumably cause an accumulation of ANF.	phosphoramidon	79-93	membrane metallo-endopeptidase	Rattus norvegicus	133-136
8355566-14	1993	It is concluded that the antihypertensive action of SCH 32615 and low doses of phosphoramidon can be attributed to the inhibition of NEP which may presumably cause an accumulation of ANF.	phosphoramidon	79-93	natriuretic peptide A	Rattus norvegicus	183-186
8341132-0	1993	Phosphoramidon-sensitive endothelin converting enzyme in cultured vascular smooth muscle cells converts big endothelin-3 to endothelin-3.	phosphoramidon	0-14	endothelin 3	Homo sapiens	108-120
8341132-0	1993	Phosphoramidon-sensitive endothelin converting enzyme in cultured vascular smooth muscle cells converts big endothelin-3 to endothelin-3.	phosphoramidon	0-14	endothelin 3	Homo sapiens	124-136
8341132-1	1993	Incubation of big endothelin-3 (big ET-3, 1-41) with the membrane fraction obtained from cultured vascular smooth muscle cells (VSMCs) resulted in time-dependent increases in immunoreactive-ET (IR-ET), which were suppressed by phosphoramidon.	phosphoramidon	227-241	endothelin 3	Homo sapiens	18-30
8341132-1	1993	Incubation of big endothelin-3 (big ET-3, 1-41) with the membrane fraction obtained from cultured vascular smooth muscle cells (VSMCs) resulted in time-dependent increases in immunoreactive-ET (IR-ET), which were suppressed by phosphoramidon.	phosphoramidon	227-241	endothelin 3	Homo sapiens	36-40
8341132-5	1993	This ET-3 generation from exogenously applied big ET-3 was also suppressed by phosphoramidon.	phosphoramidon	78-92	endothelin 3	Homo sapiens	5-9
8341132-5	1993	This ET-3 generation from exogenously applied big ET-3 was also suppressed by phosphoramidon.	phosphoramidon	78-92	endothelin 3	Homo sapiens	50-54
8341132-6	1993	We conclude that the phosphoramidon-sensitive ET converting enzyme in VSMCs converts big ET-1 and big ET-3 to their mature form.	phosphoramidon	21-35	endothelin 1	Homo sapiens	89-106
1468574-0	1992	Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells.	phosphoramidon	10-24	endothelin 2	Homo sapiens	32-44
1468574-0	1992	Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells.	phosphoramidon	10-24	endothelin 2	Homo sapiens	61-73
1468574-4	1992	Phosphoramidon decreased the amount of ET-2 and increased that of big ET-2(1-38) dose-dependently.	phosphoramidon	0-14	endothelin 2	Homo sapiens	39-43
1468574-4	1992	Phosphoramidon decreased the amount of ET-2 and increased that of big ET-2(1-38) dose-dependently.	phosphoramidon	0-14	endothelin 2	Homo sapiens	70-74
1471681-7	1992	Phosphoramidon significantly inhibited the vasoconstrictor effect of big endothelin-1 (p < 0.039, paired t test).	phosphoramidon	0-14	endothelin 1	Homo sapiens	73-85
1469102-9	1992	In human fetal lung organ cultures, inhibition of CD10/NEP with either phosphoramidon or SCH32615 increases thymidine incorporation by 166-182% (P < 0.025).	phosphoramidon	71-85	membrane metalloendopeptidase	Homo sapiens	50-54
1362724-4	1992	Phosphoramidon (10(-5) M) significantly potentiated relaxations to low doses of VIP with no effect on i-NANC responses.	phosphoramidon	0-14	vasoactive intestinal peptide	Homo sapiens	80-83
1469102-9	1992	In human fetal lung organ cultures, inhibition of CD10/NEP with either phosphoramidon or SCH32615 increases thymidine incorporation by 166-182% (P < 0.025).	phosphoramidon	71-85	membrane metalloendopeptidase	Homo sapiens	55-58
1281168-4	1992	Specifically, in tumor necrosis factor (TNF)-treated immunocytes, we demonstrate the effects of increased NEP expression on altering the stimulatory activities of the neuropeptides met-enkephalin, melanocyte-stimulating hormone and substance P. We demonstrate the significance of NEP in modulating these responses through the use of specific enzyme inhibitors such as phosphoramidon, thiorphan and captopril.	phosphoramidon	368-382	tumor necrosis factor	Homo sapiens	17-38
1469621-6	1992	Phosphoramidon (100 microM, endothelin-converting enzyme inhibitor) and BQ-123 (0.3 microM, ETA receptor antagonist) abolished the preischemic increase in coronary perfusion pressure induced by big ET-1 as well as its proischemic effect, whereas only BQ-123 abolished the cardiac effect of ET-1.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	198-202
1469621-6	1992	Phosphoramidon (100 microM, endothelin-converting enzyme inhibitor) and BQ-123 (0.3 microM, ETA receptor antagonist) abolished the preischemic increase in coronary perfusion pressure induced by big ET-1 as well as its proischemic effect, whereas only BQ-123 abolished the cardiac effect of ET-1.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	290-294
1451739-0	1992	The vasoconstrictor action of big endothelin-1 is phosphoramidon-sensitive in rabbit saphenous artery, but not in saphenous vein.	phosphoramidon	50-64	endothelin-1	Oryctolagus cuniculus	34-46
1451739-4	1992	Phosphoramidon (100 microM), a metalloproteinase inhibitor, antagonised the contractile action of big endothelin-1 in the artery but not in the vein.	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	102-114
1333512-7	1992	In support of this observation, the inhibition of endopeptidase on adult polymorphonuclear neutrophils leukocytes by phosphoramidon was associated with an augmentation of chemotaxis to 10(-9) and 10(-10) mol/L fMLP.	phosphoramidon	117-131	formyl peptide receptor 1	Homo sapiens	210-214
1475409-7	1992	Formation of the hydrolysis product was prevented by the NEP-24.11-inhibitor phosphoramidon (1 microM).	phosphoramidon	77-91	membrane metallo-endopeptidase	Rattus norvegicus	57-66
1281168-4	1992	Specifically, in tumor necrosis factor (TNF)-treated immunocytes, we demonstrate the effects of increased NEP expression on altering the stimulatory activities of the neuropeptides met-enkephalin, melanocyte-stimulating hormone and substance P. We demonstrate the significance of NEP in modulating these responses through the use of specific enzyme inhibitors such as phosphoramidon, thiorphan and captopril.	phosphoramidon	368-382	tumor necrosis factor	Homo sapiens	40-43
1281168-4	1992	Specifically, in tumor necrosis factor (TNF)-treated immunocytes, we demonstrate the effects of increased NEP expression on altering the stimulatory activities of the neuropeptides met-enkephalin, melanocyte-stimulating hormone and substance P. We demonstrate the significance of NEP in modulating these responses through the use of specific enzyme inhibitors such as phosphoramidon, thiorphan and captopril.	phosphoramidon	368-382	membrane metalloendopeptidase	Homo sapiens	106-109
1400023-3	1992	Phosphoramidon significantly potentiated the endothelin-1-induced contraction in a concentration-dependent fashion in both guinea pig trachea and human bronchus, and it shifted the concentration-response curves to the left.	phosphoramidon	0-14	endothelin-1	Cavia porcellus	45-57
1426005-16	1992	We conclude that in the rat: (1) bigET-1 may affect RVR by both a direct effect and through phosphoramidon-sensitive conversion to ET-1; (2) the direct vasoconstrictor effect of bigET-1 might be expressed during endothelin-converting enzyme inhibition; (3) metalloproteases are involved in ET-1 degradation.	phosphoramidon	92-106	endothelin 1	Rattus norvegicus	36-40
1426005-16	1992	We conclude that in the rat: (1) bigET-1 may affect RVR by both a direct effect and through phosphoramidon-sensitive conversion to ET-1; (2) the direct vasoconstrictor effect of bigET-1 might be expressed during endothelin-converting enzyme inhibition; (3) metalloproteases are involved in ET-1 degradation.	phosphoramidon	92-106	endothelin 1	Rattus norvegicus	131-135
1398887-0	1992	Phosphoramidon-sensitive effects of big endothelins in the perfused rabbit kidney.	phosphoramidon	0-14	endothelin 1	Homo sapiens	40-51
1398887-5	1992	A metalloprotease inhibitor, phosphoramidon (100 microM, 60 minutes), reduced the prostanoid release and pressor responses induced by big endothelin-1 and -2 without affecting the response induced by endothelin-1, -2, and -3.	phosphoramidon	29-43	endothelin-1	Oryctolagus cuniculus	138-157
1398887-6	1992	These results suggest the presence of a phosphoramidon-sensitive endothelin converting enzyme that converts the precursors of endothelin-1 and -2, but not of endothelin-3, in the renal vasculature of the rabbit.	phosphoramidon	40-54	endothelin-1	Oryctolagus cuniculus	126-145
1528868-1	1992	A phosphoramidon-sensitive, membrane-bound metalloprotease that cleaves big endothelin 1 (big-ET-1) to ET-1 was obtained from human umbilical vein endothelial cells and also from bovine aortic endothelial cells by isolation of plasma-membrane vesicles free of lysosomes.	phosphoramidon	2-16	endothelin 1	Homo sapiens	76-88
1528868-1	1992	A phosphoramidon-sensitive, membrane-bound metalloprotease that cleaves big endothelin 1 (big-ET-1) to ET-1 was obtained from human umbilical vein endothelial cells and also from bovine aortic endothelial cells by isolation of plasma-membrane vesicles free of lysosomes.	phosphoramidon	2-16	endothelin 1	Homo sapiens	94-98
1528868-1	1992	A phosphoramidon-sensitive, membrane-bound metalloprotease that cleaves big endothelin 1 (big-ET-1) to ET-1 was obtained from human umbilical vein endothelial cells and also from bovine aortic endothelial cells by isolation of plasma-membrane vesicles free of lysosomes.	phosphoramidon	2-16	endothelin 1	Homo sapiens	103-107
1424102-1	1992	The s.c. administration of [Met5]-enkephalin to 10-day-old rats pretreated with the mixture of 3 peptidase inhibitors, amastatin, captopril and phosphoramidon, produced the inhibition of tail-flick response and loss of righting reflex.	phosphoramidon	144-158	proenkephalin	Rattus norvegicus	34-44
1422599-15	1992	Collectively, the results indicate that the haemodynamic effects of proendothelin-2 and -3 in vivo in conscious rats are probably due to their conversion to endothelin-2 and -3, respectively, by an enzyme(s) that is inhibited by phosphoramidon.	phosphoramidon	229-243	endothelin 2	Rattus norvegicus	71-90
1329092-4	1992	This value is in line with the concentrations obtained with [Met]enkephalin, tested in the presence of the specific neutral endopeptidase 24.11 inhibitor phosphoramidon, and this opioid"s synthetic analog [D-Ala2, Met5]enkephalin which, like [D-Ala2]deltorphin I, is resistant to proteolytic degradation.	phosphoramidon	154-168	membrane metalloendopeptidase	Homo sapiens	116-143
1516701-3	1992	Phosphoramidon, an inhibitor of neutral endopeptidase 24,11, almost completely suppressed the production of three fragments, but one fragment was not affected by the inhibitor.	phosphoramidon	0-14	membrane metallo-endopeptidase	Rattus norvegicus	32-59
1516701-4	1992	Analysis of N-terminal sequences of the degradation products revealed that the phosphoramidon-sensitive fragments were generated by cleavage at the Ser5-Leu6 bond of endothelin 1 that was identical with its cleavage site by purified rat endopeptidase 24,11, reported previously.	phosphoramidon	79-93	endothelin 1	Rattus norvegicus	166-178
1381726-7	1992	Lysylbradykinin was also degraded by NEP-24.11 (0.80 +/- 0.19 nmol/min per well); however, in the presence of phosphoramidon, AmM-mediated conversion to bradykinin (3.74 +/- 0.46 nmol/min per well) could be demonstrated.	phosphoramidon	110-124	kininogen 1	Homo sapiens	5-15
1400023-6	1992	Phosphoramidon significantly potentiated the endothelin-1-induced contraction in the capsaicin-treated tissues, suggesting that endothelin-1 causes the contraction, at least in part, without releasing tachykinins.	phosphoramidon	0-14	endothelin 1	Homo sapiens	45-57
1400023-6	1992	Phosphoramidon significantly potentiated the endothelin-1-induced contraction in the capsaicin-treated tissues, suggesting that endothelin-1 causes the contraction, at least in part, without releasing tachykinins.	phosphoramidon	0-14	endothelin 1	Homo sapiens	128-140
1393292-14	1992	These data show that rat brain contains a phosphoramidon- and EDTA-inhibitable ECE which maybe similar to that present in endothelial cells.	phosphoramidon	42-56	endothelin converting enzyme 1	Rattus norvegicus	79-82
1527713-0	1992	Phosphoramidon abolishes the increases in endothelin-1 release induced by ischemia-hypoxia in isolated perfused guinea pig lungs.	phosphoramidon	0-14	endothelin-1	Cavia porcellus	42-54
1393287-8	1992	Incubation of human isolated bronchi with the NEP inhibitor phosphoramidon (10(-5) M) induced a rightward shift of the concentration-response curve induced by big ET-1 (10(-9) M to 3 x 10(-7) M).	phosphoramidon	60-74	membrane metalloendopeptidase	Homo sapiens	46-49
1618346-0	1992	Phosphoramidon-sensitive endothelin-converting enzyme in vascular endothelial cells converts big endothelin-1 and big endothelin-3 to their mature form.	phosphoramidon	0-14	endothelin 1	Homo sapiens	97-109
1393287-8	1992	Incubation of human isolated bronchi with the NEP inhibitor phosphoramidon (10(-5) M) induced a rightward shift of the concentration-response curve induced by big ET-1 (10(-9) M to 3 x 10(-7) M).	phosphoramidon	60-74	endothelin 1	Homo sapiens	163-167
1393292-2	1992	It has been demonstrated previously that conversion of big endothelin-1 (bET-1) to endothelin-1 (ET-1) is inhibited in vitro and in vivo by phosphoramidon.	phosphoramidon	140-154	endothelin 1	Rattus norvegicus	59-71
1393292-2	1992	It has been demonstrated previously that conversion of big endothelin-1 (bET-1) to endothelin-1 (ET-1) is inhibited in vitro and in vivo by phosphoramidon.	phosphoramidon	140-154	endothelin 1	Rattus norvegicus	83-95
1393292-2	1992	It has been demonstrated previously that conversion of big endothelin-1 (bET-1) to endothelin-1 (ET-1) is inhibited in vitro and in vivo by phosphoramidon.	phosphoramidon	140-154	endothelin 1	Rattus norvegicus	74-78
1393292-4	1992	Here we expand upon our previous observation that rat brain contains phosphoramidon-inhibitable endothelin converting enzyme (ECE) and show that this activity is not uniformly distributed throughout the <protein-id="29588">brain.	phosphoramidon	69-83	endothelin converting enzyme 1	Rattus norvegicus	126-129
1393292-10	1992	Washing of the pellet with KCl (1 M) and extraction with the detergent CHAPS (20 mM) revealed a phosphoramidon-inhibitable ECE within the residual particulate fraction (nominally classified as the cytoskeletal fraction).	phosphoramidon	96-110	endothelin converting enzyme 1	Rattus norvegicus	123-126
1497648-1	1992	Experiments were conducted to determine the importance of the carbohydrate moiety of phosphoramidon in the inhibition of the pressor response to big endothelin-1 in anesthetized rats.	phosphoramidon	85-99	endothelin 1	Rattus norvegicus	149-161
1497648-2	1992	Big endothelin-1 produced a 42% increase in mean arterial pressure which was nearly abolished by co-infusion of phosphoramidon.	phosphoramidon	112-126	endothelin 1	Rattus norvegicus	4-16
1378731-4	1992	Transient transfection of COS-7 cells with the cloned preproET-3 cDNA resulted in the production of mature ET-3 and this production was inhibited by phosphoramidon, a metaloprotease inhibitor.	phosphoramidon	149-163	endothelin 3	Rattus norvegicus	54-64
1378731-4	1992	Transient transfection of COS-7 cells with the cloned preproET-3 cDNA resulted in the production of mature ET-3 and this production was inhibited by phosphoramidon, a metaloprotease inhibitor.	phosphoramidon	149-163	endothelin 3	Rattus norvegicus	60-64
1378731-5	1992	This suggested that a phosphoramidon sensitive mechanism was involved in the production of ET-3 in the transfected COS-7 cells.	phosphoramidon	22-36	endothelin 3	Rattus norvegicus	91-95
1504735-0	1992	Human brain contains a metalloprotease that converts big endothelin-1 to endothelin-1 and is inhibited by phosphoramidon and EDTA.	phosphoramidon	106-120	endothelin 1	Homo sapiens	57-69
1504735-0	1992	Human brain contains a metalloprotease that converts big endothelin-1 to endothelin-1 and is inhibited by phosphoramidon and EDTA.	phosphoramidon	106-120	endothelin 1	Homo sapiens	73-85
1397024-7	1992	at the dose of 5 mg/kg, 5 min before the challenge, phosphoramidon almost totally inhibited the bronchoconstrictor and pressor responses induced by 10 nmol/kg big ET-1, whereas thiorphan (5 mg/kg) partially reduced the increase in PIP and exerted a minimal effect on the changes in MBP.	phosphoramidon	52-66	endothelin-1	Cavia porcellus	163-167
1618346-0	1992	Phosphoramidon-sensitive endothelin-converting enzyme in vascular endothelial cells converts big endothelin-1 and big endothelin-3 to their mature form.	phosphoramidon	0-14	endothelin 3	Homo sapiens	118-130
1618346-2	1992	This increasing activity was markedly suppressed by phosphoramidon, which is known to inhibit the conversion of big ET-1(1-39) to ET-1(1-21).	phosphoramidon	52-66	endothelin 1	Homo sapiens	116-120
1618346-2	1992	This increasing activity was markedly suppressed by phosphoramidon, which is known to inhibit the conversion of big ET-1(1-39) to ET-1(1-21).	phosphoramidon	52-66	endothelin 1	Homo sapiens	130-134
1629095-7	1992	Phosphoramidon, an inhibitor of metalloproteinase, suppressed the pressor effect of big ET-1 (P less than 0.01) and the increase in the concentration of ET-1 in the perfusate (P less than 0.05).	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	88-92
1629095-7	1992	Phosphoramidon, an inhibitor of metalloproteinase, suppressed the pressor effect of big ET-1 (P less than 0.01) and the increase in the concentration of ET-1 in the perfusate (P less than 0.05).	phosphoramidon	0-14	endothelin-1	Oryctolagus cuniculus	153-157
1311412-3	1992	The latter but not the former activity was inhibited in a concentration-dependent manner by phosphoramidon (approximate IC50, 1 microM) and converted bET-1 to ET-1 at a rate of 0.6 nmol/hr/mg of protein.	phosphoramidon	92-106	endothelin 1	Rattus norvegicus	151-155
1507681-4	1992	We studied the effect of phosphoramidon on bronchoconstriction induced by ET-1.	phosphoramidon	25-39	endothelin-1	Cavia porcellus	74-78
1507681-8	1992	Phosphoramidon potentiated ET-1 induced bronchoconstriction significantly.	phosphoramidon	0-14	endothelin-1	Cavia porcellus	27-31
1507681-11	1992	sGaw, after inhalation of phosphoramidon, was significantly reduced when exposed to ET-1.	phosphoramidon	26-40	endothelin-1	Cavia porcellus	84-88
1507681-12	1992	Phosphoramidon also potentiated ET-1 induced bronchoconstriction in vivo.	phosphoramidon	0-14	endothelin-1	Cavia porcellus	32-36
1507681-15	1992	Phosphoramidon inhibited an analysis of ET-1.	phosphoramidon	0-14	endothelin-1	Cavia porcellus	40-44
1312017-3	1992	However, addition of phosphoramidon, an inhibitor of ET-converting enzyme, to the medium reduced the production of ET-1 and thus the receptors on HUVECs were made available for exogenously added [125I]ET-1.	phosphoramidon	21-35	endothelin 1	Homo sapiens	115-119
1312017-3	1992	However, addition of phosphoramidon, an inhibitor of ET-converting enzyme, to the medium reduced the production of ET-1 and thus the receptors on HUVECs were made available for exogenously added [125I]ET-1.	phosphoramidon	21-35	endothelin 1	Homo sapiens	201-205
1602404-14	1992	Furthermore, phosphoramidon (0.25 mg/kg/min x 30) abolished pressor response to big endothelin-1 (5 micrograms/kg, i.v.)	phosphoramidon	13-27	endothelin 1	Rattus norvegicus	84-96
1504719-0	1992	Phosphoramidon potentiates the contractile response to endothelin-3, but not endothelin-1 in isolated airway tissue.	phosphoramidon	0-14	endothelin 3	Homo sapiens	55-67
1504719-2	1992	Phosphoramidon (10 microM) markedly increased the contractile response to endothelin-3 in human and rabbit bronchus in vitro.	phosphoramidon	0-14	endothelin 3	Homo sapiens	74-86
1504719-3	1992	In human tissue the contractile response to 0.3 microM endothelin-3 was significantly increased from 54 +/- 12% to 137 +/- 34% (of the response to 1 nM acetylcholine) in the presence of phosphoramidon.	phosphoramidon	186-200	endothelin 3	Homo sapiens	55-67
1504719-16	1992	These results suggest that a phosphoramidon-sensitive enzyme (probably neutral endopeptidase) found in lung, may be responsible for local degradation of endothelin-3, but not endothelin-l in human and rabbit isolated bronchus.	phosphoramidon	29-43	endothelin 3	Homo sapiens	153-165
1318210-5	1992	The neutral endopeptidase inhibitor phosphoramidon (1 microM) increased the potency of ANF-(5-27) in both epithelium-intact and epithelium-denuded guinea-pig tracheal rings.	phosphoramidon	36-50	natriuretic peptide A	Rattus norvegicus	87-90
1318210-6	1992	In contrast, removal of the epithelium from rat trachea, or pretreatment with phosphoramidon (1 microM) decreased relaxant responsiveness to ANF-(5-27).	phosphoramidon	78-92	natriuretic peptide A	Rattus norvegicus	141-144
1540181-2	1992	ECEs derived from these epithelial cells were very similar to the endothelial ECE in the following biochemical properties: 1) The optimum pH was 7.0; 2) the Km value for big ET-1 was approximately 30 microM; 3) the enzyme was potently inhibited by EDTA, o-phenanthroline and phosphoramidon; and 4) the enzyme did not convert big ET-2 or big ET-3.	phosphoramidon	275-289	endothelin converting enzyme 1	Homo sapiens	0-3
1540181-2	1992	ECEs derived from these epithelial cells were very similar to the endothelial ECE in the following biochemical properties: 1) The optimum pH was 7.0; 2) the Km value for big ET-1 was approximately 30 microM; 3) the enzyme was potently inhibited by EDTA, o-phenanthroline and phosphoramidon; and 4) the enzyme did not convert big ET-2 or big ET-3.	phosphoramidon	275-289	endothelin 1	Homo sapiens	174-178
1540181-3	1992	These data suggest that phosphoramidon-sensitive ECE is involved in the processing of big ET-1 to ET-1 in the renal tubule.	phosphoramidon	24-38	endothelin converting enzyme 1	Homo sapiens	49-52
1540181-3	1992	These data suggest that phosphoramidon-sensitive ECE is involved in the processing of big ET-1 to ET-1 in the renal tubule.	phosphoramidon	24-38	endothelin 1	Homo sapiens	90-102
1311412-6	1992	Within the rat brain, phosphoramidon-inhibitable conversion of bET-1 to ET-1 was detected principally in the cytoskeletal fraction, i.e., that fraction from the membrane that was not solubilized by detergent treatment.	phosphoramidon	22-36	endothelin 1	Rattus norvegicus	64-68
1377128-6	1992	However, with high concentrations of endothelins (greater than 10(-9) M, second stage of contraction), phosphoramidon was less potent than epithelium removal in enhancing the contractile responses.	phosphoramidon	103-117	endothelin 1	Homo sapiens	37-48
1310003-9	1992	Both agents markedly inhibited the degradation of GRP, indicating that this process involves a lysosomal pathway and a phosphoramidon-sensitive pathway, possibly involving the EC 3.4.24.11 enzyme.	phosphoramidon	119-133	gastrin releasing peptide	Homo sapiens	50-53
1309957-4	1992	The conclusion that this alpha-MSH resulted from conversion of the parasite ACTH by neutral endopeptidase 24.11 (NEP) present on these cells was supported by the fact that the alpha-MSH level in the medium was markedly reduced by addition of the specific NEP inhibitor phosphoramidon.	phosphoramidon	269-283	proopiomelanocortin	Homo sapiens	25-34
1309957-4	1992	The conclusion that this alpha-MSH resulted from conversion of the parasite ACTH by neutral endopeptidase 24.11 (NEP) present on these cells was supported by the fact that the alpha-MSH level in the medium was markedly reduced by addition of the specific NEP inhibitor phosphoramidon.	phosphoramidon	269-283	proopiomelanocortin	Homo sapiens	76-80
1309957-4	1992	The conclusion that this alpha-MSH resulted from conversion of the parasite ACTH by neutral endopeptidase 24.11 (NEP) present on these cells was supported by the fact that the alpha-MSH level in the medium was markedly reduced by addition of the specific NEP inhibitor phosphoramidon.	phosphoramidon	269-283	membrane metalloendopeptidase	Homo sapiens	84-111
1309957-4	1992	The conclusion that this alpha-MSH resulted from conversion of the parasite ACTH by neutral endopeptidase 24.11 (NEP) present on these cells was supported by the fact that the alpha-MSH level in the medium was markedly reduced by addition of the specific NEP inhibitor phosphoramidon.	phosphoramidon	269-283	membrane metalloendopeptidase	Homo sapiens	113-116
1309957-4	1992	The conclusion that this alpha-MSH resulted from conversion of the parasite ACTH by neutral endopeptidase 24.11 (NEP) present on these cells was supported by the fact that the alpha-MSH level in the medium was markedly reduced by addition of the specific NEP inhibitor phosphoramidon.	phosphoramidon	269-283	proopiomelanocortin	Homo sapiens	176-185
1309958-4	1992	The addition to the incubation medium of phosphoramidon, a specific inhibitor of neutral endopeptidase 24.11, blocked inactivation of granulocytes by ACTH.	phosphoramidon	41-55	proopiomelanocortin	Homo sapiens	150-154
1731782-6	1992	Phosphoramidon specifically inhibited the Big ET-1 pressor response.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	46-50
1797310-10	1991	Phosphoramidon (50 microM), a metalloprotease inhibitor, markedly reduced the eicosanoid releasing properties of big-ET-1 (n = 4, P less than 0.01) in guinea-pig perfused lungs without affecting the release stimulated by ET-1.	phosphoramidon	0-14	endothelin 1	Homo sapiens	117-121
1596675-14	1992	ET-1-induced accumulation of [3H]-InsPs was not significantly affected by indomethacin (5 microM), nordihydroguaiaretic acid (NDGA, 10 microM), WEB 2086 (10 microM) or phosphoramidon (10 microM).4.	phosphoramidon	168-182	endothelin 1	Rattus norvegicus	0-4
1282965-7	1992	In all tissues studied, the ECE activity was significantly inhibited by phosphoramidon or ethylenediaminetetra-acetate.	phosphoramidon	72-86	endothelin converting enzyme 1	Homo sapiens	28-31
1579051-0	1992	Big endothelin-1-induced sudden death is inhibited by phosphoramidon in mice.	phosphoramidon	54-68	endothelin 1	Mus musculus	4-16
1579051-4	1992	A metalloproteinase inhibitor, phosphoramidon, although failing to inhibit sudden death induced by ET-1, suppressed bET-1-induced lethality and elevation of plasma IR-ET-1 probably due to an inhibition of the enzymatic conversion of bET-1 to ET-1.	phosphoramidon	31-45	endothelin 1	Mus musculus	117-121
1579051-4	1992	A metalloproteinase inhibitor, phosphoramidon, although failing to inhibit sudden death induced by ET-1, suppressed bET-1-induced lethality and elevation of plasma IR-ET-1 probably due to an inhibition of the enzymatic conversion of bET-1 to ET-1.	phosphoramidon	31-45	endothelin 1	Mus musculus	117-121
1755833-2	1991	The concentration of both big ET-1 and ET-1 was significantly increased in EA.hy 926 culture medium by phosphoramidon, a metalloproteinase inhibitor, suggesting that phosphoramidon sensitive protease(s) may be responsible for the degradation of ET-1 and big ET-1.	phosphoramidon	103-117	endothelin 1	Homo sapiens	30-34
1755833-2	1991	The concentration of both big ET-1 and ET-1 was significantly increased in EA.hy 926 culture medium by phosphoramidon, a metalloproteinase inhibitor, suggesting that phosphoramidon sensitive protease(s) may be responsible for the degradation of ET-1 and big ET-1.	phosphoramidon	103-117	endothelin 1	Homo sapiens	39-43
1755833-2	1991	The concentration of both big ET-1 and ET-1 was significantly increased in EA.hy 926 culture medium by phosphoramidon, a metalloproteinase inhibitor, suggesting that phosphoramidon sensitive protease(s) may be responsible for the degradation of ET-1 and big ET-1.	phosphoramidon	103-117	endothelin 1	Homo sapiens	39-43
1755833-2	1991	The concentration of both big ET-1 and ET-1 was significantly increased in EA.hy 926 culture medium by phosphoramidon, a metalloproteinase inhibitor, suggesting that phosphoramidon sensitive protease(s) may be responsible for the degradation of ET-1 and big ET-1.	phosphoramidon	103-117	endothelin 1	Homo sapiens	39-43
1959670-0	1991	Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells.	phosphoramidon	0-14	endothelin 1	Homo sapiens	42-54
1959670-0	1991	Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells.	phosphoramidon	0-14	endothelin 1	Homo sapiens	84-96
1959670-5	1991	The apparent conversion of exogenously applied big ET-1 to ET-1 and its inhibition by phosphoramidon were observed using cultured VSMCs, although the enzyme inhibitor did not influence the basal secretion of IR-ET from VSMCs.	phosphoramidon	86-100	endothelin 1	Homo sapiens	51-63
1815503-3	1991	The solubilized proteinase was capable of converting big ET-1 to ET-1 with an optimum pH of 6.5, and the conversion was dose-dependently suppressed by phosphoramidon (IC50 = 0.5 microM).	phosphoramidon	151-165	endothelin 1	Rattus norvegicus	57-69
1953706-0	1991	Importance of the C-terminal region of big endothelin-1 for specific conversion by phosphoramidon-sensitive endothelin converting enzyme.	phosphoramidon	83-97	endothelin 1	Homo sapiens	43-55
1953706-1	1991	Based on our previous findings that phosphoramidon-sensitive endothelin (ET) converting enzyme (ECE) converts human big ET-1 but does not big ET-3, we investigated structural requirement for substrate peptide.	phosphoramidon	36-50	endothelin converting enzyme 1	Homo sapiens	96-99
1953706-1	1991	Based on our previous findings that phosphoramidon-sensitive endothelin (ET) converting enzyme (ECE) converts human big ET-1 but does not big ET-3, we investigated structural requirement for substrate peptide.	phosphoramidon	36-50	endothelin 1	Homo sapiens	120-124
1778905-7	1991	The endopeptidase inhibitors phosphoramidon and thiorphan (5 x 10(-6) M) potentiated the action of VIP.	phosphoramidon	29-43	VIP peptides	Cavia porcellus	99-102
1797310-10	1991	Phosphoramidon (50 microM), a metalloprotease inhibitor, markedly reduced the eicosanoid releasing properties of big-ET-1 (n = 4, P less than 0.01) in guinea-pig perfused lungs without affecting the release stimulated by ET-1.	phosphoramidon	0-14	endothelin 1	Homo sapiens	221-225
1872872-1	1991	Incubation of big endothelin-1 (big ET-1, 1-39) with the membrane fraction obtained from cultured vascular smooth muscle cells (VSMCs) resulted in an increase in immunoreactive-ET (IR-ET), which was inhibited by EDTA but not by phosphoramidon, a metalloproteinase inhibitor.	phosphoramidon	228-242	endothelin 1	Homo sapiens	18-30
1766477-0	1991	Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens.	phosphoramidon	14-28	endothelin 1	Rattus norvegicus	87-99
1766477-6	1991	Treatment of the preparations with phosphoramidon (50 mumol/l) markedly reduced the twitch enhancement by big-ET-1 without affecting the response to ET-1.	phosphoramidon	35-49	endothelin 1	Rattus norvegicus	110-114
1766477-7	1991	Our results suggest the presence of a specific phosphoramidon-sensitive endothelin-converting enzyme which converts big-ET-1 to ET-1 in the rat vas deferens.	phosphoramidon	47-61	endothelin 1	Rattus norvegicus	120-124
1766477-7	1991	Our results suggest the presence of a specific phosphoramidon-sensitive endothelin-converting enzyme which converts big-ET-1 to ET-1 in the rat vas deferens.	phosphoramidon	47-61	endothelin 1	Rattus norvegicus	128-132
1872872-1	1991	Incubation of big endothelin-1 (big ET-1, 1-39) with the membrane fraction obtained from cultured vascular smooth muscle cells (VSMCs) resulted in an increase in immunoreactive-ET (IR-ET), which was inhibited by EDTA but not by phosphoramidon, a metalloproteinase inhibitor.	phosphoramidon	228-242	endothelin 1	Homo sapiens	36-40
1872872-6	1991	This ET-1 generation from exogenously applied big ET-1 was markedly inhibited by the addition of phosphoramidon, although the inhibitor did not influence the basal secretion of ET-1-like materials.	phosphoramidon	97-111	endothelin 1	Homo sapiens	5-9
1872872-6	1991	This ET-1 generation from exogenously applied big ET-1 was markedly inhibited by the addition of phosphoramidon, although the inhibitor did not influence the basal secretion of ET-1-like materials.	phosphoramidon	97-111	endothelin 1	Homo sapiens	50-54
1872872-6	1991	This ET-1 generation from exogenously applied big ET-1 was markedly inhibited by the addition of phosphoramidon, although the inhibitor did not influence the basal secretion of ET-1-like materials.	phosphoramidon	97-111	endothelin 1	Homo sapiens	50-54
2069564-0	1991	Phosphoramidon inhibits the conversion of intracisternally administered big endothelin-1 to endothelin-1.	phosphoramidon	0-14	endothelin 1	Canis lupus familiaris	76-88
1782996-0	1991	Influence of thiorphan and phosphoramidon on the relaxant effect of vasoactive intestinal polypeptide and non-adrenergic non-cholinergic neurone stimulation in the rat gastric fundus.	phosphoramidon	27-41	vasoactive intestinal peptide	Rattus norvegicus	68-101
1912989-15	1991	6 The results are consistent with the involvement of phosphoramidon-sensitive enzyme systems in the conversion of human proendothelin [1-38] to endothelin-1 in vivo.	phosphoramidon	53-67	endothelin 1	Homo sapiens	144-156
2069564-0	1991	Phosphoramidon inhibits the conversion of intracisternally administered big endothelin-1 to endothelin-1.	phosphoramidon	0-14	endothelin 1	Canis lupus familiaris	92-104
2069564-6	1991	All changes induced by big ET-1 were effectively prevented with phosphoramidon.	phosphoramidon	64-78	endothelin 1	Canis lupus familiaris	27-31
1650147-4	1991	Simultaneous intravenous infusion of phosphoramidon (0.25 mg.kg-1.min-1), an inhibitor of metalloprotease activity including neutral endopeptidase EC 3.4.24.11 (NEP), completely prevented these effects of Big ET.	phosphoramidon	37-51	membrane metallo-endopeptidase	Rattus norvegicus	161-164
1650011-5	1991	The neutral endopeptidase inhibitor phosphoramidon (10(-5) M) potentiated the effect of VIP, so that the CBF dose-response curve for VIP was shifted to lower concentrations by 0.5 log U.	phosphoramidon	36-50	VIP peptides	Oryctolagus cuniculus	88-91
1788141-2	1991	125I-labeled endothelin-1 was degraded by both tissues in a phosphoramidon-sensitive way, suggesting a role of endopeptidase 24.11 in the in vitro metabolism of this peptide.	phosphoramidon	60-74	endothelin 1	Homo sapiens	13-25
2059203-0	1991	Evidence for phosphoramidon-sensitive conversion of big endothelin-1 to endothelin-1 in isolated rat mesenteric artery.	phosphoramidon	13-27	endothelin 1	Rattus norvegicus	56-68
2059203-0	1991	Evidence for phosphoramidon-sensitive conversion of big endothelin-1 to endothelin-1 in isolated rat mesenteric artery.	phosphoramidon	13-27	endothelin 1	Rattus norvegicus	72-84
2059203-1	1991	The effect of phosphoramidon, a metalloproteinase inhibitor, on the pressor response to big endothelin-1 (big ET-1) in the isolated perfused rat mesenteric artery was examined.	phosphoramidon	14-28	endothelin 1	Rattus norvegicus	92-104
2059203-1	1991	The effect of phosphoramidon, a metalloproteinase inhibitor, on the pressor response to big endothelin-1 (big ET-1) in the isolated perfused rat mesenteric artery was examined.	phosphoramidon	14-28	endothelin 1	Rattus norvegicus	110-114
2059203-5	1991	Big ET-1 (5 X 10(-8) M)-induced pressor action was accompanied by an increase in immunoreactive (IR)-ET in the perfusate, and this increase was suppressed by the addition of phosphoramidon.	phosphoramidon	174-188	endothelin 1	Rattus norvegicus	4-8
1650011-5	1991	The neutral endopeptidase inhibitor phosphoramidon (10(-5) M) potentiated the effect of VIP, so that the CBF dose-response curve for VIP was shifted to lower concentrations by 0.5 log U.	phosphoramidon	36-50	VIP peptides	Oryctolagus cuniculus	133-136
1650011-6	1991	The administration of VIP increased cyclic AMP levels in epithelial cells, an effect that was also potentiated by phosphoramidon.	phosphoramidon	114-128	VIP peptides	Oryctolagus cuniculus	22-25
1710881-4	1991	Phosphoramidon (10(-7) to 10(-5) M) potentiated the substance P-induced contraction in a dose-dependent fashion, and phosphoramidon shifted the dose-response curve to lower concentrations.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	52-63
1647702-3	1991	Infusion of the NEP inhibitor phosphoramidon increased [ANP] and urine guanosine 3",5"-cyclic monophosphate (cGMP) excretion in both weanling and adult rats.	phosphoramidon	30-44	membrane metallo-endopeptidase	Rattus norvegicus	16-19
1851748-4	1991	Inhibition of GRP degradation by human H345 cell membranes through the use of phenanthroline or phosphoramidon permitted the development of binding assays for the GRP receptor in detergent-solubilized crude membrane preparations.	phosphoramidon	96-110	gastrin releasing peptide	Homo sapiens	14-17
1833101-10	1991	NEP activity in the rat kidney was inhibited by the specific NEP inhibitors (SCH39370, phosphoramidon and thiorphan) at micromolar concentrations.	phosphoramidon	87-101	membrane metallo-endopeptidase	Rattus norvegicus	0-3
1833101-10	1991	NEP activity in the rat kidney was inhibited by the specific NEP inhibitors (SCH39370, phosphoramidon and thiorphan) at micromolar concentrations.	phosphoramidon	87-101	membrane metallo-endopeptidase	Rattus norvegicus	61-64
1992461-6	1991	However, the metalloprotease inhibitors phosphoramidon and thiorphan dose-dependently inhibited the pressor response to big ET-1, although phosphoramidon was substantially more potent than thiorphan.	phosphoramidon	139-153	endothelin 1	Rattus norvegicus	124-128
2045432-8	1991	Inhibition of NEP in uterine strips with phosphoramidon resulted in a marked potentiation of oxytocin-induced contractions.	phosphoramidon	41-55	membrane metallo-endopeptidase	Rattus norvegicus	14-17
1991995-3	1991	The enzymatic activity was characterized as NEP on the basis of the values of kinetic parameters (Km = 61 microM, Kcat = 1,692 min-1, and Kcat/Km = 28 min-1 microM-1) and the values of IC50 of two NEP inhibitors phosphoramidon and thiorphan (7.4 nM and 8.4 nM, respectively).	phosphoramidon	212-226	membrane metalloendopeptidase	Homo sapiens	44-47
2018520-2	1991	The hydrolysis of LHRH by pig kidney brush border membranes is inhibited by phosphoramidon (I50 = 5.6 nM) implicating endopeptidase-24.11 in the initiation of hydrolysis.	phosphoramidon	76-90	gonadotropin-releasing hormone receptor	Sus scrofa	18-22
2018530-3	1991	Specific [125I]-ET-1 (50 pM) binding (defined with 100 nM ET-1) to A10 cell membranes was increased in a concentration dependent manner by the selective NEP inhibitors thiorphan, phosphoramidon, and SQ 28,603 [(+/-)-N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine] with EC50 values of 9.4, 28.4, and 5.7 nM respectively.	phosphoramidon	179-193	membrane metalloendopeptidase	Homo sapiens	153-156
2018530-6	1991	Thiorphan, phosphoramidon, and SQ 28,603 inhibited A10 cell NEP activity with IC50 values of 5.3, 36.5, and 6.0 nM respectively, which was similar to values obtained with KNEP (3.6, 22.6, and 3.5 nM).	phosphoramidon	11-25	membrane metalloendopeptidase	Homo sapiens	60-63
1652635-3	1991	The tracheal relaxing activity of VIP was potentiated by enkephalinase inhibitors, thiorphan and phosphoramidon, while the activity of HDM was not potentiated.	phosphoramidon	97-111	VIP peptides	Cavia porcellus	34-37
1825449-2	1991	Addition of ANF but not [Tyr8]ANF-(5-27) decreased ciliary beat frequency in a dose-dependent fashion; the maximal decrease from the baseline value was 24.1 +/- 1.5% (+/- SE, P less than 0.001), and a half-maximal inhibitory concentration (IC50) was 3 x 10(-12) M. Inhibition of neutral endopeptidase activity by phosphoramidon (10(-6) M) or thiorphan (10(-6) M) potentiated the effect of ANF so that the dose-response curve for ANF was shifted to lower concentrations by approximately 0.5 log units (P less than 0.05, in each case).	phosphoramidon	313-327	natriuretic peptides A	Oryctolagus cuniculus	12-15
1825449-4	1991	The intracellular cGMP levels were increased by ANF, an effect that was further potentiated by phosphoramidon or thiorphan.	phosphoramidon	95-109	natriuretic peptides A	Oryctolagus cuniculus	48-51
1991823-3	1991	Furthermore, since neutral endopeptidase 24.11 (enkephalinase; CD10/NEP) exists in invertebrate immunocyte membranes, we demonstrate that its specific inhibitor, phosphoramidon, potentiates the effects of the heptapeptide in inducing conformational change in both human and invertebrate granulocytes.	phosphoramidon	162-176	membrane metalloendopeptidase	Homo sapiens	19-46
1991823-3	1991	Furthermore, since neutral endopeptidase 24.11 (enkephalinase; CD10/NEP) exists in invertebrate immunocyte membranes, we demonstrate that its specific inhibitor, phosphoramidon, potentiates the effects of the heptapeptide in inducing conformational change in both human and invertebrate granulocytes.	phosphoramidon	162-176	membrane metalloendopeptidase	Homo sapiens	63-67
1991823-3	1991	Furthermore, since neutral endopeptidase 24.11 (enkephalinase; CD10/NEP) exists in invertebrate immunocyte membranes, we demonstrate that its specific inhibitor, phosphoramidon, potentiates the effects of the heptapeptide in inducing conformational change in both human and invertebrate granulocytes.	phosphoramidon	162-176	membrane metalloendopeptidase	Homo sapiens	68-71
1992461-0	1991	Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	58-70
1992461-0	1991	Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	108-120
1992461-0	1991	Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	108-120
1992461-6	1991	However, the metalloprotease inhibitors phosphoramidon and thiorphan dose-dependently inhibited the pressor response to big ET-1, although phosphoramidon was substantially more potent than thiorphan.	phosphoramidon	40-54	endothelin 1	Rattus norvegicus	124-128
1992461-8	1991	In a rabbit lung membrane preparation, ECE activity was identified that was blocked by the metalloprotease inhibitors phosphoramidon and 1,10-phenanthroline in a concentration-dependent manner.	phosphoramidon	118-132	endothelin converting enzyme 1	Rattus norvegicus	39-42
1993071-0	1991	Phosphoramidon inhibits the intracellular conversion of big endothelin-1 to endothelin-1 in cultured endothelial cells.	phosphoramidon	0-14	endothelin 1	Homo sapiens	60-72
1993071-0	1991	Phosphoramidon inhibits the intracellular conversion of big endothelin-1 to endothelin-1 in cultured endothelial cells.	phosphoramidon	0-14	endothelin 1	Homo sapiens	76-88
1725371-3	1991	In phosphoramidon-treated guinea pigs, ET-1 (5 micrograms/ml) exposure for 30 min evoked a slight but non-significant enhancement of the ACh-induced BR.	phosphoramidon	3-17	endothelin-1	Cavia porcellus	39-43
1725374-2	1991	The formation of this ET-1-like activity from bET was partially inhibited by phosphoramidon (54 micrograms/ml), but not by pepstatin-A (1 microgram/ml), epoxysuccinyl-L-leucylamido(guanidino)butane (E-64, 10 micrograms/ml) or phenylmethylsulfonyl fluoride (PMSF, 25 micrograms/ml).	phosphoramidon	77-91	endothelin 1	Homo sapiens	22-26
1725321-3	1991	Phosphoramidon reduced the secretion of ET-1 and concomitantly enhanced the release of big ET-1 from cultured ECs.	phosphoramidon	0-14	endothelin 1	Bos taurus	40-44
1725321-3	1991	Phosphoramidon reduced the secretion of ET-1 and concomitantly enhanced the release of big ET-1 from cultured ECs.	phosphoramidon	0-14	endothelin 1	Bos taurus	91-95
1725347-0	1991	Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1.	phosphoramidon	74-88	endothelin 1	Homo sapiens	10-20
1725347-0	1991	Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1.	phosphoramidon	74-88	endothelin 1	Homo sapiens	113-125
1725347-10	1991	We further suggest that to induce the release of prostanoids in perfused lungs, human big ET needs to be converted to ET-1 by a phosphoramidon-sensitive endothelin-converting enzyme (ECE).	phosphoramidon	128-142	endothelin 1	Homo sapiens	118-122
1725347-10	1991	We further suggest that to induce the release of prostanoids in perfused lungs, human big ET needs to be converted to ET-1 by a phosphoramidon-sensitive endothelin-converting enzyme (ECE).	phosphoramidon	128-142	endothelin converting enzyme 1	Homo sapiens	153-181
1725347-10	1991	We further suggest that to induce the release of prostanoids in perfused lungs, human big ET needs to be converted to ET-1 by a phosphoramidon-sensitive endothelin-converting enzyme (ECE).	phosphoramidon	128-142	endothelin converting enzyme 1	Homo sapiens	183-186
1943466-0	1991	Phosphoramidon inhibits the vasoconstrictor effects evoked by big endothelin-1 but not the elevation of plasma endothelin-1 in vivo.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	66-78
1875792-0	1991	Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid.	phosphoramidon	0-14	endothelin 1	Canis lupus familiaris	106-118
1875792-1	1991	There is increasing evidence that the conversion of big endothelin-1 (big ET-1) to endothelin-1 (ET-1) is specifically inhibited by the metalloproteinase inhibitor phosphoramidon.	phosphoramidon	164-178	endothelin 1	Canis lupus familiaris	56-68
1875792-1	1991	There is increasing evidence that the conversion of big endothelin-1 (big ET-1) to endothelin-1 (ET-1) is specifically inhibited by the metalloproteinase inhibitor phosphoramidon.	phosphoramidon	164-178	endothelin 1	Canis lupus familiaris	74-78
1875792-1	1991	There is increasing evidence that the conversion of big endothelin-1 (big ET-1) to endothelin-1 (ET-1) is specifically inhibited by the metalloproteinase inhibitor phosphoramidon.	phosphoramidon	164-178	endothelin 1	Canis lupus familiaris	83-95
1875792-1	1991	There is increasing evidence that the conversion of big endothelin-1 (big ET-1) to endothelin-1 (ET-1) is specifically inhibited by the metalloproteinase inhibitor phosphoramidon.	phosphoramidon	164-178	endothelin 1	Canis lupus familiaris	97-101
1725435-5	1991	When cultured ECs were incubated with phosphoramidon, time-dependent secretion of ET-1 and CTF from the cells was markedly suppressed.	phosphoramidon	38-52	endothelin 1	Rattus norvegicus	82-94
1725435-6	1991	In contrast, the secretion of big ET-1 was increased by phosphoramidon.	phosphoramidon	56-70	endothelin 1	Rattus norvegicus	34-38
1725435-8	1991	Moreover, phosphoramidon potently inhibited the hypertensive effect of big ET-1 without affecting the ET-1-induced hypertension in anesthetized rats.	phosphoramidon	10-24	endothelin 1	Rattus norvegicus	75-79
1725435-9	1991	From these findings, it seems reasonable to consider that phosphoramidon-sensitive and membrane-bound metalloproteinase, which is not a neutral endopeptidase 24.11, is the most plausible candidate for big ET-1-converting enzyme in vivo.	phosphoramidon	58-72	endothelin 1	Rattus norvegicus	205-209
1826753-7	1991	The effect of big-ET-1[1-38], but not ET-1, was blocked by pretreatment with the enzyme inhibitor phosphoramidon (10 mg/kg, s.c., 30 min prior), implying that the big-ET-1[1-38] must first be enzymatically cleaved, presumably to ET-1, in order to elicit the abdominal constriction response.	phosphoramidon	98-112	endothelin 1	Mus musculus	18-22
1943466-1	1991	Intravenous injections of big endothelin (ET)-1 (700 pmol/kg) in the pig increased arterial plasma levels of ET-1-like immunoreactivity (ET-1-LI) from 11.1 +/- 0.7 pM to 46.3 +/- 6.7 pM in the control situation and from 11.5 +/- 0.4 pM to 58.2 +/- 17 pM in the presence of the neutral endopeptidase inhibitor phosphoramidon (3 mg/kg).	phosphoramidon	309-323	endothelin 1	Rattus norvegicus	30-40
1943480-0	1991	Functional evidence for the presence of a phosphoramidon-sensitive enzyme in rat brain that converts big endothelin-1 to endothelin-1.	phosphoramidon	42-56	endothelin 1	Rattus norvegicus	105-117
1943480-0	1991	Functional evidence for the presence of a phosphoramidon-sensitive enzyme in rat brain that converts big endothelin-1 to endothelin-1.	phosphoramidon	42-56	endothelin 1	Rattus norvegicus	121-133
1943480-7	1991	Pretreatment with phosphoramidon, a metalloprotease inhibitor (90 nmol), abolished the hemodynamic responses elicited by BigET-1 (MAP = -9 +/- 2%; RBF = -3 +/- 2%) but not those produced by ET-1.	phosphoramidon	18-32	microtubule-associated protein 9	Rattus norvegicus	121-138
1943480-7	1991	Pretreatment with phosphoramidon, a metalloprotease inhibitor (90 nmol), abolished the hemodynamic responses elicited by BigET-1 (MAP = -9 +/- 2%; RBF = -3 +/- 2%) but not those produced by ET-1.	phosphoramidon	18-32	endothelin 1	Rattus norvegicus	124-128
20504728-0	1991	Phosphoramidon potentiates the endothelin-1-induced bronchopulmonary response in guinea-pigs.	phosphoramidon	0-14	endothelin-1	Cavia porcellus	31-43
20504728-1	1991	We investigated the effect of the endopeptidase-inhibitor, phosphoramidon, on the bronchopulmonary response induced by endothelin-1 in vivo or in isolated perfused lungs.	phosphoramidon	59-73	endothelin-1	Cavia porcellus	119-131
20504728-3	1991	When awake animals were pretreated by an aerosol of phosphoramidon (0.1 mM, for 15 min), the bronchopulmonary response induced by 1 and 3 ?g/ml endothelin-1 was markedly enhanced.	phosphoramidon	52-66	endothelin-1	Cavia porcellus	144-156
20504728-5	1991	Treatment of awake animals with an aerosol of phosphoramidon before lung recollection led to a significant potentiation of the endothelin-1-induced increase in pulmonary inflation pressure.	phosphoramidon	46-60	endothelin-1	Cavia porcellus	127-139
20504728-6	1991	These results demonstrate that phosphoramidon potentiates the in vivo and in vitro bronchopulmonary response evoked by low doses of endothelin-1 and suggest that endopeptidase-like enzymes present in the airway tissue modulate the effect of the peptide.	phosphoramidon	31-45	endothelin-1	Cavia porcellus	132-144
2174414-5	1990	Upon incubation of alpha-MSH with GLL-19 and G361 cell membranes, 3 degradation products were completely abolished in the presence of phosphoramidon.	phosphoramidon	134-148	proopiomelanocortin	Homo sapiens	19-28
2082818-5	1990	It exhibited optimal activity against Azocoll at pH 5 and 45 degrees C. It was stable at low pH and heat labile above 50 degrees C. It exhibited specificity toward peptide bonds formed by the amino group of hydrophobic amino acids (isoleucine, leucine, and phenylalanine) and its NH2-terminal amino acid sequence showed a high degree of similarity with that of Bacillus subtilis neutral metalloprotease A. Acidolysin is the first phosphoramidon-sensitive, acidic zinc metalloprotease reported.	phosphoramidon	430-444	CA_C1293	Clostridium acetobutylicum ATCC 824	387-402
2082818-5	1990	It exhibited optimal activity against Azocoll at pH 5 and 45 degrees C. It was stable at low pH and heat labile above 50 degrees C. It exhibited specificity toward peptide bonds formed by the amino group of hydrophobic amino acids (isoleucine, leucine, and phenylalanine) and its NH2-terminal amino acid sequence showed a high degree of similarity with that of Bacillus subtilis neutral metalloprotease A. Acidolysin is the first phosphoramidon-sensitive, acidic zinc metalloprotease reported.	phosphoramidon	430-444	CA_C1293	Clostridium acetobutylicum ATCC 824	468-483
1709505-2	1990	Phosphoramidon (0.002-2.0 nmol), an endopeptidase-24.11 inhibitor, simultaneously injected with SP or NK A, remarkably enhanced and prolonged SP- or NK A-induced behavioural response in a dose-dependent manner.	phosphoramidon	0-14	tachykinin 1	Mus musculus	102-106
1963889-6	1990	The reduction between 5 min and 4 h was not offset by an appreciable increase in the number of irregular neutrophils, unless NEP was inhibited by phosphoramidon.	phosphoramidon	146-160	membrane metallo-endopeptidase	Rattus norvegicus	125-128
1709505-2	1990	Phosphoramidon (0.002-2.0 nmol), an endopeptidase-24.11 inhibitor, simultaneously injected with SP or NK A, remarkably enhanced and prolonged SP- or NK A-induced behavioural response in a dose-dependent manner.	phosphoramidon	0-14	tachykinin 1	Mus musculus	149-153
1709505-5	1990	When phosphoramidon was injected together with bestatin and captopril which have no significant effect alone, SP- or NK A-induced behavioral response was significantly increased.	phosphoramidon	5-19	tachykinin 1	Mus musculus	117-121
2206130-0	1990	Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme.	phosphoramidon	0-14	endothelin 1	Homo sapiens	75-87
2175178-4	1990	The degradation of BNP was significantly reduced by phosphoramidon (t1/2, 11.28 +/- 0.49 min) and captopril (t1/2, 6.99 +/- 0.34 min).	phosphoramidon	52-66	natriuretic peptide B	Rattus norvegicus	19-22
2241940-0	1990	Inhibition of biological actions of big endothelin-1 by phosphoramidon.	phosphoramidon	56-70	endothelin 1	Rattus norvegicus	40-52
2241940-3	1990	Phosphoramidon blocked the vasoconstriction caused by 30 nM big ET-1, but was ineffective on the action of 0.3 nM ET-1.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	64-68
2241940-4	1990	Also in vivo, phosphoramidon had no effect on the ET-1-induced pressor actions, but blocked the pressor and airway-contractile responses to big ET-1 in rats and/or guinea pigs.	phosphoramidon	14-28	endothelin 1	Rattus norvegicus	144-148
2241940-5	1990	Thus, it is likely that the vascular responses to exogenous big ET-1 are at least in part due to its conversion to ET-1 by a phosphoramidon-sensitive ET converting enzyme(s) in the vascular smooth muscle in vitro and in vivo.	phosphoramidon	125-139	endothelin 1	Rattus norvegicus	64-68
2241940-5	1990	Thus, it is likely that the vascular responses to exogenous big ET-1 are at least in part due to its conversion to ET-1 by a phosphoramidon-sensitive ET converting enzyme(s) in the vascular smooth muscle in vitro and in vivo.	phosphoramidon	125-139	endothelin 1	Rattus norvegicus	115-119
2206130-0	1990	Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme.	phosphoramidon	0-14	endothelin 1	Homo sapiens	140-152
2206130-1	1990	Time-dependent secretion of immunoreactive-endothelin (IR-ET) from cultured porcine aortic endothelial cells was markedly suppressed by phosphoramidon is due to proteinase inhibitor.	phosphoramidon	136-150	endogenous retrovirus group K member 25	Homo sapiens	161-171
2206130-2	1990	Analysis of the culture supernatant with or without phosphoramidon by reverse-phase high performance liquid chromatography confirmed that the suppression of IR-ET secretion by phosphoramidon is due to a decreae in secretion of endothelin-1-like materials.	phosphoramidon	176-190	endothelin 1	Homo sapiens	227-239
2206130-4	1990	These data strongly suggest that phosphoramidon suppresses the secretion of ET-1 from cultured endothelial cells by inhibiting the conversion of big ET-1 to ET-1.	phosphoramidon	33-47	endothelin 1	Homo sapiens	76-80
2206130-4	1990	These data strongly suggest that phosphoramidon suppresses the secretion of ET-1 from cultured endothelial cells by inhibiting the conversion of big ET-1 to ET-1.	phosphoramidon	33-47	endothelin 1	Homo sapiens	149-161
2375683-3	1990	The activity of NEP assessed by an NEP inhibitor phosphoramidon-sensitive Met5-enkephalin degrading activity was present in neutrophils (59.0 +/- 9.1 pmol/min 10(6) cells); however, the NEP activity was virtually absent in mononuclear cells, eosinophils and basophils.	phosphoramidon	49-63	membrane metalloendopeptidase	Homo sapiens	16-19
2226629-0	1990	Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1.	phosphoramidon	0-14	endothelin 1	Rattus norvegicus	89-101
2376002-6	1990	Phosphoramidon, thiorphan and metal ion chelators inhibited NEP-like activity of all the 3 tissues studied; other protease inhibitors, however, were ineffective.	phosphoramidon	0-14	membrane metalloendopeptidase	Homo sapiens	60-63
1694188-3	1990	Enzyme staining was completely blocked by three potent NEP inhibitors (thiorphan, phosphoramidon, and JHF-26) at a concentration of 50 nM, supporting the specificity of this method to visualize sites of NEP activity selectively.	phosphoramidon	82-96	membrane metallo-endopeptidase	Rattus norvegicus	55-58
1694188-3	1990	Enzyme staining was completely blocked by three potent NEP inhibitors (thiorphan, phosphoramidon, and JHF-26) at a concentration of 50 nM, supporting the specificity of this method to visualize sites of NEP activity selectively.	phosphoramidon	82-96	membrane metallo-endopeptidase	Rattus norvegicus	203-206
2187492-2	1990	The protease inhibitors aprotinin, leupeptin, phosphoramidon, and soybean trypsin inhibitors significantly potentiated the bronchodilator response to VIP.	phosphoramidon	46-60	vasoactive intestinal peptide	Homo sapiens	150-153
2196967-6	1990	The supersensitivity to VIP, following epithelium removal was abolished by phosphoramidon or thiorphan (NEP inhibitors), but unaffected by captopril (an ACE inhibitor).	phosphoramidon	75-89	VIP peptides	Cavia porcellus	24-27
2375683-3	1990	The activity of NEP assessed by an NEP inhibitor phosphoramidon-sensitive Met5-enkephalin degrading activity was present in neutrophils (59.0 +/- 9.1 pmol/min 10(6) cells); however, the NEP activity was virtually absent in mononuclear cells, eosinophils and basophils.	phosphoramidon	49-63	membrane metalloendopeptidase	Homo sapiens	35-38
2375683-3	1990	The activity of NEP assessed by an NEP inhibitor phosphoramidon-sensitive Met5-enkephalin degrading activity was present in neutrophils (59.0 +/- 9.1 pmol/min 10(6) cells); however, the NEP activity was virtually absent in mononuclear cells, eosinophils and basophils.	phosphoramidon	49-63	membrane metalloendopeptidase	Homo sapiens	35-38
2405705-9	1990	Metabolism of the aminopeptidase-resistant analogue [D-Ala2][Leu5]enkephalin by membranes was unaffected by amastatin and weakly inhibited by phosphoramidon affected by amastatin and weakly inhibited by phosphoramidon and captopril.	phosphoramidon	142-156	proenkephalin	Rattus norvegicus	66-76
2159651-6	1990	The neutral endopeptidase inhibitor phosphoramidon (5 x 10(-6) M) enhanced responses of NS to VIP but did not affect responses to NS in the absence of VIP.	phosphoramidon	36-50	VIP peptides	Cavia porcellus	94-97
2138018-6	1990	Thus, we conclude that cultured bovine aortic endothelial cells produce a potentially novel phosphoramidon-insensitive metalloendopeptidase that removes the COOH-terminal tripeptide from 125I-hANF.	phosphoramidon	92-106	HESX homeobox 1	Homo sapiens	192-196
1689554-2	1990	The tissues were placed in organ baths containing modified Krebs-Ringer solution, and isometric contractions to SP were monitored in the presence of phosphoramidon, an inhibitor of neutral endopeptidase (NEP).	phosphoramidon	149-163	neprilysin	Oryctolagus cuniculus	181-202
1689554-2	1990	The tissues were placed in organ baths containing modified Krebs-Ringer solution, and isometric contractions to SP were monitored in the presence of phosphoramidon, an inhibitor of neutral endopeptidase (NEP).	phosphoramidon	149-163	neprilysin	Oryctolagus cuniculus	204-207
2405705-9	1990	Metabolism of the aminopeptidase-resistant analogue [D-Ala2][Leu5]enkephalin by membranes was unaffected by amastatin and weakly inhibited by phosphoramidon affected by amastatin and weakly inhibited by phosphoramidon and captopril.	phosphoramidon	203-217	proenkephalin	Rattus norvegicus	66-76
8269939-1	1993	Phosphoramidon-sensitive endothelin-converting enzyme of bovine endothelial cells showed substrate selectivity for big endothelin-1 (ET-1) when compared to big ET-1(1-38), big ET-2(1-37), big ET-2(1-38) and big ET-3(1-41).	phosphoramidon	0-14	endothelin 1	Bos taurus	119-131
1712001-2	1990	To determine whether NEP regulates SP-induced activation of human neutrophils, we examined the effect of the NEP inhibitor phosphoramidon on SP-induced superoxide generation and chemotaxis in human blood neutrophils.	phosphoramidon	123-137	tachykinin precursor 1	Homo sapiens	141-143
1712001-5	1990	Thus, phosphoramidon (10(-6) M) shifted the dose-response curves of SP-induced superoxide generation and chemotaxis of the neutrophils to the left by 0.5-0.6 log.	phosphoramidon	6-20	tachykinin precursor 1	Homo sapiens	68-70
1712001-6	1990	Phosphoramidon prevented the hydrolysis of SP by the neutrophils, the NEP activity of the neutrophils being assessed as 125 +/- 13 pmol of SP/min/10(6) cells.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	43-45
1712001-6	1990	Phosphoramidon prevented the hydrolysis of SP by the neutrophils, the NEP activity of the neutrophils being assessed as 125 +/- 13 pmol of SP/min/10(6) cells.	phosphoramidon	0-14	tachykinin precursor 1	Homo sapiens	139-141
8269939-1	1993	Phosphoramidon-sensitive endothelin-converting enzyme of bovine endothelial cells showed substrate selectivity for big endothelin-1 (ET-1) when compared to big ET-1(1-38), big ET-2(1-37), big ET-2(1-38) and big ET-3(1-41).	phosphoramidon	0-14	endothelin 1	Bos taurus	133-137
8269939-1	1993	Phosphoramidon-sensitive endothelin-converting enzyme of bovine endothelial cells showed substrate selectivity for big endothelin-1 (ET-1) when compared to big ET-1(1-38), big ET-2(1-37), big ET-2(1-38) and big ET-3(1-41).	phosphoramidon	0-14	endothelin 1	Bos taurus	160-164
8269939-1	1993	Phosphoramidon-sensitive endothelin-converting enzyme of bovine endothelial cells showed substrate selectivity for big endothelin-1 (ET-1) when compared to big ET-1(1-38), big ET-2(1-37), big ET-2(1-38) and big ET-3(1-41).	phosphoramidon	0-14	endothelin 2	Bos taurus	176-180
8269939-1	1993	Phosphoramidon-sensitive endothelin-converting enzyme of bovine endothelial cells showed substrate selectivity for big endothelin-1 (ET-1) when compared to big ET-1(1-38), big ET-2(1-37), big ET-2(1-38) and big ET-3(1-41).	phosphoramidon	0-14	endothelin 2	Bos taurus	192-196
2593007-5	1989	The specificity of the method was demonstrated using the selective NEP inhibitors thiorphan, phosphoramidon, and JHF26.	phosphoramidon	93-107	membrane metallo-endopeptidase	Rattus norvegicus	67-70
2483550-3	1989	The enkephalinase (endopeptidase 24.11) inhibitor phosphoramidon (10(-5) M) potentiated the effect of SP (10(-7) M).	phosphoramidon	50-64	tachykinin precursor 1	Homo sapiens	102-104
2531122-7	1989	This activity could be blocked by phosphoramidon, a specific inhibitor of NEP.	phosphoramidon	34-48	membrane metalloendopeptidase	Homo sapiens	74-77
2695341-3	1989	Phosphoramidon potentiated responses to VIP in intact but not de-epithelialised preparations, and had no effect on i-NANC responses.	phosphoramidon	0-14	VIP peptides	Cavia porcellus	40-43
2476956-11	1989	In the presence of phosphoramidon, removal of the epithelium slightly enhanced the contractile responses to NKA and [Nle]NKA(4-10) but not to SP and NKB.	phosphoramidon	19-33	tachykinin precursor 1	Homo sapiens	108-111
2482461-3	1989	Endopeptidase-24.11 (EC 3.4.24.11) purified from C6 cell membranes also cleaved SP at the same three peptide bonds in a manner sensitive to phosphoramidon.	phosphoramidon	140-154	tachykinin precursor 1	Homo sapiens	80-82
2476956-11	1989	In the presence of phosphoramidon, removal of the epithelium slightly enhanced the contractile responses to NKA and [Nle]NKA(4-10) but not to SP and NKB.	phosphoramidon	19-33	tachykinin precursor 1	Homo sapiens	121-124
2554881-8	1989	The cleavage of CCK-8 and gastrin analogues was inhibited by ACE inhibitors (Captopril and EDTA), but not by other enzyme inhibitors (phosphoramidon, thiorphan, bestatin etc.).	phosphoramidon	134-148	cholecystokinin	Oryctolagus cuniculus	16-19
2548762-2	1989	Relative to baseline values in rats with remnant kidneys, phosphoramidon led to elevations of plasma ANP levels and concomitant increases in urinary sodium excretion, fractional excretion of sodium, glomerular filtration rate, filtration fraction, and urinary cyclic GMP excretion.	phosphoramidon	58-72	natriuretic peptide A	Rattus norvegicus	101-104
2554881-8	1989	The cleavage of CCK-8 and gastrin analogues was inhibited by ACE inhibitors (Captopril and EDTA), but not by other enzyme inhibitors (phosphoramidon, thiorphan, bestatin etc.).	phosphoramidon	134-148	gastrin	Oryctolagus cuniculus	26-33
2478526-5	1989	The peptidase activity of alpha 2 M-VVP complex was inhibited by low-molecular-weight inhibitors such as phosphoramidon, but IgG antibody against VVP failed to neutralize its peptidase activity.	phosphoramidon	105-119	alpha-2-macroglobulin	Homo sapiens	26-35
2521492-6	1989	The activity was blocked by two selective inhibitors of NEP, thiorphan and phosphoramidon.	phosphoramidon	75-89	membrane metalloendopeptidase	Homo sapiens	56-59
2479934-7	1989	Intra-NTS injection of phosphoramidon, an inhibitor of endo 24.11 activity, completely blocked the effects of a subsequent injection of SP.	phosphoramidon	23-37	tachykinin precursor 1	Homo sapiens	136-138
2531377-5	1989	Degradation of ANF was inhibited by EDTA and phosphoramidon.	phosphoramidon	45-59	natriuretic peptide A	Homo sapiens	15-18
2745298-4	1989	Phosphoramidon (10(-5) M) did not change resting tension but shifted the concentration-response curves to neurotensin to lower concentrations (P less than 0.001), whereas inhibitors of kininase II, aminopeptidases, serine proteases, and carboxypeptidase N were without effect.	phosphoramidon	0-14	neurotensin/neuromedin N	Cavia porcellus	106-117
2745298-5	1989	Removing the epithelium increased the contractile response to neurotensin (P less than 0.001), and phosphoramidon further increased the response to neurotensin in these tissues (P less than 0.001).	phosphoramidon	99-113	neurotensin/neuromedin N	Cavia porcellus	148-159
2521492-7	1989	CALLA antigen purified from the NALM-6 leukemic cell line by affinity to 44C10-IgG Sepharose retained a peptidase activity that was completely blocked by thiorphan and phosphoramidon.	phosphoramidon	168-182	membrane metalloendopeptidase	Homo sapiens	0-5
2464059-8	1989	NKA- and NKB-induced contractions were also enhanced significantly by phosphoramidon.	phosphoramidon	70-84	tachykinin-3	Cavia porcellus	9-12
2558508-2	1989	Each kininase activity was determined by measuring the hydrolysis of bradykinin in the presence of specific inhibitors of kininase I (2-mercaptomethyl-3-guanidinoethylthiopropanoic acid), kininase II (captopril) and NEP (phosphoramidon) in 8 normal subjects.	phosphoramidon	221-235	kininogen 1	Homo sapiens	69-79
2463769-2	1989	Leucine-thiorphan and phosphoramidon shifted the concentration-response curves of SP to lower concentrations in all tissues studied, but the sensitivity to SP was greater and the effect of leucine-thiorphan was less in the ferret, a finding that correlated with the observation that the ferret ileum contained substantially less NEP activity than rat ileum.	phosphoramidon	22-36	membrane metallo-endopeptidase	Rattus norvegicus	329-332
2601566-1	1989	The potencies of thiorphan and phosphoramidon as inhibitors of neutral endopeptidase 24.11 (NEP) are significantly affected by pH.	phosphoramidon	31-45	membrane metallo-endopeptidase	Rattus norvegicus	63-90
2601566-1	1989	The potencies of thiorphan and phosphoramidon as inhibitors of neutral endopeptidase 24.11 (NEP) are significantly affected by pH.	phosphoramidon	31-45	membrane metallo-endopeptidase	Rattus norvegicus	92-95
2601566-4	1989	NEP activity is readily inhibited by phosphoramidon upon mixing, while thiorphan becomes a more potent inhibitor only after preincubation with the enzyme.	phosphoramidon	37-51	membrane metallo-endopeptidase	Rattus norvegicus	0-3
2463981-8	1988	The tachykinin antagonist [D-Arg1,D-Pro2,D-Trp7,9,Leu11]-substance P abolished the effects of phosphoramidon on the atropine-resistant response to vagus nerve stimulation (2 Hz, P less than 0.005).	phosphoramidon	94-108	arginase-1	Cavia porcellus	29-33
3548829-5	1987	Formation of neurotensin-(1-11) and -(1-10) was completely inhibited by phosphoramidon (Ki = 6 nM), an inhibitor of endopeptidase 24.11, but not by captopril, an inhibitor of peptidyl dipeptidase A. Incubation of neurotensin with purified endopeptidase 24.11 from pig stomach also resulted in cleavage of the Tyr-11-Ile-12 and Pro-10-Tyr-11 bonds.	phosphoramidon	72-86	neurotensin	Homo sapiens	13-24
3288636-2	1988	This activity, present in plasma membrane-enriched fractions of neutrophil lysates, was also inhibited over 90% by phosphoramidon, an inhibitor of neutral endopeptidase (NEP, EC 3.4.24.11).	phosphoramidon	115-129	membrane metalloendopeptidase	Homo sapiens	147-168
3288636-2	1988	This activity, present in plasma membrane-enriched fractions of neutrophil lysates, was also inhibited over 90% by phosphoramidon, an inhibitor of neutral endopeptidase (NEP, EC 3.4.24.11).	phosphoramidon	115-129	membrane metalloendopeptidase	Homo sapiens	170-173
3259597-5	1988	IL-1 beta was protected by the presence in the incubation medium of phosphoramidon, a specific inhibitor of endopeptidase 24.11.	phosphoramidon	68-82	interleukin 1 beta	Homo sapiens	0-9
2448422-8	1988	Degradation of MBP in myelin membranes was partially inhibited by only 5-20% using leupeptin (20 microM) but up to 50% by dithiothreitol mM), phenylmethylsulphonyl fluoride (1 mM), and phosphoramidon (50 microM) but up to 50% by dithiothreitol (DDT, 10 mM).	phosphoramidon	185-199	myelin basic protein	Rattus norvegicus	15-18
2980283-2	1988	This study investigated the effect of enkephalinase inhibition with phosphoramidon (10(-5) M) on contractile responses to neurokinin A, eledoisin, physalaemin and substance P in human isolated bronchial smooth muscle.	phosphoramidon	68-82	tachykinin precursor 1	Homo sapiens	122-134
2461706-1	1988	Hydrolysis of peptides by the phosphoramidon-insensitive rat kidney enzyme "endopeptidase-2" and by rat microvillar membranes.	phosphoramidon	30-44	meprin A subunit alpha	Rattus norvegicus	76-91
2969444-5	1988	Phosphoramidon, an inhibitor of endopeptidase, prevented the degradation of ANP in proximal convoluted tubule and glomerulus by 68% and 89%, respectively, but not in cortical thick ascending limb and cortical collecting tubule.	phosphoramidon	0-14	natriuretic peptide A	Homo sapiens	76-79
2966343-2	1988	Cleavage at this site represents the major ANF degradative activity in rat kidney, and is inhibited by the known metalloendoprotease inhibitors, thiorphan, phosphoramidon and zincov with IC50 values in the nanomolar range.	phosphoramidon	156-170	natriuretic peptide A	Rattus norvegicus	43-46
2445957-2	1987	The calpain inhibitor leupeptin and the enkephalinase inhibitors thiorphan and phosphoramidon increased markedly SPLI overflow, whereas the two ACE inhibitors, captopril and enalaprilat (up to 10 microM in the superfusing medium), were inactive.	phosphoramidon	79-93	membrane metallo-endopeptidase	Rattus norvegicus	40-53
3117045-1	1987	Purification and properties of the phosphoramidon-insensitive endopeptidase ("endopeptidase-2") from rat kidney.	phosphoramidon	35-49	meprin A subunit alpha	Rattus norvegicus	78-94
3548829-5	1987	Formation of neurotensin-(1-11) and -(1-10) was completely inhibited by phosphoramidon (Ki = 6 nM), an inhibitor of endopeptidase 24.11, but not by captopril, an inhibitor of peptidyl dipeptidase A. Incubation of neurotensin with purified endopeptidase 24.11 from pig stomach also resulted in cleavage of the Tyr-11-Ile-12 and Pro-10-Tyr-11 bonds.	phosphoramidon	72-86	neurotensin	Sus scrofa	213-224
3548429-8	1987	[3H]LHRH was cleaved by BBM or by endopeptidase-24.11 from porcine PT to metabolites 2, 4, small amounts of 3, and less than Glu-His-Trp-Ser-Tyr-Gly, but cleavage was strongly inhibited by the specific inhibitor phosphoramidon.	phosphoramidon	212-226	gonadotropin releasing hormone 1	Rattus norvegicus	4-8
2826799-3	1987	The enzymatic preparation from membranes is inhibited by low concentrations of the ACE inhibitors, SQ 14225 and SQ 20881 (IC50 of 0.6 and 15 nM, respectively), and is weakly inhibited by the neutral endopeptidase inhibitors, phosphoramidon and thiorphan (IC50 of 30 microM and ca.	phosphoramidon	225-239	angiotensin I converting enzyme	Rattus norvegicus	83-86
2878955-9	1987	Both the carboxypeptidase and aminopeptidase activities had neutral pH optima and were inhibited by o-phenanthroline, but were unaffected by inhibitors of neutral endopeptidases (phosphoramidon) or angiotensin-converting enzyme (Captopril).	phosphoramidon	179-193	carboxypeptidase Q	Homo sapiens	30-44
3443423-10	1987	It is concluded that bestatin and phosphoramidon, injected into the carotid artery, inhibit the activity of aminopeptidase and "enkephalinase", thus producing an accumulation of enkephalins in the central nervous system.	phosphoramidon	34-48	membrane metallo-endopeptidase	Rattus norvegicus	127-142
3090452-1	1986	Both the MAO-B inhibitor deprenyl (2.5-10 mg/kg, ip, 60 min prior) and the MAO-B substrate beta-phenylethylamine (PEA, 40 micrograms, icv) potentiated the analgesic action of the enkephalinase inhibitor phosphoramidon (250 micrograms, icv) in animals allowed normal sleep.	phosphoramidon	203-217	monoamine oxidase B	Rattus norvegicus	75-80
2877660-4	1986	When Leu-enkephalin was the substrate, however, the effects of phosphoramidon and bestatin were marked and those of N-ethylmaleimide and diisopropylphosphorofluoridate were negligibly small.	phosphoramidon	63-77	prodynorphin	Mus musculus	5-19
3540390-3	1986	Additionally, the enkephalin-hydrolyzing aminopeptidase, endopeptidase-24.11 and peptidyl dipeptidase A in rat vas deferens were found to be inhibited maximally with 1 microM of amastatin, 1 microM of phosphoramidon and 1 microM of captopril, respectively.	phosphoramidon	201-215	proenkephalin	Rattus norvegicus	18-28
3539055-1	1986	The effect of the enkephalinase inhibitor phosphoramidon on the withdrawal syndrome following acute and chronic morphine-induced physical dependence in mice, was investigated.	phosphoramidon	42-56	membrane metallo endopeptidase	Mus musculus	18-31
3532054-8	1986	In contrast, the formation of YGG was completely prevented by Thiorphan (IC50 value = 9 nM) and phosphoramidon, two inhibitors of "enkephalinase" (EC 3.4.24.11; membrane metallo-endopeptidase), thus identifying the latter as the YGG-forming enzyme.	phosphoramidon	96-110	membrane metallo-endopeptidase	Rattus norvegicus	131-145
3901041-1	1985	Intraventricular administration of enkephalinase inhibitor, phosphoramidon (1 X 10(-8)-5.6 X 10(-7) moles ICV) induced a behavioural syndrome consisting of excessive grooming with the body scratching as the most prominent symptom and wet-dog-shakes (WDS).	phosphoramidon	60-74	membrane metallo-endopeptidase	Rattus norvegicus	35-48
3957894-2	1986	The inhibitor constant of PLT, Ki, and the dissociation constant of thermolysin(E)-PLT(I) complex, Kd, are found to be smaller by a factor of 4 to 300, depending on pH, resulting in stronger binding, than those of talopeptin and phosphoramidon, but all of them show similar pH dependence.	phosphoramidon	229-243	N-acylethanolamine acid amidase	Homo sapiens	83-86
3123978-1	1986	Enkephalinase inhibitors phosphoramidon, thiorphan or phelorphan suppressed naloxone-precipitated withdrawal symptoms in acute and chronic morphine dependent mice and rats.	phosphoramidon	25-39	membrane metallo endopeptidase	Mus musculus	0-13
3909153-3	1985	These cells cleaved the NEP substrate glutaryl (Glut)-Ala-Ala-Phe-(4-methoxynaphthylamine) (Glut-Ala-Ala-Phe-MNA) at a rate of 9.5 nmol X hr-1 per 10(6) cells, and phosphoramidon (1 microM) inhibited the hydrolysis by 90%.	phosphoramidon	164-178	membrane metalloendopeptidase	Homo sapiens	24-27
3909153-6	1985	A washed membrane fraction from human neutrophils rapidly cleaved 0.5 mM Glut-Ala-Ala-Phe-MNA (96 nmol X min-1 X mg-1) and the hydrolysis was inhibited by phosphoramidon and by specific antiserum to human renal NEP.	phosphoramidon	155-169	membrane metalloendopeptidase	Homo sapiens	211-214
3909153-8	1985	The membrane-bound enzyme cleaved the peptide substrates at the same site as the homogeneous human renal NEP, and phosphoramidon and thiorphan inhibited the hydrolysis.	phosphoramidon	114-128	membrane metalloendopeptidase	Homo sapiens	105-108
2995126-5	1985	A combination of phosphoramidon and bestatin abolished the hydrolysis of neurokinin B by synaptic membranes.	phosphoramidon	17-31	tachykinin precursor 3	Sus scrofa	73-85
3957894-2	1986	The inhibitor constant of PLT, Ki, and the dissociation constant of thermolysin(E)-PLT(I) complex, Kd, are found to be smaller by a factor of 4 to 300, depending on pH, resulting in stronger binding, than those of talopeptin and phosphoramidon, but all of them show similar pH dependence.	phosphoramidon	229-243	N-acylethanolamine acid amidase	Homo sapiens	26-29
2409961-6	1985	Synaptic membrane preparations from human striatum and diencephalon hydrolysed substance P at the same sites as did preparations of pig striatal synaptic membranes, and hydrolysis was substantially abolished by phosphoramidon.	phosphoramidon	211-225	tachykinin precursor 1	Homo sapiens	79-90
2409262-6	1985	The degradation of porcine insulin in subcutaneous tissue was inhibited by bacitracin, leupeptin, phosphoramidon, and Z-Gly-Pro-Leu-Gly, though the human insulin degradation was not.	phosphoramidon	98-112	insulin	Homo sapiens	27-34
2412213-2	1985	GRP10 was catabolized by gastric muscle peptidases (specific activity 1.8 nmol min-1 mg-1 protein) by hydrolysis of the His8-Leu9 bond and catabolism was inhibited by phosphoramidon (I50 approx.	phosphoramidon	167-181	gastrin releasing peptide	Homo sapiens	0-5
2412213-2	1985	GRP10 was catabolized by gastric muscle peptidases (specific activity 1.8 nmol min-1 mg-1 protein) by hydrolysis of the His8-Leu9 bond and catabolism was inhibited by phosphoramidon (I50 approx.	phosphoramidon	167-181	CD59 molecule (CD59 blood group)	Homo sapiens	79-89
2412213-2	1985	GRP10 was catabolized by gastric muscle peptidases (specific activity 1.8 nmol min-1 mg-1 protein) by hydrolysis of the His8-Leu9 bond and catabolism was inhibited by phosphoramidon (I50 approx.	phosphoramidon	167-181	CD7 molecule	Homo sapiens	125-129
2412213-4	1985	The same bond in GRP10 was cleaved by purified endopeptidase-24.11, and hydrolysis was equally sensitive to inhibition by phosphoramidon.	phosphoramidon	122-136	gastrin releasing peptide	Homo sapiens	17-22
2412213-7	1985	It is concluded that a membrane-bound peptidase in the stomach wall catabolizes and inactivates GRP10 and SP and that, in its specificity and sensitivity to phosphoramidon, this peptidase resembles endopeptidase-24.11.	phosphoramidon	157-171	gastrin releasing peptide	Homo sapiens	96-101
2412213-7	1985	It is concluded that a membrane-bound peptidase in the stomach wall catabolizes and inactivates GRP10 and SP and that, in its specificity and sensitivity to phosphoramidon, this peptidase resembles endopeptidase-24.11.	phosphoramidon	157-171	tachykinin precursor 1	Homo sapiens	106-108
6433386-1	1984	In order to elucidate the relationship between REM sleep and the enkephalinergic system, the effects of REM sleep deprivation (REMSD), stress and the enkephalinase inhibitor phosphoramidon on handling-induced convulsions were studied in mice.	phosphoramidon	174-188	membrane metallo endopeptidase	Mus musculus	150-163
6395608-2	1984	Both N2O (70% in 30% O2) and the relatively selective enkephalinase inhibitor phosphoramidon (350 micrograms i.c.v.	phosphoramidon	78-92	membrane metallo-endopeptidase	Rattus norvegicus	54-67
6395608-5	1984	The rapidly developed tolerance to N2O analgesia does not affect the anaesthetic state since the animals remained motionless for the duration of exposure lasting 3 h. In the animals treated with the enkephalinase inhibitor phosphoramidon, no development of tolerance to N2O-antinociception occurred during the exposure lasting 3 h. The results indicate that tolerance to N2O analgesia can be abolished by activation of the enkephalinergic system, which might suggest a possible insufficiency of this system during tolerance to N2O.	phosphoramidon	223-237	membrane metallo-endopeptidase	Rattus norvegicus	199-212
6617101-3	1983	Dipeptidyl peptidase IV activity of human renal microvilli could be inhibited by di-isopropylphosphorofluoridate and neutral endopeptidase activity by phosphoramidon.	phosphoramidon	151-165	dipeptidyl peptidase 4	Homo sapiens	0-23
7052059-4	1982	The hydrolysis of the Gly3-Phe4 bond of Leu-enkephalin by synaptic membranes prepared from pig brain was partially inhibited by phosphoramidon and thiorphan.	phosphoramidon	128-142	proenkephalin	Sus scrofa	44-54
6190172-2	1983	The hydrolysis of an enkephalin analogue (Tyr-D-Ala-Gly-Phe-Leu) at the Gly-Phe bond was completely inhibited by phosphoramidon.	phosphoramidon	113-127	proenkephalin	Sus scrofa	21-31
31204686-0	2019	Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan.	phosphoramidon	55-69	membrane metalloendopeptidase	Homo sapiens	29-39
33256013-2	2020	Treatment of mice with the neprilysin (NEP)-inhibitor phosphoramidon was previously shown to improve the metabolic stability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	54-68	membrane metallo endopeptidase	Mus musculus	27-37
33256013-2	2020	Treatment of mice with the neprilysin (NEP)-inhibitor phosphoramidon was previously shown to improve the metabolic stability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	54-68	membrane metallo endopeptidase	Mus musculus	39-42
33917140-11	2021	The ECE inhibitor phosphoramidon induced autophagy.	phosphoramidon	18-32	endothelin converting enzyme 1	Homo sapiens	4-7
33917140-12	2021	Furthermore, phosphoramidon inhibited ER stress and the NLRP3 inflammasome in tubular epithelial cells.	phosphoramidon	13-27	NLR family pyrin domain containing 3	Homo sapiens	56-61
33917140-13	2021	In an adenine diet-induced CKD mouse model, phosphoramidon attenuated the progression of CKD by regulating autophagy, the NLRP3 inflammasome and ER stress.	phosphoramidon	44-58	NLR family, pyrin domain containing 3	Mus musculus	122-127
31077356-7	2019	177 Lu-DOTAGA-PEG2 -RM26 demonstrated quantitative labeling yield at high molar activity (450 GBq/mumol), high in vivo stability (5 min pi &gt;98% of radioligand remained when coinjected with phosphoramidon), high affinity to GRPR (KD = 0.4 +- 0.2 nM), and favorable biodistribution (1 hr pi tumor uptake was higher than in healthy tissues, including the kidneys).	phosphoramidon	192-206	insulin-like growth factor 2	Mus musculus	14-18
30963606-7	2019	111 In-SB9 was more stable than 111 In-AMBA, but coinjection of the neprilysin (NEP) inhibitor phosphoramidon (PA) stabilized both in vivo.	phosphoramidon	95-109	membrane metallo endopeptidase	Mus musculus	68-78
30963606-7	2019	111 In-SB9 was more stable than 111 In-AMBA, but coinjection of the neprilysin (NEP) inhibitor phosphoramidon (PA) stabilized both in vivo.	phosphoramidon	95-109	membrane metallo endopeptidase	Mus musculus	80-83
30963606-7	2019	111 In-SB9 was more stable than 111 In-AMBA, but coinjection of the neprilysin (NEP) inhibitor phosphoramidon (PA) stabilized both in vivo.	phosphoramidon	111-113	membrane metallo endopeptidase	Mus musculus	68-78
31204686-2	2019	The structure of the soluble extracellular domain (residues 55-750) of rabbit neprilysin was solved both in its native form at 2.1 A resolution, and bound to the inhibitors phosphoramidon and thiorphan at 2.8 and 3.0 A resolution, respectively.	phosphoramidon	173-187	membrane metalloendopeptidase	Homo sapiens	78-88
30002107-13	2019	Coadministration of phosphoramidon or thiorphan increases 177Lu-DOTA-MG11 uptake significantly in the CCK2R(+) tumors and stomach.	phosphoramidon	20-34	cholecystokinin B receptor	Homo sapiens	102-107
30897789-5	2019	Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo.	phosphoramidon	97-111	membrane metallo endopeptidase	Mus musculus	137-147
30897789-5	2019	Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo.	phosphoramidon	97-111	membrane metallo endopeptidase	Mus musculus	149-152
30897789-5	2019	Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo.	phosphoramidon	113-115	membrane metallo endopeptidase	Mus musculus	137-147
30897789-5	2019	Their biological profiles were compared in PC-3 cells and in mice without or with coinjection of phosphoramidon (PA) to induce transient neprilysin (NEP) inhibition in vivo.	phosphoramidon	113-115	membrane metallo endopeptidase	Mus musculus	149-152
30871262-2	2019	Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake.	phosphoramidon	124-138	membrane metallo endopeptidase	Mus musculus	97-107
30871262-2	2019	Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake.	phosphoramidon	124-138	membrane metallo endopeptidase	Mus musculus	109-112
30871262-2	2019	Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake.	phosphoramidon	140-142	membrane metallo endopeptidase	Mus musculus	97-107
30871262-2	2019	Switching radiometal from 68Ga to 111In impaired tumor targeting in mice, but coinjection of the neprilysin (NEP)-inhibitor phosphoramidon (PA) stabilized 111In-SB3 in circulation and remarkably increased tumor uptake.	phosphoramidon	140-142	membrane metallo endopeptidase	Mus musculus	109-112
30537985-3	2018	We found that 5-hydroxyindolacetic acid (5-HIAA), the final metabolite of serotonin, considered until now as a dead-end and inactive product of serotonin catabolism, significantly reduces brain Abeta in the transgenic APPSWE mouse model for AD-related Abeta pathology and in the phosphoramidon-induced cerebral NEP inhibition mouse model.	phosphoramidon	279-293	histocompatibility 2, class II antigen A, beta 1	Mus musculus	194-199
29664606-7	2018	Coinjection of the radioconjugates with the neprilysin (NEP)-inhibitor phosphoramidon led to full stabilization of 111In/177Lu-SB3 in peripheral mouse blood and resulted in markedly enhanced radiolabel uptake in the PC-3 tumors.	phosphoramidon	71-85	membrane metallo endopeptidase	Mus musculus	44-54
29556947-5	2018	A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA).	phosphoramidon	134-148	membrane metallo endopeptidase	Mus musculus	95-116
29556947-5	2018	A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA).	phosphoramidon	134-148	membrane metallo endopeptidase	Mus musculus	118-121
29556947-5	2018	A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA).	phosphoramidon	150-152	membrane metallo endopeptidase	Mus musculus	95-116
29556947-5	2018	A novel approach to increase in vivo stability of radiopeptides is by co-administration of the neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA).	phosphoramidon	150-152	membrane metallo endopeptidase	Mus musculus	118-121
29556947-18	2018	CONCLUSIONS: Co-administration of PA increased in vivo tumor targeting capacity of [111In]SB3, making this an attractive combination for GRPR-targeted tumor imaging.	phosphoramidon	34-36	gastrin releasing peptide receptor	Mus musculus	137-141
30082509-0	2018	Phosphoramidon inhibits the integral membrane protein zinc metalloprotease ZMPSTE24.	phosphoramidon	0-14	zinc metallopeptidase STE24	Homo sapiens	75-83
30082509-3	2018	As part of an effort to understand the structural and functional relationships between ZMPSTE24 and soluble zinc metalloproteases, the inhibition of ZMPSTE24 by phosphoramidon [N-(alpha-rhamnopyranosyl-oxyhydroxyphosphinyl)-Leu-Trp], a transition-state analog and competitive inhibitor of multiple soluble zinc metalloproteases, especially gluzincins, has been characterized functionally and structurally.	phosphoramidon	161-175	zinc metallopeptidase STE24	Homo sapiens	149-157
30082509-4	2018	The functional results, the determination of preliminary IC50 values by the use of an intramolecular quenched-fluorescence fluorogenic peptide assay, indicate that phosphoramidon inhibits ZMPSTE24 in a manner consistent with competitive inhibition.	phosphoramidon	164-178	zinc metallopeptidase STE24	Homo sapiens	188-196
30082509-5	2018	The structural results, a 3.85 A resolution X-ray crystal structure of a ZMPSTE24-phosphoramidon complex, indicate that the overall binding mode observed between phosphoramidon and soluble gluzincins is conserved.	phosphoramidon	82-96	zinc metallopeptidase STE24	Homo sapiens	73-81
29664606-7	2018	Coinjection of the radioconjugates with the neprilysin (NEP)-inhibitor phosphoramidon led to full stabilization of 111In/177Lu-SB3 in peripheral mouse blood and resulted in markedly enhanced radiolabel uptake in the PC-3 tumors.	phosphoramidon	71-85	membrane metallo endopeptidase	Mus musculus	56-59
26996808-6	2016	Modeling was performed using the experimental 3D structure of human endothelin-converting enzyme-1 in the presence of the metabolite phosphoramidon.	phosphoramidon	133-147	endothelin converting enzyme 1	Homo sapiens	68-98
26882895-1	2016	BACKGROUND: We have recently shown that treatment of mice with the neutral endopeptidase (NEP) inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	105-119	membrane metallo endopeptidase	Mus musculus	90-93
26882895-1	2016	BACKGROUND: We have recently shown that treatment of mice with the neutral endopeptidase (NEP) inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	121-123	membrane metallo endopeptidase	Mus musculus	90-93
28636973-4	2017	On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	87-101	membrane metallo endopeptidase	Mus musculus	41-62
28636973-4	2017	On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	87-101	membrane metallo endopeptidase	Mus musculus	64-67
28636973-4	2017	On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	103-105	membrane metallo endopeptidase	Mus musculus	41-62
28636973-4	2017	On the other hand, in-situ inhibition of neutral endopeptidase (NEP) by coinjection of phosphoramidon (PA) was shown to significantly improve the in vivo stability and tumor uptake of biodegradable radiopeptides.	phosphoramidon	103-105	membrane metallo endopeptidase	Mus musculus	64-67
27840228-10	2017	Both phosphoramidon (inhibitor of the known dynorphin converting enzyme neprilysin) and opiorphin (inhibitor of neprilysin and aminopeptidase N) blocked cortical bioconversion to dynorphin B(1-7), wheras only opiorphin blocked striatal bioconversion to dynorphin B(2-13).	phosphoramidon	5-19	membrane metalloendopeptidase	Homo sapiens	72-82
27840228-10	2017	Both phosphoramidon (inhibitor of the known dynorphin converting enzyme neprilysin) and opiorphin (inhibitor of neprilysin and aminopeptidase N) blocked cortical bioconversion to dynorphin B(1-7), wheras only opiorphin blocked striatal bioconversion to dynorphin B(2-13).	phosphoramidon	5-19	opiorphin prepropeptide	Homo sapiens	209-218
26882895-12	2016	During the dose dependence study in mice, PA turned out to be more efficacious in enhancing tumor uptake of [(111)In-DOTA]MG11 in the CCK2R-positive tumors compared to equimolar amounts of TO.	phosphoramidon	42-44	cholecystokinin B receptor	Mus musculus	134-139
26882895-15	2016	NEP inhibition with the clinically tested NEP inhibitors TO and Race resulted in significant enhancement of tumor-to-kidney ratios vs. CONTROLS: However, compared with PA, TO and its prodrug Race induced less potent increases of tumor uptake, highlighting the significance of inhibitor type, administration route, and dose for implementing a first proof-of-principle study in human.	phosphoramidon	168-170	membrane metallo endopeptidase	Mus musculus	0-3
27062279-11	2016	In P1 arteries, constriction to thrombin or A23187 was inhibited by endothelial-denudation, by ET-1 receptor antagonists (BQ123 plus BQ788) or by inhibition of endothelin-converting enzyme (phosphoramidon or SM19712).	phosphoramidon	190-204	coagulation factor II	Mus musculus	32-40
26844849-6	2016	After coinjection of the NEP inhibitor, phosphoramidon (PA), the stability of [(111)In]CP04 and [(111)In-DOTA]MG0 in peripheral mouse blood increased, with an exceptional &gt;14-fold improvement monitored for [(111)In-DOTA]MG11.	phosphoramidon	56-58	membrane metallo endopeptidase	Mus musculus	25-28
26881775-6	2016	Accordingly, in functional experiments, CD10-A375 showed significantly greater cell proliferation in vitro and higher tumorigenicity in vivo; CD10 enzymatic inhibitors, thiorphan and phosphoramidon, significantly blocked the tumor growth of CD10-A375 in mice.	phosphoramidon	183-197	membrane metallo endopeptidase	Mus musculus	40-44
26881775-6	2016	Accordingly, in functional experiments, CD10-A375 showed significantly greater cell proliferation in vitro and higher tumorigenicity in vivo; CD10 enzymatic inhibitors, thiorphan and phosphoramidon, significantly blocked the tumor growth of CD10-A375 in mice.	phosphoramidon	183-197	membrane metallo endopeptidase	Mus musculus	142-146
26881775-6	2016	Accordingly, in functional experiments, CD10-A375 showed significantly greater cell proliferation in vitro and higher tumorigenicity in vivo; CD10 enzymatic inhibitors, thiorphan and phosphoramidon, significantly blocked the tumor growth of CD10-A375 in mice.	phosphoramidon	183-197	membrane metallo endopeptidase	Mus musculus	142-146
26844849-6	2016	After coinjection of the NEP inhibitor, phosphoramidon (PA), the stability of [(111)In]CP04 and [(111)In-DOTA]MG0 in peripheral mouse blood increased, with an exceptional &gt;14-fold improvement monitored for [(111)In-DOTA]MG11.	phosphoramidon	40-54	membrane metallo endopeptidase	Mus musculus	25-28
26300210-7	2015	Secondly, we noted impressive enhancement of [(111)In]1/2/3 localization in AR42J and A431-CCK2R(+) tumors in mice after PA coinjection.	phosphoramidon	121-123	cholecystokinin B receptor	Mus musculus	91-96
26722377-4	2016	Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic (68)Ga-/(177)Lu-JMV4168 GRPR-antagonist.	phosphoramidon	70-84	membrane metallo endopeptidase	Mus musculus	55-58
26722377-4	2016	Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic (68)Ga-/(177)Lu-JMV4168 GRPR-antagonist.	phosphoramidon	70-84	gastrin releasing peptide receptor	Mus musculus	223-227
26722377-4	2016	Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic (68)Ga-/(177)Lu-JMV4168 GRPR-antagonist.	phosphoramidon	86-88	membrane metallo endopeptidase	Mus musculus	55-58
26722377-4	2016	Here we show for the first time that co-injection of a NEP inhibitor (phosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic efficacy of the theranostic (68)Ga-/(177)Lu-JMV4168 GRPR-antagonist.	phosphoramidon	86-88	gastrin releasing peptide receptor	Mus musculus	223-227
26722377-11	2016	This data shows that co-injection of the enzyme inhibitor PA greatly enhances the theranostic potential of GRPR-radioantagonists for future application in PCa patients.	phosphoramidon	58-60	gastrin releasing peptide receptor	Homo sapiens	107-111
26158215-7	2015	Coinjection of the NEP inhibitor phosphoramidon (PA) with radiolabeled gastrin and other peptide analogs has been recently proposed as a new promising strategy to increase bioavailability and tumor-localization of radiopeptides in tumor sites.	phosphoramidon	33-47	membrane metalloendopeptidase	Homo sapiens	19-22
26158215-7	2015	Coinjection of the NEP inhibitor phosphoramidon (PA) with radiolabeled gastrin and other peptide analogs has been recently proposed as a new promising strategy to increase bioavailability and tumor-localization of radiopeptides in tumor sites.	phosphoramidon	33-47	gastrin	Homo sapiens	71-78
26158215-7	2015	Coinjection of the NEP inhibitor phosphoramidon (PA) with radiolabeled gastrin and other peptide analogs has been recently proposed as a new promising strategy to increase bioavailability and tumor-localization of radiopeptides in tumor sites.	phosphoramidon	49-51	membrane metalloendopeptidase	Homo sapiens	19-22
26158215-7	2015	Coinjection of the NEP inhibitor phosphoramidon (PA) with radiolabeled gastrin and other peptide analogs has been recently proposed as a new promising strategy to increase bioavailability and tumor-localization of radiopeptides in tumor sites.	phosphoramidon	49-51	gastrin	Homo sapiens	71-78
26158215-8	2015	Specifically, co-administration of PA with the truncated gastrin analog [(111)In-DOTA]MG11 ([((111)In-DOTA)DGlu(10)]gastrin(10-17)) impressively enhanced the levels of intact radiopeptide in mouse circulation and has led to an 8-fold increase of CCK2R-positive tumor uptake in SCID mice.	phosphoramidon	35-37	gastrin	Mus musculus	116-123
25457559-5	2015	Oral gamma-hydroxybutyrate also counteracted phosphoramidon-induced brain neprilysin inhibition and Abeta accumulation.	phosphoramidon	45-59	membrane metallo endopeptidase	Mus musculus	74-84
25836673-5	2015	Chick embryos treated by phosphoramidon, which blocks the generation of endothelin-3, failed to develop enteric ganglia in the very distal bowel, characteristic of an HSCR-like phenotype.	phosphoramidon	25-39	endothelin 3	Gallus gallus	72-84
25457559-5	2015	Oral gamma-hydroxybutyrate also counteracted phosphoramidon-induced brain neprilysin inhibition and Abeta accumulation.	phosphoramidon	45-59	amyloid beta (A4) precursor protein	Mus musculus	100-105
25286347-4	2014	In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA).	phosphoramidon	208-222	membrane metallo endopeptidase	Mus musculus	101-122
25488751-5	2015	While we found that radiolabeled peptides based on the native kallidin sequence were ineffective at visualizing B1R-positive tumors, peptidase inhibition with phosphoramidon greatly enhanced B1R visualization in vivo.	phosphoramidon	159-173	bradykinin receptor B1	Homo sapiens	191-194
25286347-4	2014	In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA).	phosphoramidon	208-222	membrane metallo endopeptidase	Mus musculus	124-127
25286347-4	2014	In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA).	phosphoramidon	224-226	membrane metallo endopeptidase	Mus musculus	101-122
25286347-4	2014	In addition, to improve in vivo stability of the peptide against in vivo degradation by the protease neutral endopeptidase (NEP), the authors coinjected [(177)Lu]DOTA-GRP(13-27) with the potent NEP inhibitor phosphoramidon (PA).	phosphoramidon	224-226	membrane metallo endopeptidase	Mus musculus	124-127
25286347-10	2014	From biodistribution and ex vivo autoradiography studies, coadministration of both lysine and PA with [(177)Lu]DOTA-GRP(13-27) appeared to induce a clear improvement of tumor uptake as well as lower levels of renal radioactivity, causing a promising ninefold increase in tumor/kidney ratios.	phosphoramidon	94-96	gastrin releasing peptide	Mus musculus	116-119
24287321-4	2014	Through single coinjection of the neutral endopeptidase inhibitor phosphoramidon (PA), we were able to provoke remarkable rises in the percentages of circulating intact somatostatin, gastrin, and bombesin radiopeptides in mouse models, resulting in a remarkable increase in uptake in tumor xenografts in mice.	phosphoramidon	66-80	gastrin	Mus musculus	183-190
25165447-5	2014	Of particular interest are endopeptidases that are sensitive to the neprilysin (NEP) inhibitors thiorphan and phosphoramidon (i.e., are "NEP-like") as these inhibitors induce a dramatic increase in Abeta levels in rodents.	phosphoramidon	110-124	membrane metalloendopeptidase	Homo sapiens	68-78
25165447-5	2014	Of particular interest are endopeptidases that are sensitive to the neprilysin (NEP) inhibitors thiorphan and phosphoramidon (i.e., are "NEP-like") as these inhibitors induce a dramatic increase in Abeta levels in rodents.	phosphoramidon	110-124	membrane metalloendopeptidase	Homo sapiens	80-83
25165447-5	2014	Of particular interest are endopeptidases that are sensitive to the neprilysin (NEP) inhibitors thiorphan and phosphoramidon (i.e., are "NEP-like") as these inhibitors induce a dramatic increase in Abeta levels in rodents.	phosphoramidon	110-124	membrane metalloendopeptidase	Homo sapiens	137-140
25165447-5	2014	Of particular interest are endopeptidases that are sensitive to the neprilysin (NEP) inhibitors thiorphan and phosphoramidon (i.e., are "NEP-like") as these inhibitors induce a dramatic increase in Abeta levels in rodents.	phosphoramidon	110-124	amyloid beta precursor protein	Homo sapiens	198-203
24287321-4	2014	Through single coinjection of the neutral endopeptidase inhibitor phosphoramidon (PA), we were able to provoke remarkable rises in the percentages of circulating intact somatostatin, gastrin, and bombesin radiopeptides in mouse models, resulting in a remarkable increase in uptake in tumor xenografts in mice.	phosphoramidon	82-84	gastrin	Mus musculus	183-190
24000822-0	2014	Exploring mode of phosphoramidon and Abeta peptide binding to hECE-1 by molecular dynamics and docking studies.	phosphoramidon	18-32	endothelin converting enzyme 1	Homo sapiens	62-68
23963369-5	2013	Inhibition studies suggested that processes sensitive to insulin and phosphoramidon, which inhibit neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme, are involved not only in degradation, but also in elimination of hAbeta(1-40).	phosphoramidon	69-83	membrane metallo endopeptidase	Mus musculus	99-109
24000822-2	2014	In the present study we have performed molecular dynamics (MD) simulation of crystal structure complex of hECE-1 and its inhibitor phosphoramidon with Zn ion to understand the dynamic behavior of active site residues.	phosphoramidon	131-145	endothelin converting enzyme 1	Homo sapiens	106-112
24000822-4	2014	The L-leucyl-L-tryptophan moiety and N-phosphoryl moiety of phosphoramidon was found in the S1 and S2 pockets of hECE-1 respectively.	phosphoramidon	60-74	endothelin converting enzyme 1	Homo sapiens	113-119
23963369-5	2013	Inhibition studies suggested that processes sensitive to insulin and phosphoramidon, which inhibit neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme, are involved not only in degradation, but also in elimination of hAbeta(1-40).	phosphoramidon	69-83	insulin degrading enzyme	Mus musculus	111-135
20941644-0	2011	Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice.	phosphoramidon	11-25	tensin 2	Mus musculus	73-76
23868737-1	2013	OBJECTIVE: Previous in vitro studies have shown that the degradation of [Leu5]enkephalin during incubation with cerebral membrane preparations is almost completely prevented by a mixture of three peptidase inhibitors such as amastatin, captopril, and phosphoramidon.	phosphoramidon	251-265	proenkephalin	Rattus norvegicus	78-88
23528219-2	2013	Both are degraded by the neutral endopeptidase (NEP) which can be blocked by phosphoramidon.	phosphoramidon	77-91	membrane metalloendopeptidase	Homo sapiens	25-46
23528219-2	2013	Both are degraded by the neutral endopeptidase (NEP) which can be blocked by phosphoramidon.	phosphoramidon	77-91	membrane metalloendopeptidase	Homo sapiens	48-51
23528219-10	2013	The inhibition of sweating by phosphoramidon may involve an increase in SP, a reduction in CGRP-degradation fragments or a direct inhibitory action of phosphoramidon.	phosphoramidon	30-44	tachykinin precursor 1	Homo sapiens	72-74
23528219-10	2013	The inhibition of sweating by phosphoramidon may involve an increase in SP, a reduction in CGRP-degradation fragments or a direct inhibitory action of phosphoramidon.	phosphoramidon	30-44	calcitonin related polypeptide alpha	Homo sapiens	91-95
22642296-9	2012	SC44463, BB94 and Phosphoramidon were computationally docked into the 3 day structure of the human MMP7 ZBD and TAD and thermolysin using the docking program GOLD.	phosphoramidon	18-32	matrix metallopeptidase 7	Homo sapiens	99-103
21937235-4	2011	Recently, the X-ray crystal structure of human NEP complexed with phosphoramidon has been reported and provided insights into the active site specificity of NEP.	phosphoramidon	66-80	membrane metalloendopeptidase	Homo sapiens	47-50
21937235-4	2011	Recently, the X-ray crystal structure of human NEP complexed with phosphoramidon has been reported and provided insights into the active site specificity of NEP.	phosphoramidon	66-80	membrane metalloendopeptidase	Homo sapiens	157-160
21651905-6	2011	Application of captopril 1 muM (angiotensin-converting enzyme inhibitor) or phosphoramidon 10 muM (neutral endopeptidase inhibitor) induced a leftward shift of bradykinin-elicited responses in human umbilical vein with endothelium while no effect was observed in tissues denuded of endothelium under the same treatment.	phosphoramidon	76-90	latexin	Homo sapiens	94-97
21651905-6	2011	Application of captopril 1 muM (angiotensin-converting enzyme inhibitor) or phosphoramidon 10 muM (neutral endopeptidase inhibitor) induced a leftward shift of bradykinin-elicited responses in human umbilical vein with endothelium while no effect was observed in tissues denuded of endothelium under the same treatment.	phosphoramidon	76-90	kininogen 1	Homo sapiens	160-170
21459096-8	2011	The neutral endopeptidase (NEP) inhibitor, phosphoramidon, blocked inactivation of CNP and CD-NP, but not BNP or DNP.	phosphoramidon	43-57	membrane metalloendopeptidase	Homo sapiens	4-25
21459096-8	2011	The neutral endopeptidase (NEP) inhibitor, phosphoramidon, blocked inactivation of CNP and CD-NP, but not BNP or DNP.	phosphoramidon	43-57	membrane metalloendopeptidase	Homo sapiens	27-30
21459096-8	2011	The neutral endopeptidase (NEP) inhibitor, phosphoramidon, blocked inactivation of CNP and CD-NP, but not BNP or DNP.	phosphoramidon	43-57	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	83-86
23911580-8	2013	The inhibition of ECE-1 activity was very strong, similar to the classic ECE inhibitor phosphoramidon, the addition of exogenous zinc restored enzymatic activity.	phosphoramidon	87-101	endothelin converting enzyme 1	Rattus norvegicus	18-23
23911580-8	2013	The inhibition of ECE-1 activity was very strong, similar to the classic ECE inhibitor phosphoramidon, the addition of exogenous zinc restored enzymatic activity.	phosphoramidon	87-101	endothelin converting enzyme 1	Rattus norvegicus	18-21
24069438-8	2013	Notably, purified LasB reproduced most of the effects of the LasB-containing secretomes, and these were drastically reduced in the presence of the LasB-selective inhibitor, phosphoramidon.	phosphoramidon	173-187	elastase LasB	Pseudomonas aeruginosa PAO1	18-22
24069438-8	2013	Notably, purified LasB reproduced most of the effects of the LasB-containing secretomes, and these were drastically reduced in the presence of the LasB-selective inhibitor, phosphoramidon.	phosphoramidon	173-187	elastase LasB	Pseudomonas aeruginosa PAO1	61-65
24069438-8	2013	Notably, purified LasB reproduced most of the effects of the LasB-containing secretomes, and these were drastically reduced in the presence of the LasB-selective inhibitor, phosphoramidon.	phosphoramidon	173-187	elastase LasB	Pseudomonas aeruginosa PAO1	61-65
23113990-3	2012	To explore the structural differences between XCE and ECE-1, homology model of XCE was built using the complex structure of ECE-1 with phosphoramidon (pdb-id: 3DWB) as template.	phosphoramidon	135-149	endothelin converting enzyme like 1	Homo sapiens	79-82
23113990-4	2012	Phosphoramidon was docked into the binding site of XCE whereas phosphate oxygen of the inhibitor was used as water molecule to design the apo forms of both enzymes.	phosphoramidon	0-14	endothelin converting enzyme like 1	Homo sapiens	51-54
22554773-9	2012	Nebulized phosphoramidon (1 mM, 1 min), a neutral endopeptidase 24.11 inhibitor, significantly enhanced the response induced by toluene (135 ppm, 10 min) compared with nebulized 0.9% saline (1 min).	phosphoramidon	10-24	membrane metallo-endopeptidase	Rattus norvegicus	42-69
22387410-8	2012	OCCs are resistant to Abeta challenge in any of the conditions tested (variation of [K+]e, presence or absence of serum, or addition of the neprilysin blocker phosphoramidon).	phosphoramidon	159-173	membrane metallo endopeptidase	Mus musculus	140-150
20941644-0	2011	Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice.	phosphoramidon	11-25	membrane metallo-endopeptidase-like 1	Mus musculus	77-81
20941644-5	2011	An alternative model of amyloidosis utilizes intracerebroventricular infusion of thiorphan or phosphoramidon to block the activity of key Abeta degrading enzymes (NEP, NEP2) resulting in accumulation of Abeta.	phosphoramidon	94-108	amyloid beta precursor protein	Homo sapiens	138-143
20941644-5	2011	An alternative model of amyloidosis utilizes intracerebroventricular infusion of thiorphan or phosphoramidon to block the activity of key Abeta degrading enzymes (NEP, NEP2) resulting in accumulation of Abeta.	phosphoramidon	94-108	membrane metalloendopeptidase	Homo sapiens	163-166
20941644-5	2011	An alternative model of amyloidosis utilizes intracerebroventricular infusion of thiorphan or phosphoramidon to block the activity of key Abeta degrading enzymes (NEP, NEP2) resulting in accumulation of Abeta.	phosphoramidon	94-108	membrane metalloendopeptidase like 1	Homo sapiens	168-172
20941644-5	2011	An alternative model of amyloidosis utilizes intracerebroventricular infusion of thiorphan or phosphoramidon to block the activity of key Abeta degrading enzymes (NEP, NEP2) resulting in accumulation of Abeta.	phosphoramidon	94-108	amyloid beta precursor protein	Homo sapiens	203-208
20941644-6	2011	Here, we demonstrate that intranasal administration of phosphoramidon produces significantly elevated cerebral Abeta levels in wild-type mice.	phosphoramidon	55-69	amyloid beta (A4) precursor protein	Mus musculus	111-116
20941644-7	2011	Furthermore, intranasal phosphoramidon administration in double knockout mice lacking NEP and NEP2 also showed increased levels of Abeta(40).	phosphoramidon	24-38	tensin 2	Mus musculus	86-89
20941644-7	2011	Furthermore, intranasal phosphoramidon administration in double knockout mice lacking NEP and NEP2 also showed increased levels of Abeta(40).	phosphoramidon	24-38	membrane metallo-endopeptidase-like 1	Mus musculus	94-98
20941644-7	2011	Furthermore, intranasal phosphoramidon administration in double knockout mice lacking NEP and NEP2 also showed increased levels of Abeta(40).	phosphoramidon	24-38	amyloid beta (A4) precursor protein	Mus musculus	131-136
20941644-8	2011	These data show that intranasal delivery of drugs can be used to model AD and suggest that other phosphoramidon-sensitive peptidases are degrading Abeta in NEP/NEP2-deficient mice.	phosphoramidon	97-111	amyloid beta (A4) precursor protein	Mus musculus	147-152
20941644-8	2011	These data show that intranasal delivery of drugs can be used to model AD and suggest that other phosphoramidon-sensitive peptidases are degrading Abeta in NEP/NEP2-deficient mice.	phosphoramidon	97-111	tensin 2	Mus musculus	156-159
20941644-8	2011	These data show that intranasal delivery of drugs can be used to model AD and suggest that other phosphoramidon-sensitive peptidases are degrading Abeta in NEP/NEP2-deficient mice.	phosphoramidon	97-111	membrane metallo-endopeptidase-like 1	Mus musculus	160-164
19962413-2	2010	The big ET-1-induced vasoconstriction (a) developed more rapidly (i.e., was greater in the first 30 min) in the diabetic group than in the age-matched controls, and (b) in each group was largely suppressed by phosphoramidon [nonselective endothelin-converting enzyme (ECE)/neutral endopeptidase (NEP) inhibitor] or CGS35066 (selective ECE inhibitor), but not by thiorphan (selective NEP inhibitor).	phosphoramidon	209-223	endothelin 1	Rattus norvegicus	8-12
21174590-3	2011	RESULTS: In human umbilical vein endothelial cells, both phosphoramidon, an inhibitor of ECE-1, and TIMP-2 decreased VEGF-induced ET-1 production.	phosphoramidon	57-71	endothelin converting enzyme 1	Homo sapiens	89-94
21174590-3	2011	RESULTS: In human umbilical vein endothelial cells, both phosphoramidon, an inhibitor of ECE-1, and TIMP-2 decreased VEGF-induced ET-1 production.	phosphoramidon	57-71	vascular endothelial growth factor A	Homo sapiens	117-121
21174590-3	2011	RESULTS: In human umbilical vein endothelial cells, both phosphoramidon, an inhibitor of ECE-1, and TIMP-2 decreased VEGF-induced ET-1 production.	phosphoramidon	57-71	endothelin 1	Homo sapiens	130-134
20796280-7	2010	Phosphoramidon increased sperm progressive motility and its effects were reduced in the presence of the tachykinin receptor antagonists SR140333 (NK1 receptor-selective) and SR48968 (NK2 receptor-selective) but unmodified in the presence of SR142801 (NK3 receptor-selective).	phosphoramidon	0-14	tachykinin receptor 1	Homo sapiens	146-158
20796280-7	2010	Phosphoramidon increased sperm progressive motility and its effects were reduced in the presence of the tachykinin receptor antagonists SR140333 (NK1 receptor-selective) and SR48968 (NK2 receptor-selective) but unmodified in the presence of SR142801 (NK3 receptor-selective).	phosphoramidon	0-14	tachykinin receptor 2	Homo sapiens	183-195
20796280-7	2010	Phosphoramidon increased sperm progressive motility and its effects were reduced in the presence of the tachykinin receptor antagonists SR140333 (NK1 receptor-selective) and SR48968 (NK2 receptor-selective) but unmodified in the presence of SR142801 (NK3 receptor-selective).	phosphoramidon	0-14	tachykinin receptor 3	Homo sapiens	251-263
20522806-4	2010	METHODS AND RESULTS: After NO synthase inhibition (L-NAME), thrombin contracted aged arteries, which was inhibited by endothelial denudation, ET(A) receptor antagonism (BQ123), and ECE inhibition (phosphoramidon, SM19712) or by inhibiting exocytosis (TAT-NSF, N-ethylmaleimide-sensitive factor inhibitor).	phosphoramidon	197-211	coagulation factor II, thrombin	Homo sapiens	60-68
20088804-4	2010	Of particular interest are endopeptidases that are sensitive to the neprilysin inhibitors thiorphan and phosphoramidon (i.e. "NEP-like") as these inhibitors induce a dramatic increase in Abeta levels resulting in rapid plaque formation in wild-type rodents.	phosphoramidon	104-118	membrane metalloendopeptidase	Homo sapiens	68-78
20088804-4	2010	Of particular interest are endopeptidases that are sensitive to the neprilysin inhibitors thiorphan and phosphoramidon (i.e. "NEP-like") as these inhibitors induce a dramatic increase in Abeta levels resulting in rapid plaque formation in wild-type rodents.	phosphoramidon	104-118	membrane metalloendopeptidase	Homo sapiens	126-129
20088804-4	2010	Of particular interest are endopeptidases that are sensitive to the neprilysin inhibitors thiorphan and phosphoramidon (i.e. "NEP-like") as these inhibitors induce a dramatic increase in Abeta levels resulting in rapid plaque formation in wild-type rodents.	phosphoramidon	104-118	amyloid beta precursor protein	Homo sapiens	187-192
21224067-2	2011	Endopeptidases sensitive to inhibition by thiorphan and phosphoramidon are especially important, because these inhibitors induce dramatic Abeta accumulation (~30- to 50-fold) and pathological deposition in rodents.	phosphoramidon	56-70	amyloid beta (A4) precursor protein	Mus musculus	138-143
21224067-4	2011	However, genetic ablation of NEP results in only modest increases (~1.5- to 2-fold) in Abeta, indicating that other thiorphan/phosphoramidon-sensitive endopeptidases are at work.	phosphoramidon	126-140	membrane metallo endopeptidase	Mus musculus	29-32
21224067-5	2011	Of particular interest is the NEP homolog neprilysin 2 (NEP2), which is thiorphan/phosphoramidon-sensitive and degrades Abeta.	phosphoramidon	82-96	membrane metallo endopeptidase	Mus musculus	30-33
21224067-5	2011	Of particular interest is the NEP homolog neprilysin 2 (NEP2), which is thiorphan/phosphoramidon-sensitive and degrades Abeta.	phosphoramidon	82-96	membrane metallo-endopeptidase-like 1	Mus musculus	42-54
21224067-5	2011	Of particular interest is the NEP homolog neprilysin 2 (NEP2), which is thiorphan/phosphoramidon-sensitive and degrades Abeta.	phosphoramidon	82-96	membrane metallo-endopeptidase-like 1	Mus musculus	56-60
21224067-5	2011	Of particular interest is the NEP homolog neprilysin 2 (NEP2), which is thiorphan/phosphoramidon-sensitive and degrades Abeta.	phosphoramidon	82-96	amyloid beta (A4) precursor protein	Mus musculus	120-125
21224067-10	2011	Treatment of these double-knockout mice with phosphoramidon resulted in elevations of Abeta, suggesting that yet other NEP-like Abeta-degrading endopeptidases are contributing to Abeta catabolism.	phosphoramidon	45-59	amyloid beta (A4) precursor protein	Mus musculus	86-91
21224067-10	2011	Treatment of these double-knockout mice with phosphoramidon resulted in elevations of Abeta, suggesting that yet other NEP-like Abeta-degrading endopeptidases are contributing to Abeta catabolism.	phosphoramidon	45-59	membrane metallo endopeptidase	Mus musculus	119-122
21224067-10	2011	Treatment of these double-knockout mice with phosphoramidon resulted in elevations of Abeta, suggesting that yet other NEP-like Abeta-degrading endopeptidases are contributing to Abeta catabolism.	phosphoramidon	45-59	amyloid beta (A4) precursor protein	Mus musculus	128-133
21224067-10	2011	Treatment of these double-knockout mice with phosphoramidon resulted in elevations of Abeta, suggesting that yet other NEP-like Abeta-degrading endopeptidases are contributing to Abeta catabolism.	phosphoramidon	45-59	amyloid beta (A4) precursor protein	Mus musculus	128-133
19520130-10	2009	The enhanced effect of the combination of substance P with morphine was reduced significantly by co-administration of phosphoramidon, an inhibitor of endopeptidase-24.11.	phosphoramidon	118-132	tachykinin 1	Mus musculus	42-53
19780404-3	2009	In recent studies we found that pharmacological inhibition of NEP by phosphoramidon resulted in elevated plasma levels of SP and greater oxidative stress.	phosphoramidon	69-83	membrane metallo-endopeptidase	Rattus norvegicus	62-65
18992253-5	2009	Here, we present the crystal structure of the extracellular domain (residues 90-770) of human ECE-1 (C428S) with the generic metalloprotease inhibitor phosphoramidon determined at 2.38 A resolution.	phosphoramidon	151-165	endothelin converting enzyme 1	Homo sapiens	94-99
19151386-6	2009	ET-1 precursor big ET-1 elicited time-dependent vasoconstriction over 20 minutes, which was blocked by the ECE-1 inhibitor phosphoramidon.	phosphoramidon	123-137	endothelin 1	Homo sapiens	0-4
19151386-6	2009	ET-1 precursor big ET-1 elicited time-dependent vasoconstriction over 20 minutes, which was blocked by the ECE-1 inhibitor phosphoramidon.	phosphoramidon	123-137	endothelin 1	Homo sapiens	19-23
19151386-6	2009	ET-1 precursor big ET-1 elicited time-dependent vasoconstriction over 20 minutes, which was blocked by the ECE-1 inhibitor phosphoramidon.	phosphoramidon	123-137	endothelin converting enzyme 1	Homo sapiens	107-112
18772340-5	2008	Furthermore, we have previously shown that both the endothelin-converting enzyme-1 (ECE-1) inhibitor, phosphoramidon, as well as a novel ET-1 receptor A antagonist synthesized by our group, control premature delivery in a mouse model of inflammation-associated preterm delivery.	phosphoramidon	102-116	endothelin converting enzyme 1	Mus musculus	84-89
18804491-6	2008	The acidic (pH optimum 5.5), membrane-bound, thiorphan- (ED(50) 1.2+/-0.2 nM) and phosphoramidon (ED(50) 150+/-25 pM) sensitive, endothelin-1 inactivating peptidase (K(M) 0.12+/-0.03 microM) was present in the mucosal cells of duodenum and small intestine.	phosphoramidon	82-96	endothelin 1	Rattus norvegicus	129-141
18586023-9	2008	In contrast, treatment with phosphoramidon further enhanced left ventricular endothelin-1 level and norepinephrine overflow, and significantly worsened cardiac dysfunction after ischemia/reperfusion.	phosphoramidon	28-42	endothelin 1	Rattus norvegicus	77-89
18322380-2	2008	The results obtained revealed that intracerebroventricular injection of the protease inhibitor phosphoramidon into wild-type mice for up to a month elevated the soluble and deposited brain Abeta levels and concomitantly induced the neurodegeneration of distinct hippocampal neurons as well as neuroinflammation.	phosphoramidon	95-109	amyloid beta (A4) precursor protein	Mus musculus	189-194
18463098-8	2008	Interestingly, the mRNA levels of endogenous fly NEP genes and phosphoramidon-sensitive NEP activity declined during aging in fly brains, as observed in mammals.	phosphoramidon	63-77	Neprilysin 1	Drosophila melanogaster	88-91
18607539-2	2008	Male Sprague-Dawley rats (180g) were fed MgD (approximately 50 mg Mg/kg) or Mg-sufficient (MgS, 608 mg Mg/kg) diets for 7 days +/- NEP inhibitor phosphoramidon (PR, 5 mg/kg/day, s.c.).	phosphoramidon	145-159	membrane metallo-endopeptidase	Rattus norvegicus	131-134
18307123-1	2008	Phosphoramidon blocks the formation of endothelin-1 (ET-1), a proinflammatory mediator implicated in the pathogenesis of a variety of lung diseases.	phosphoramidon	0-14	endothelin 1	Homo sapiens	39-51
18307123-1	2008	Phosphoramidon blocks the formation of endothelin-1 (ET-1), a proinflammatory mediator implicated in the pathogenesis of a variety of lung diseases.	phosphoramidon	0-14	endothelin 1	Homo sapiens	53-57
18307123-4	2008	The results indicate that phosphoramidon significantly reduces LPS-induced pulmonary inflammation as measured by lung histology, neutrophil content of bronchoalveolar lavage (BAL) fluid, percent tumor necrosis factor receptor 1 (TNFR1)-labeled BAL macrophages, and alveolar septal cell apoptosis.	phosphoramidon	26-40	TNF receptor superfamily member 1A	Homo sapiens	195-227
18307123-4	2008	The results indicate that phosphoramidon significantly reduces LPS-induced pulmonary inflammation as measured by lung histology, neutrophil content of bronchoalveolar lavage (BAL) fluid, percent tumor necrosis factor receptor 1 (TNFR1)-labeled BAL macrophages, and alveolar septal cell apoptosis.	phosphoramidon	26-40	TNF receptor superfamily member 1A	Homo sapiens	229-234
18296865-1	2008	Previous in vitro studies have shown that the degradation of [Leu(5)]enkephalin during incubation with cerebral membrane preparations is almost completely prevented by a mixture of three peptidase inhibitors: amastatin, captopril, and phosphoramidon.	phosphoramidon	235-249	proenkephalin	Rattus norvegicus	69-79
18055635-7	2007	This endopeptidase activity was inhibited by the neprilysin inhibitors phosphoramidon (IC(50,) 0.15 micromol l(-1)) and thiorphan (IC(50,) 1.2 micromol l(-1)).	phosphoramidon	71-85	Neprilysin-like 11	Drosophila melanogaster	49-59
17904426-6	2007	ECE and its product ET-1(1-21) were detected in aorta and vena cava, and the ECE inhibitors phosphoramidon and CGS-26393 reduced big ET-1-induced contraction.	phosphoramidon	92-106	endothelin converting enzyme 1	Rattus norvegicus	77-80
18758506-5	2008	In our previous work, we have shown that blockade of ET-1 synthesis through the use of the metalloproteinase inhibitor phosphoramidon results in control of preterm labor.	phosphoramidon	119-133	endothelin 1	Mus musculus	53-57
18645412-7	2008	The constriction response to topically applied 100 nM CARTp was blocked by both the endothelin A (ETA) receptor antagonist BQ-123 (10 microM) and the inhibitor of endothelin-converting enzyme, phosphoramidon (100 nM).	phosphoramidon	193-207	CART prepropeptide	Rattus norvegicus	54-59
17643133-5	2007	CGS-26303 and phosphoramidon, though not thiorphan, a neutral endopeptidase (NEP) inhibitor, stimulated ECE-1 expression in cells (maximal effect at 16 h, 25 microM).	phosphoramidon	14-28	endothelin converting enzyme 1	Homo sapiens	104-109
17643133-4	2007	KEY RESULTS: ECE-1 activity was completely inhibited by CGS-26303 25 microM and phosphoramidon 100 microM.	phosphoramidon	80-94	endothelin converting enzyme 1	Homo sapiens	13-18
17878706-1	2007	Previous in vitro studies have shown that the degradation of [Met(5)]enkephalin-Arg(6)-Phe(7) during incubation with cerebral membrane preparations is largely prevented by a mixture of three peptidase inhibitors: amastatin, captopril, and phosphoramidon.	phosphoramidon	239-253	proenkephalin	Rattus norvegicus	69-79
17196890-6	2007	Furthermore, pretreatment with ET converting enzyme inhibitor phosphoramidon (10 nmol) abolished the cardiovascular effects evoked by icv injection of ET-1(1-31) or big ET-1.	phosphoramidon	62-76	endothelin 1	Rattus norvegicus	151-155
17196890-6	2007	Furthermore, pretreatment with ET converting enzyme inhibitor phosphoramidon (10 nmol) abolished the cardiovascular effects evoked by icv injection of ET-1(1-31) or big ET-1.	phosphoramidon	62-76	endothelin 1	Rattus norvegicus	169-173
17466482-4	2007	In endothelium-intact rings, phosphoramidon (1 mmol/l), a nonselective ECE/neutral endopeptidase (NEP) inhibitor, produced a rightward displacement of the concentration-response curves and reduced the maximal contractile response to Big-ET-1.	phosphoramidon	29-43	endothelin converting enzyme 1	Rattus norvegicus	71-74
17466482-4	2007	In endothelium-intact rings, phosphoramidon (1 mmol/l), a nonselective ECE/neutral endopeptidase (NEP) inhibitor, produced a rightward displacement of the concentration-response curves and reduced the maximal contractile response to Big-ET-1.	phosphoramidon	29-43	membrane metallo-endopeptidase	Rattus norvegicus	98-101
17466482-4	2007	In endothelium-intact rings, phosphoramidon (1 mmol/l), a nonselective ECE/neutral endopeptidase (NEP) inhibitor, produced a rightward displacement of the concentration-response curves and reduced the maximal contractile response to Big-ET-1.	phosphoramidon	29-43	endothelin 1	Rattus norvegicus	237-241
17466482-5	2007	However, in endothelium-denuded rings phosphoramidon reduced the maximum contraction for Big-ET-1 but did not alter the potency when compared to the curves obtained in the absence of the inhibitor.	phosphoramidon	38-52	endothelin 1	Rattus norvegicus	93-97
17507367-8	2007	Finally, treatment of cultured myofibroblasts with an NEP inhibitor (phosphoramidon) downregulated the expression of profibrotic transforming growth factor-beta1, whereas addition of BK decreased the expression of collagens I and III which was reversed by a BK-2R antagonist.	phosphoramidon	69-83	membrane metalloendopeptidase	Homo sapiens	54-57